Biochemical mechanism of apoptotic execution by Samejima, Kumiko
BIOCHEMICAL MECHANISM OF 
APOPTOTIC EXECTUION 
KuMIK0 SAMEJIMA 
A THESIS PRESENTED FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
UNIVERSITY OF EDINBURGH 
October 2000 
ACKNOWLEDGMENTS 
I really appreciate my supervisor, Bill Earnshaw for giving me the 
opportunity to work in his laboratory, for great suggestions, a lot of time, 
and heart-warming support when I needed it. I would also like to 
acknowledge our wonderful collaborator Dr. Scott Kaufmann at the Mayo 
Clinic, Rochester MN. 
I would like to say thank you to all members of the lab, present and 
past, who taught me from scratch and the effort for understanding my 
Japanese-English. I will not forget you all, Richard Adams, Alexandra 
Ainsztein, Mar Carmera, Carol Cooke, Jeff Craig, Helen Dodson, Francoise 
Durrieu, Sander Henzing, Damien Hudson, Nadia Korfali, Luis M. Martins, 
Ciaran Morrison, Anca Petruti-Mot, Sandrine Ruchaud, Tone Shigenobu, 
Atushi Takahashi, Paola Vagnarelli, Pascal Villa, Peter Warburton, Sally 
Wheatley, and Chuck Yang. lit particular, Stefanie-Kandals Lewis for her 
advice both in the lab and in baby-care. I am happy with my outcome 
during my Ph D. I am also sure that we can be proud of our productivity 
(nine babies from one lab in three years!). 
Thank you to the members of the Heck lab and Lewis lab for their 
support and all the people from ICMB who helped me in the past four years. 
I am very grateful for my husband, Itaru, about his suggestion to 
apply to Bill's lab and his continuous support. I love my baby, Mami. 
Finally I thank my parents for their love and support over the years. 
11 
ABSTRACT 
Apoptosis is a major form of physiological cell death characterized by 
morphological and biochemical changes including nuclear and cytoplasmic 
condensation, followed by cellular disassembly into membrane-enclosed 
vesicles, and internucleosomal DNA cleavage. These changes are 
accompanied by the activation of caspases and DNases. 
Cytoplasmic extracts from chicken DU249 cells at various stages 
along the apoptotic pathway were prepared to analyze changes in nuclear 
morphology during apoptotic execution. When isolated interphase nuclei 
were exposed to S/M extracts prepared from morphologically normal cells 
in the "committed stage stage of the apoptotic pathway, they became 
condensed and the DNA was cleaved. These changes were dependent on 
caspase activity. In contrast, when the same nuclei were exposed to E/X 
extracts, prepared from morphologically apoptotic cells, they underwent 
apoptotic changes in a caspase-independent manner. These results suggest 
that nuclear disassembly is driven largely by factors activated downstream 
of the caspases at the onset of apoptotic execution. One such factor, the 
caspase-activated DNase, CAD/CPAN/DFF40, can induce apoptotic 
chromatin condensation in isolated HeLa cell nuclei in the absence of other 
cytosolic factors. However, as morphological changes occur even when 
CAD activity is inhibited, CAD cannot be the sole factor triggered by 
caspases. Indeed, in this study it was found that DNA topoisomerase ha 
111 
(topo II(), which is essential both for chromosome condensation and 
segregation in mitosis, also functions during apoptotic execution. 
Simultaneous inhibition of topo IIcs plus either caspases or CAD completely 
abolished apoptotic chromatin condensation. Furthermore it was 
demonstrated that CAD functionally interacts with topo ha. 
The localization of CAD and its inhibitor ICAD in nonapoptotic cells 
has remained controversial. ICAD exists in two forms, ICAD-L and ICAD-S, 
which are transcribed from a single gene by alternative splicing. They differ 
at the C-terminus: 70 amino acids of ICAD-L are replaced by four different 
amino acids [VGKN] in ICAD-S. CAD is associated with ICAD-L in 
healthy cells and it has been proposed that a major function of ICAD-L is to 
sequester CAD in the cytoplasm. In this study it was found that a 
GFP:ICAD-L fusion protein localized to cell nuclei, while GFP:ICAD-S was 
distributed throughout the cell. These data are in agreement with the 
presence of a NLS in the COOH-terminal 20 amino acids of ICAD-L, a 
region absent from ICAD-S. In addition, GFP:CAD was found mostly in the 
nucleus. These localization patterns were confirmed by cell fractionation and 
western blotting for the endogenous protein. Thus these data demonstrate 
that the CAD/ICAD-L complex should be nuclear in intact cells. 
This study presented the first evidence that activities such as CAD 
and topo II that function downstream of caspases in apoptosis are largely 
responsible for nuclear disassembly. Furthermore, it is demonstrated that 
iv 
CAD and topo II which are located in the nucleus in healthy cells, have 
interactions but work in parallel during chromatin condensation. 
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1.1 What is apoptosis and why is apoptosis research important? 
1.1.1 Definition of apoptosis 
Apoptosis and necrosis are two major types of cell death. Apoptosis 
is a physiological process and a major form of programmed cell death and is 
essential for development, tissue homeostasis, and host defense against 
viruses (Wyllie, 1980; Raff, 1992; Thompson, 1995; Nagata, 1997). In 
contrast, necrosis occurs accidentally when cells are exposed to a serious 
physical or chemical insult. Differential features and the significance of 
apoptosis and necrosis are summarized in table 1. 
During the last decade, apoptosis research has become an exciting 
area principally because of its essential involvement in many biological 
processes and systems. In a human body about a hundred thousand cells 
are produced every second by mitosis, and a similar number die by 
apoptosis. Apoptosis is characterized by a series of distinct morphological 
and biochemical changes, including nuclear and cytoplasmic condensation, 
DNA fragmentation, and alterations in cell membrane composition (Kerr, 
1971; Wylie, 1980). These changes have been observed in almost all cell 
types, suggesting the presence of a common death pathway. 

Table 1. Differential features and significance of apoptosis and necrosis 
Apoptosis 
Morphological Membrane blebbing, but no loss of integrity 
features Aggregation of chromatin at the nuclear membrane 
Shrinking of cytoplasm and condensation of nucleus 
Formation of membrane bound vesicles (apoptotic 
bodies) 
Biochemical Tightly regulated process involving activation of 
features enzymatic steps 
Internucleosomal DNA fragmentation (DNA ladder) 
Release of various factors (cytochrome C, AIF) from 
mitochondria 
Activation of caspase cascade 
Alteration in membrane asymmetry (translocation of 
phosphatidyl-serine from the cytoplasmic to the 
extracellular side of the membrane) 
Physiological Affects individual cells 
significance Phagocytosis by adjacent cells or macrophages 
No inflammatory response 
Necrosis 
Morphological Loss of membrane integrity 
features Swelling of cytoplasm, mitochondria and other organelles 
Complete cell lysis 
Biochemical Loss of regulation of ion homeostasis 
features Random digestion of DNA 
Physiological Affects groups of contiguous cells 
significance Phagocytosis by macrophages 
Significant inflammatory response 
1.1.2 Apoptosis in physiological conditions 
Only recently has it been recognized that massive numbers of cells are 
eliminated by apoptosis in physiological conditions, presumably because 
usually less than 1% of cells are detected as apoptotic in tissue (Wyllie, 1994). 
Apoptosis is a mechanism of cell clearance in many physiological processes 
such as embryogenesis, metamorphosis (Vaux and Korsmeyer, 1999). For 
example, loss of the tadpole's tail involves cell death (Kerr, Harmon et al., 
1974). Massive cell death is also observed during the metamorphosis of 
insects (Schwartz and Truman, 1982). During vertebrate nervous system 
development, as much as 85% of certain cell populations of developing 
neurons undergo cell death (Cowan, Fawcett et al., 1984; Hamburger, 1992). 
Apoptosis plays an important role in the establishment of the immune 
system: 95% of T-cells are eliminated by apoptosis without leaving the 
thymus. Adult animals must maintain the correct number of cells within 
each tissue, and thus cells that have already functioned die as younger cells 
are generated to replace them. In other words, the coordinate regulation of 
cell proliferation and cell death provides precise control over tissue size 
(Hinsull, Bellamy et al., 1977). Cells that pose a danger to the host are 
eliminated by cell death: cells infected by viruses can be removed before the 
virus spreads. As shown above, apoptosis is involved in many aspects of 
life. Thus any disregulation in the apoptotic process can cause serious 
trouble, as shown below. 
'3 
1.1.3 Apoptosis in disease 
It is now clear that defects in apoptosis occur in several types of 
disorders in the human body. Inappropriate activation of the apoptotic 
pathway has been implicated in a number of acute and chronic neuro-
degenerative diseases. In Alzheimer's disease, Parkinson's disease, and 
Huntington's disease, there is now increasing evidence that apoptotic cell 
death contributes to the loss of specific neuronal populations (Friedlander 
and Yuan, 1998). Autoimmunity is a consequence of defects occurring in the 
signaling, execution and clearance pathways involved in apoptosis. For 
example, defects in the CD95 pathway, which is one of the major apoptotic 
pathways (see chapter 1.2.1), are found in autoimmune diseases such as in 
the autoimmune lymphoproliferative syndrome (ALPS) (Fisher, Rosenberg 
et al., 1995). Inherited non-lethal human caspase 10 abnormalities cause 
pleiotropic apoptosis defects underlying autoimmunity in the ALPS type II 
syndrome (Wang, Zheng et al., 1999). The accumulation of neoplastic cells 
can occur through enhanced proliferation, diminished cell turnover, or a 
combination of both processes. The demonstration that Bcl-2 can inhibit cell 
death upon forced overexpression provided the first concrete example of an 
oncogene that acts by inhibiting cell turnover rather than enhancing 
proliferation (Tsujimoto, Cossman et al., 1985). Since deregulation of almost 
any component of the apoptotic machinery can contribute to the 
transformation process, studies of the mechanism of apoptosis may help in 
the design of cancer therapies (Kaufmann and Earnshaw, 2000). 
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1.1.4 Major components involved in apoptosis are conserved 
The basic scheme of the apoptosis pathway is evolutionarily 
conserved from nematodes to humans in general. Genetic studies in 
Caenorhabditis elegans, in which 131 of the 1090 somatic cells generated 
during development are destined to die, has provided a framework for 
understanding the components responsible for programmed cell death both 
in C. elegans and higher organisms (Ellis and Horvitz, 1986; Liu and 
Hengartner, 1999). Figure 1 shows 15 genes of C. elegans that function in 
programmed cell death. The basic scheme of the apoptosis effector 
mechanism is depicted in figure 2, which compares homologous proteins in 
nematodes and vertebrates. Caspases, a family of cysteine-dependent 
aspartate-directed proteases, play critical roles in initiation and execution of 
the apoptotic pathway. The activation and regulation mechanisms of 
caspases are discussed in Chapter 1.2. Caspases themselves and their 
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Figure 1. The genetic pathway for programmed cell death in C. elegans. In 
the nematode C. elegans, genetic studies led to the discovery of 15 genes 
involved in programmed cell death. These 15 genes have been divided into 
four groups based on the order of their activity during the process of 
programmed cell death: ces-TI and ces-2 are involved in the decision making, 
ced-3, ced-4, ced-8, ced-9, and egl-1 in the process of execution, ced-1 ced-2, ced-
5, ced-6, ced-7 and ced-10 in the engulfment of dying cells by engulfing cells, 
and nuc-1 in the degradation of cell corpses within engulfing cells. Adapted 
from reference (Liu and Hengartner, 1999). 
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Figure 2. Conservation of the execution step in the genetic pathway for 
programmed cell death. In C. elegans, the execution step in the genetic 
pathway for programmed cell death comprises four genes, ced-3, ced-4, ced-9 
and egl-1. All of these genes have corresponding mammalian homologues: 
CED-9 is a member of the Bcl-2 family, CED-3 is a caspase family member, 
CED-4 is homologous to the Apaf-1 protein, and EGL-1 is similar in 
structure to Bid and other BH3 domain only-containing proteins. Adapted 
from reference (Liu and Hengartner, 1999). 
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1.2 Two major apoptotic pathways and their regulation 
There are two major cell-intrinsic pathways for inducing apoptosis, 
one that begins with ligation of cell surface death receptors (receptor-
mediated apoptosis) and another that involves mitochondrial release of 
cytochrome c (stress-induced apoptosis). Each pathway activates distinct 
caspase cascades (Bratton, MacFarlane et al., 2000). 
1.2.1 Receptor-mediated apoptosis 
Within the plasma membrane of many cells are death receptors, 
which, when triggered by their corresponding ligand, result in receptor 
trimerization and initiate rapid activation of caspases. Figure 3 shows a 
diagram of the receptor-mediated caspase cascade. Death receptors such as 
CD95/Fas and TNFR1 are members of the tumor necrosis factor (TNF) 
receptor super family. 
In brief, CD95 molecules are pre-oligomerized in living cells through 
the interaction of the pre-ligand assembly domain (Siegel, Frederiksen et al., 
2000). Binding of Fas ligand or agonistic antibodies results in a clustering of 
the receptors' cytosolic DD (death domain) and recruitment of adapter 
molecules such as FADD (Fas-associated death domain) via homophilic DD 
interactions (Ashkenazi and Dixit, 1998). FADD contains also a DED (death 
effector domain), which can associate with similar DEDs located in the 
prodomain of caspase-8. This complex of proteins is referred as the DISC 
(death-inducing signaling complex). Clustering of procaspase-8 within this 
- 
complex promotes trans-catalysis to generate active caspase-8 (Medema, 
Scaffidi et al., 1997; Muzio, Stockwell et al., 1998). 
Similarly, trimerized TNFR1 can recruit the adapter protein TRADD 
(TNFR-associated death domain), which consequently recruits FADD and 
procaspase-8. In addition, TNFR1 can also activate NF-KB and JNK 
signaling pathways through other adapter molecules such as RIP (receptor-
interacting protein) and TRAF2 (Akiba, Nakano et al., 1998; Gravestein, 
Amsen et al., 1998). Activation of these signaling pathways protects against 
apoptosis. 
Upon activation, caspase-8 can activate effector caspases -3, -6 and -7 
and ensure destruction of the cell. Moreover, caspase-8-mediated cleavage 
of Bid produces a truncated protein that translocates from the cytosol to the 
mitochondria where it stimulates release of cytochrome c (Li, Zhu et al., 1998; 
Luo, Budihardjo et al., 1998). This can couple the death-receptor stimulation 
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Figure 3. Receptor-mediated caspase cascade. Binding of ligand or 
agonisitic antobodies to CD95 and TNFR1 receptors initiates recruitment of 
various adapter proteins through homophilic DD interactions, including 
FADD, which directly binds and promotes trans-catalytic activation of 
caspase-8. Stimulation of TNFR1 also activates NF-KB and JNK signaling 
pathways through RIP and TRAF2, respectively. Adapted from reference 
(Bratton et al., 2000). 
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1.2.2 Stress-induced apoptosis 
The other major apoptotic pathway, the stress-induced apoptosis, is 
shown in figure 4. In brief, a number of cellular signals induce perturbations 
in the mitochondria resulting in the release of proapoptotic molecules, 
including AIF (apoptosis-inducing factor) and cytochrome c, from the 
intermembrane space into the cytoplasm (Green and Reed, 1998; Susin, 
Lorenzo et al., 1999). Cytochrome c release appears to be a common 
occurrence in apoptosis, but the mechanism controlling its release is not 
clearly understood. After release, cytochrome c interacts with Apaf-1 (CED-
4 homologue), dATP/ATP and procaspase-9 to form a complex known as 
the "apoptosome" (Li, Nijhawan et al., 1997). Caspase-9 in this complex 
activates caspase-3, -7 and consequently -6 (Li et al., 1997; Zou, Henzel et al., 
1997; Srinivasula, Ahmad et al., 1998). Activated caspases-3 -6 and -7 attack 
cellular proteins and also process other caspases including apical caspases -8 
and -9 to amplify the signal. The importance of the Apaf-1 to caspase-9 to 
caspase-3 pathway was later verified in studies using Apaf-1-/-, caspase-9-
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Figure 4. Stress-induced caspase cascade. Mitochondrial stress and/or 
proapopototic Bcl-2 proteins (e.g. tBid or Bax) induce release of cytochrome c 
into cytoplasm. Caspases -2, -3, and -9 and ATF (apoptosis-inducing factor) 
are also released from the mitochondrial intermembrane space. Cytochrome 
c and dATP induce a conformational change in Apaf-1 that allows it to 
oligomerize into an approximately 700-kDa complex (Apoptosome). 
Caspase-9 in the apoptosome activates caspases-3, -7 and consequently 
caspase-6. Adapted from reference (Bratton et al., 2000). Pro-apoptotic and 
anti-apoptotic Bcl-2 family proteins are listed below. 
12 
- 	 - 	- 	
1 r 	' rr 
1.2.3 Regulation of apoptotic pathways 
A number of proteins exist to regulate the mechanism of caspase 
activation, presumably because accidental activation of caspases is 
potentially harmful for cells. For example, the ability of the adaptors, FADD 
and Apaf-1, to activate the caspases is regulated by proteins that appear to 
directly interact with the adaptors. 
In the receptor-mediated pathway, viral FLICE (caspase-8)-inhibitable 
proteins (v-FLIPs) and cellular FLIPS (c-FLIPs) inhibit the activation of 
caspase-8 (Irmler, Thome et al., 1997) (Fig. 3). FLIP contains DEDs, and 
binds to the prodomains of procaspase 8, thereby interfering with the 
FADD-caspase-8 interaction (Tschopp, Irmler et al., 1998). 
In the stress-induced pathway, Bcl-2 family proteins either inhibit 
(Bcl-2, Bcl-XL) or promote (Bax, Bak, Bik, Bid) apoptosis through regulation 
of cytochrome c release (Fig. 4). In the case of C. elegans, CED-9 can prevent 
caspase activation by binding to the adaptor CED-4 (Chinnaiyan, 
Chaudhary et al., 1997; Spector, Desnoyers et al., 1997; Wu, Wallen et al., 
1997). Anti-apoptotic Bcl-2 family members can in turn be regulated by 
other, proapoptotic Bcl-2 family members that interact via the Bcl-2 
homology domain BH3 (Muchmore, Sattler et al., 1996; Conradt and Horvitz, 
1998). For example, the "BH-3 only" protein BAD can bind to and inhibit 
Bcl-X, and its ability to do so can be regulated by phosphorylation. This is 
one way in which signaling molecules such as PKB/AKT can promote cell 




1.3 Caspases and their role in apoptosis 
1.3.1 Structure of caspases and processing of zymogens 
The key effector components of apoptosis are caspases, a family of 
cysteine proteases that cleave their substrates adjacent to aspartate residues. 
Fourteen mammalian caspases have been identified, including 12 human 
forms. Caspases are synthesized as zymogens or proenzymes 
(approximately 30-50 kDa) containing a N-terminal prodomain together 
with one large (approximately 20 kDa) and one small (approximately 10 
kDa) subunit. Crystal structures suggest that the active enzymes are 
heterodimers, composed of two small and two large subunits, presenting 
two catalytic sites. Importantly, specific aspartic acid cleavage sites exist 
between the prodomain of a caspase and each of its subunits, allowing the 
possibility of a caspase cascade, in which one caspase can process and 
activate another (Earnshaw, Martins et al., 1999). With the exception of one 
other cell death-related protease, granzyme B, the only mammalian enzymes 
known to activate caspases are the caspases themselves (Darmon, Ley et al., 
1996; Martin, Amarante-Mendes et al., 1996). 
1.3.2 Initiator and effector caspases 
Caspases can be subdivided based on a number of criteria including 
phylogenetic analysis, substrate specificity, and the length of their 
prodomains (Fig. 5). "Initiator' caspases, including caspases -8 and- 9, 
contain long prodomains which allow them to interact with specific adaptor 
proteins. Such interactions bring initiator caspases in close proximity to one 
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another and promote the activation of one zymogen by another. Initiator 
caspases are responsible for directly or indirectly activating various 
"effector" caspases, including caspases -3, -6, and -7, which contain short 
prodomains. Effector caspases cleave a number of structural and regulatory 
proteins and are directly responsible for many of the features of apoptotic 
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Figure 5. Diagram showing the structure of the caspase zymogens. 
Initiator and effector caspases and a list of subgroups of caspases. The 
amino-terminal prodomains are shown in yellow, large subunits are in blue, 
and small subunits are shown in green. Initiator caspases have a long 
prodomain which contains either two death effector domains (DED)-caspase 
8 and 10 or a caspase recruitment domain (CARD)-caspase 9 (Chinnaiyan, 
O'Rourke et al., 1995; Hofmann, Bucher et al., 1997). Effector caspases have a 
short prodomain. The active heterotetrameric enzyme (right) results from 
proteolytic activation. Caspases can be divided into subgroups according to 
their role. The Caspase-1 subfamily is mainly responsible for inflammatory 
response. The Caspase-3 subfamily, including initiator caspases and effector 







1.3.3 Regulation of caspases 
Caspase activation is tightly regulated at several levels. Caspase 
zymogen levels are transcriptionally regulated (Droin, Dubrez et al., 1998). 
Activation of caspase zymogens by death receptor-associated scaffolds can 
be regulated by FLIP (discussed in chapter 1.2.3). Activation of procaspase-9 
by the Apaf-1:cytochrome c scaffold appears to be regulated by anti-
apoptotic Bcl-2 family (discussed in chapter 1.2.3). Caspase activation and 
activity are regulated by interactions with inhibitor-of-apoptosis (TAP) 
proteins. TAP family proteins were originally identified in viruses but seven 
mammalian homologues of baculovirus lAP proteins have been identified 
(Deveraux and Reed, 1999). It was demonstrated that several human TAP 
proteins inhibit caspases directly(Roy, Deveraux et al., 1997). It was also 
shown that lAP proteins act upstream of caspases in Drosophila (Wang, 
Hawkins et al., 1999). Finally, active caspases also appear to be regulated by 
post-translational modifications. It was demonstrated that caspases are 
phosphorylated in vivo using human leukemia HL60 cell line, and that the 
phosphorylation can affect their enzymatic activity in vitro (Martins, Kottke 
et al., 1998). 
1.3.4 Substrates of caspase and consequence of their cleavage 
More than forty caspase substrates have been identified, including a 
number of structural components of the cytoskeleton and nucleus, as well as 
numerous proteins involved in signaling pathways (Earnshaw et al., 1999). 
Figure 6 summarizes these substrates and the consequence of their 
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cleavages. The cleavages result in turning off the survival pathway and 
promoting cell death. At least 13 protein kinases are known to be cleaved 
during apoptosis. Many of these cleavages produce catalytically competent 
fragments with increased activity that promotes cell death. Furthermore 
cytoskeleton-associated cell survival pathways are disrupted. To survive, 
most normal cells in metazoans must be integrated into a tissue via contacts 
with a specific extracellular matrix and interactions with neighboring cells. 
Caspases cleave the cytoskeletal proteins on which those signaling pathways 
depend in addition to disrupting the protein kinase cascade. Transcription 
factors involved in cell survival pathways are the target of caspases. In 
addition, cellular damage-monitoring networks are disrupted. Cell cycle 
arrest and DNA repair mechanisms are impaired by caspase cleavage. 
Finally cleavages of nuclear structural proteins facilitate the apoptotic 
morphological changes and caspase cleavage activates /inactivates proteins 
such as Bid and ICAD, which have direct roles in apoptosis. Particularly, 
cleavage of ICAD liberates CAD to induce internucleosomal DNA cleavage, 
which is one of the hallmarks of apoptosis (chapter 1. 4). 
To investigate the physiological functions of each caspases, transgenic 
mice deficient in various caspases have been generated. Although to date, 
targeted disruption of caspases 1, 2, 3, 8, 9, 11 and 12 in mice have been 
reported, none of these mutations abolishes all apoptosis during 
development (Zheng and Flavell, 2000). In each case, defects in apoptosis 
are both cell type- and stimulus- dependent. Thus, apoptotic pathways 
must use different caspase repertoires in different tissues and in response to 

different stimuli. Since the design of specific small-molecule inhibitors has 
been a major challenge, this kind of genetic approach will help not only to 
understand the mechanism of apoptosis but also the contribution of 
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Figure 6. Caspase cleavages promote cell death and turn off survival 
pathways. Upon caspase cleavage, proteins shown in red promote cell 
death and proteins shown in green, which work for cell survival, become 
impaired. Proteins with * become toxic only after caspase cleavage. From 
top left, pRb (retinoblastoma), mdm2, p21, p2.7, Weel kinase, and APC 
(adenomatous polyposis coli) are involved in regulation of cell cycle and 
proliferation. NF-KB and STAT-i are involved in gene expression. 
Plakoglobin, 0-catenin, cytokeratin 18, presinilin-1, paxillin, Gas2 and 
gelsolin are abundant cytoplasmic proteins involved in signal transduction. 
Raf, FAK (focal adhesion kinase), RasGAP (Ras GTPase-activating protein), 
PP2A (Protein phosphatase 2A subunit Aa) and Akt (Protein kinase B) are 
also involved in signal transduction. Bad, Bcl-2, Bcl-XL, Bid, ICAD/DFF, 
Calpastatin, and Bap3l have direct roles in apoptosis. PAK2, Msti /Krs, 
MEKK1, PKCO, and PKC6 are kinases (Based on a figure by Bill Earnshaw). 
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1.4 CAD and ICAD family proteins and other chromatin condensation 
factors 
CAD (caspase activated deoxyribonuclease) induces internucleosomal 
DNA cleavage, which is one of the hallmarks of apoptosis (Wyllie, 1980). 
ICAD is an inhibitor of CAD. CAD, ICAD and CIDE (cell death inducing 
DFF45 like effector) proteins have homology in their N-terminus (fig. 7). 
The CIDE-N/CAD domain is responsible for interaction between these 
proteins. 
1.4.1 Identification of apoptotic nuclease 
Cleavage of chromatin at internucleosomal sites was first reported in 
dying cells by the Czech radiobiologist Miroslav Skalka (Skalka, Matyasova 
et al., 1976). Soon after, a "chromatin ladder' pattern of regular sized DNA 
fragments was recognized as characteristic of apoptosis (Wyllie, 1980). 
Despite intensive effort, the identities of the DNase(s) involved in apoptosis 
were unknown for many years. Cytosolic fractions from apoptotic cells 
contain a factor(s) that induces DNA degradation in isolated nuclei 
(Lazebnik, Cole et al., 1993; Newmeyer, Farschon et al., 1994; Enari, Hase et 
al., 1995), suggesting that a nuclease or its activating molecule(s) is generated 
in apoptotic cells. Early studies indicated that the DNase worked at a 
neutral pH and is Ca2 /Mg2 -dependent (Liu, Ribecco et al., 1999). Several 
candidates for the nuclease including DNase I, cyclophilins, DNase y  and 
DNase II (despite its acid pH dependence), were reported, but their 
properties were diverse enough to preclude identity with one another (Barry 
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and Eastman, 1993; Peitsch, Poizar et al., 1993; Montague, Gaido et al., 1994; 
Shiokawa and Tanuma, 1998). The enzyme variously called caspase-
activated DNase (CAD) / CPAN (caspase-activated nuclease)/DNA 
fragmentation factor 40 (DFF40) is the first confirmed apoptotic nuclease 
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Figure 7. ICAD, CAD family members. Schematic presentation of ICAD 
and CAD family members from human, mouse and Drosophila. All of them 
share the CIDE-N/CAD domain, which is important for homophilic 
interactions between family members. The CAD group has a catalytic 
domain which is responsible for DNase activity. The CIDE group has a 
CIDE-C domain, overexpression of which induces apoptosis. The ICAD 
group and dCAD contain caspase cleavage site(s), cleavage of which is 
necessary for the activation of CAD. Human and mouse ICAD-L and CAD 




Cytosolic extracts from living cells do not cause DNA degradation in 
nuclei, but treatment of the extracts with caspase-3 converts them to 
apoptosis-inducing, suggesting that living cells carry a proform of the 
molecules(s) that induce DNA degradation (Enari, Talanian et al., 1996). The 
nuclease responsible for DNA degradation was purified from cytosolic 
extracts of mouse T-cell lymphoma cells and named CAD (caspase-activated 
nuclease) (Enari et al., 1998). CAD exists as an inactive complex with ICAD-
L in healthy cells and cleavage of ICAD by caspase-3 liberates CAD. The 
released CAD forms a homo-oligomer that is enzymatically active (Liu, Zou 
et al., 1999). CAD is a basic protein consisting of 343 amino acids with a tell-
tale nuclear localization signal at the C-terminus. Subsequently, a human 
homologue of CAD, CPAN/DFF40, was identified (Halenbeck et al., 1998; 
Liu et al., 1998). 
CAD nuclease works best at pH 7.5, requires Mg2+,  not  Ca2+,  and is 
inhibited by Zn2 (Widlak, Li et al., 2000). It generates blunt ends or ends 
with a base 5-overhang possessing 5-phosphate 3-hydroxyl groups and is 
specific for double-stranded DNA (Widlak et al., 2000). These properties 
fulfill the criteria of the apoptotic nuclease that was proposed initially. CAD 
attacks sites that possess a dyad axis of symmetry with respect to purine and 
pyrimidine content (Widlak et al., 2000). CAD activity is enhanced by the 
presence of histone Hi, HMG-1 (high mobility group-1), HMG-2, and 
topoisomerase II, at least against naked DNA (Liu et al., 1998; Toh, Wang et 
al., 1998; Widlak et al., 2000). One of its most unusual properties is that CAD 
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is as active against chromatin as it is against naked DNA (Widlak et al., 
2000). The enzyme specifically attacks chromatin in the internucleosomal 
linker, lacks exonuclease activity and does not cause intranucleosomal 
cleavage (Widlak et al., 2000). Moreover, it has been suggested that CAD is 
also responsible for initial large-scale chromosomal DNA fragmentation (50-
200 kb) (Sakahira, Enari et al., 1999; Zhang, Lee et al., 2000). 
1.4.3 ICAD-L/-S (DFF45/DFF35) 
Cytosolic extracts from growing cells contain an inhibitory factor that 
blocks DNA fragmentation. However, treatment of extracts with caspase-3 
or with dATP and cytochrome c converts them to apoptosis-inducing 
extracts, suggesting that this inhibitory function can be inactivated by 
caspase cleavage (Liu, Zou et al., 1997). A heterodimeric protein was 
purified from HeLa cytosol and was designated DFF (DNA Fragmentation 
Factor), which consists of two subunits, 40 kDa and 45 kDa. The DFF45 
subuit is the inhibitor of the apoptotic nuclease DFF40/CAD; and cleavage 
of DFF45 by caspases at two sites generates an active nuclease (Liu et al., 
1997). Subsequently a protein called inhibitor of CAD (ICAD), which is the 
mouse homologue of DFF45, was identified (Enari Nature 1998). ICAD has 
two forms, ICAD-L and ICAD-S (also called DFF45 and DFF35) arising by 
alternative splicing of a single transcript (Sakahira, Enari et al., 1998) (Cu, 
Dong et al., 1999). Both isoforms have inhibitory activity against CAD in 
vitro; however, only ICAD-L/DFF45 seems to associate with CAD in living 
cells. Moreover, only ICAD-L/DFF45 functions as a folding chaperone 
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during the translation of CAD shown by an in vitro translation and 
baculovirus expression systems (Sakahira, Enari et al., 1999; Sakahira, 
Iwamatsu et al., 2000). DFF45/ICAD mutant mice showed activity of DFF45 
is essential for the folding of active CAD, since the CAD protein level was 
normal but CAD nuclease activity was entirely defective (Zhang, Liu et al., 
1998). 
In apoptotic cells, ICAD/DFF45 is cleaved at two sites primarily by 
caspase-3. Although both caspase-3 and caspase-7 can cleave ICAD at the 
correct sites in vitro (Liu et al., 1997; Sakahira et al., 1998), studies with 
caspase-3 knockout mouse and MCF-7 cells which lost caspase-3, showed 
that the endogenous level of caspase-7 fails to activate CAD/DFF40 (Janicke, 
Ng et al., 1998; Tang and Kidd, 1998; Wolf, Schuler et al., 1999). Cells 
transformed with a form of DFF45/ICAD-L uncleavable by caspases did not 
show DNA fragmentation after variety of apoptotic stimuli but were 
nonetheless killed by a caspase-dependent mechanism (Liu et al., 1998; 
Sakahira et al., 1998; Mcllroy, Sakahira et al., 1999). DFF45/ICAD mutant 
mice demonstrated that although DFF45/ICAD is critical for the induction 
of DNA fragmentation and chromatin condensation in vivo, it is not required 
for immune system development (Zhang et al., 1998). 
1.4.4 Localization of CAD/ICAD complex 
Localization of the inactive CAD/ICAD complex in healthy cells has 
been controversial. Originally CAD and ICAD were purified from cytosolic 
extracts and a nuclear localization signal was predicted at the carboxyl 
26 

terminus of CAD (Enari et al., 1998). It was initially proposed that the 
CAD/ICAD complex remains in the cytosol until the activation of CAD by 
destruction of ICAD, because ICAD shields the CAD NLS from nuclear 
import receptors. Activated CAD enters the nucleus due to the accessibility 
of its NLS and digests the chromosomes (Enari et al., 1998). However, we 
and other groups showed that both CAD and ICAD-L localize in the nuclei 
in living cells and we identified a functional NLS at the C-terminus of ICAD-
L (Liu et al., 1998; Samejima and Earnshaw, 1998; Samejima and Earnshaw, 
2000). 
The interaction between ICAD and CAD is first mediated by a N-term 
homology region, CIDE-N/CAD domain, and is then stabilized by 
interactions between the middle region of ICAD and the C-terminus of CAD 
(Mukae, Enari et al., 1998; Cu et al., 1999; McCarty, Toh et al., 1999). The 
solution structure of the CIDE-N/CAD domain was determined by NMR 
(Lugovskoy, Zhou et al., 1999; Uegaki, Otomo et al., 2000). The CIDE-
N/CAD domain, CAD (amino acids 1-87), contains one alpha helix and five 
beta strands. This is different from other apoptotic domains containing six 
or more compact alpha helices (Uegaki et al., 2000). The structure was 
categorized in the ubiquitin superfold family (Uegaki et al., 2000). 
1.4.5 CAD and ICAD genes and their expression 
In humans, both CAD and ICAD genes are assigned at the short arm 
of chromosome 1p36 (Mukae et al., 1998). One pseudogene of hCAD was 
also identified (Mukae et al., 1998). hCAD mRNA expression level is 
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dependent on the tissue/cell line. The expression level of hCAD seems to be 
correlated to the extent of DNA fragmentation during apoptosis in differing 
cell types (Mukae et al., 1998). 
In mouse, both the CAD and ICAD genes are assigned to the distal 
part of murine chromosome 4 which corresponds to human 1p36 (Kawane, 
Fukuyama et al., 1999). The CAD and ICAD genes comprise about 11 and 16 
kb, respectively (Kawane et al., 1999). Both CAD and ICAD mRNAs are 
expressed at high levels in spleen, thymus, small intestine and lymph nodes 
(Kawane et al., 1999). The promoter region of the CAD gene is very C and C 
rich as found in many ubiquitous house-keeping genes (75% C/C). 
However, the promoter region of ICAD has only 42% C/C and is regulated 
by different mechanisms (Kawane et al., 1999). 
1.4.6 Drosophila CAD and ICAD and other family members 
Recently Drosophila ICAD and CAD family members have been 
identified. These include dICAD/Drep-1, dCAD/Drep-4, Drep-2, Drep-3 
(Inohara and Nunez, 1999). They all have a CIDE-N/CAD domain and in 
vitro assays suggest that they interact with each other (Inohara and Nunez, 
1999). Similarities of dICAD and dCAD to the human homologues are not 
very high (identity 17% and 22%, respectively) and dICAD can neither 
inhibit nor work as a folding chaperone of mCAD (Mukae, Yokoyama et al., 
2000). Interestingly, Drosophila seems to have only the ICAD-L form which 
contains one caspase cleavage site (Mukae et al., 2000). Moreover, dCAD has 
a caspase cleavage site which has to be cleaved together with the caspase 
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cleavage site within dICAD (Yokoyama, Mukae et al., 2000). dCAD does not 
have nuclear localization signal (Yokoyama et al., 2000). All these indicate 
that the activation and regulation mechanism of ICAD/CAD in Drosophila 
may differ from those of their mammalian counterparts. The functions of 
Drep-2 and Drep-3 are not known, but they might be involved in the 
regulation of dICAD/dCAD. 
Mammals express other CAD/ICAD related proteins such as CIDE 
(cell death inducing DFF45 like effector) -A and -B and FSP-27, whose 
expression pattern is more limited than those of ICAD/CAD (Inohara, 
Koseki et al., 1998). These proteins share not only the dDE-N/CAD domain 
but also another domain, dDE-C. Overexpression of dDE-A in 293T cells 
induced apoptosis and DNA fragmentation. This activity depends on the 
dDE-C domain and is not inhibited by caspase inhibitors (Inohara et al., 
1998). DFF45 inhibits the dDE-C apoptosis-inducing activity but requires 
the dDE-N domain for the inhibition (Inohara et al., 1998). Mitochondria 
localization and dimerization are both required for CIDE-B induced 
apoptosis (Chen, Guo et al., 2000). Although it is proposed that these 
proteins have a regulatory role in CAD activation, their physiological 
functions are not known (Inohara et al., 1998). 
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1.4.7 Chromatin condensation factors 
Several proteins have been identified or claimed as chromatin 
condensation factors during apoptosis, including CAD (chapter 2), topo ha 
(chapter 4), mitochondrial flavoprotein AIF (apoptosis-inducing factor), 
acinus, L-DNase II, Catheptin, DNase I, and DNase II (Sahara, Aoto et al., 
1999; Susin et al., 1999; Zamzami and Kroemer, 1999). For example, once 
apoptosis is induced, AIF translocates from the mitochondria to the nucleus 
and causes partial chromatin condensation at the periphery of the nucleus. 
AIF causes degradation of DNA into fragments greater than around 50 kb in 
length (Susin et al., 1999). Acinus localizes in the nucleus of healthy cells and 
cleavage of acinus by caspase-3 and an additional (unknown) protease 
induces chromatin condensation in vitro. Acinus does not induce DNA 
cleavage (Sahara et al., 1999). It is not known why there are so many 
chromatin condensation factors. These factors might work in a cell/tissue 
specific manner or work in a co-operative way. They might be redundant to 




1.5 Cell free systems for the study of apoptosis 
1.5.1 Advantages of cell free systems 
Biochemical analysis of apoptotic pathways would have been difficult 
without the use of cell free system. Several cell free systems have been 
devised that recapitulate the morphological changes of apoptosis using 
components isolated from cells such as nuclei, cytoplasm, and organelles 
(Lazebnik et al., 1993; Chow, Weis et al., 1995; Earnshaw, 1995; Enari et al., 
1995; Martin, Newmeyer et al., 1995; Liu, Kim et al., 1996; Zamzami, Susin et 
al., 1996). 
One advantage of the cell free system approach is that it can 
overcome the stochastic nature of the onset of apoptotic events in cell 
populations. Upon receipt of an apoptotic stimulus, cells enter a condemned 
phase, a latent period during which the cells are committed to apoptosis but 
show no overt signs of the cell death process. This condemned phase is 
followed by an execution phase, during which the cells develop the 
sequential morphological changes characteristic of apoptosis. The 
condemned phase is highly variable in length among individual cells. Thus, 
cells harvested at any moment from a culture undergoing apoptosis will be a 
mixture of those in the condemned phase and those in different stages of the 
execution phase. This greatly complicates the biochemical analysis of 
apoptotic events. Biochemical analysis of apoptosis in tissues is even more 
difficult, since generally less than one percent of cells can be seen as 




In a cell free system, added exogenous nuclei reproduce apoptotic 
changes in a highly synchronous manner. Isolated nuclei from healthy cells 
exhibit nuclear and chromatin condensation and ultimately result in 
apoptotic bodies. Internucleosomal DNA cleavage is also observed. 
1.5.2 S/M extracts 
The first cell free system for apoptosis was developed in our 
laboratory, using extracts from chicken DU249 hepatoma cells committed to 
apoptosis as a consequence of a 12 hr cell cycle arrest with aphidicolin 
(Wood and Earnshaw, 1990). After release from the S-phase block, these 
DU249 cells proceed normally through the reminder of the cell cycle. 8-10 hr 
after mitosis, the cells begin to enter the apoptotic execution phase and 
display an apoptotic morphology. To prepare the extracts, condemned 
phase cells are harvested in the intervening mitosis, at which time they 
appear normal by both light and electron microscopy. In practice, 6 hr after 
release from the S-phase block, cells are blocked again in M-phase with 
nocodazole. Harvested cells are washed, lysed and centrifuged. The highly 
concentrated cytoplasmic fraction, obtained as a supernatant, was termed 
S/M extract due to the double block in S-phase and M-phase. The S/M 
extracts are capable of inducing all morphological and biochemical changes 
characteristic of apoptosis in isolated nuclei in the presence of an ATP 
regeneration system (Lazebnik et al., 1993). The entire apoptotic process is 
inhibited in vitro by caspase inhibitors (Lazebnik, Kaufmann et al., 1994) or 
millimolar concentration of Zn2 (Lazebnik et al., 1993). Although nuclei 
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from a wide range of healthy cells are used in these studies, the extracts 
themselves are derived from the cytoplasm of the DU249 cells (Lazebnik et 
al., 1993), thus supporting the view that cytoplasmic factors and events have 
an essential role in the apoptotic pathway (Jacobson, Burne et al., 1994; 
Schulze-Osthoff, Walczak et al., 1994; Nakajima, Golstein et al., 1995; Martins 
and Earnshaw, 1996; Kroemer, Zamzami et al., 1997). 
1.5.3 Contributions of cell free systems to studies of apoptosis 
The first two caspase substrates, PARP and lamins were identified 
employing S/M extracts (Lazebnik et al., 1994; Lazebnik, Takahashi et al., 
1995). Since then many other caspase substrates have been identified using 
a variety of in vitro systems (Earnshaw et al., 1999). Moreover involvement 
of mitochondria in the apoptotic process was first shown in apoptotic 
Xenopus egg extracts (Newmeyer et al., 1994). Subsequently it was shown 
that addition of cytochrome c and dATP or ATP can convert non-apoptotic 
extracts to apoptotic extract (Liu et al., 1996). Apaf-1, DFF and CAD which 
are also key components of apoptosis process were then isolated from such 
extracts (Liu et al., 1997; Zou et al., 1997; Enari et al., 1998). 
In chapter 2, we describe an extention of this approach by preparing 
extracts from cells at various stages of the apoptotic pathway in order to 
further evaluate caspase involvement in nuclear disassembly. 

1.6 Purpose of this study 
1.6.1 Purpose of this study 
The aim of this study was to elucidate the biochemical mechanisms 
which underlie the morphological changes of the nucleus during apoptotic 
execution. Although caspases are known to play essential roles during 
apoptosis, it was not clear whether caspases directly drive the nuclear 
disassembly or whether downstream factors activated by caspases play such 
a role. In this study, chromatin condensation and DNA fragmentation were 
employed as an assay for nuclear apoptosis. 
1.6.2 Studies with cell free systems 
Cell free systems were employed to clarify the role of caspases in 
nuclear disassembly. These systems have a number of advantages for the 
study of apoptotic nuclear morphological changes. First, nuclei incubated in 
the extracts synchronously enter apoptotic execution phase. Second, 
biochemical approaches such as fractionation and addition of inhibitors are 
possible. Third, it is possible to prepare extracts which represent different 
stages of apoptosis such as the condemned and execution phases. The 
results obtained with these extracts are shown in Chapters 2 and 4. 
1.6.3 Localization of CAD and ICAD 
Proteins have to be expressed and/or activated at the right time in the 
right place to control the progression of apoptosis. Following the 
identification of chromatin condensation factors, it is important to 

investigate their localization before and during apoptosis. It was reported 
that nuclear transport is necessary for nuclear apoptosis in Fas-mediated 
apoptosis (Yasuhara, Eguchi et al., 1997). Originally CAD and ICAD were 
isolated from cytosolic extracts. Thus it was claimed that CAD is the factor 
which is transported into the nucleus upon the onset of apoptosis. This 
hypothesis was examined in this study (Chapter 3). 
1.6.4 Role of topoisomerase ha in apoptosis 
It was suspected that topoisomerase II, which catalyzes DNA 
topological transformations in normal cells might also involved in chromatin 
condensation during apoptosis. Recently it was reported that topo ha is 
involved in reversible high molecular weight DNA cleavage after oxidative 
stress (Li, Chen et al., 1999). Indeed this study provided evidence that topo 
II does have a role during apoptosis (Chapter 4). 

Chapter 2 
2. Transition from caspase-dependent to caspase-independent 
mechanisms at the onset of apoptotic execution 
2.1 Introduction 
The involvement of caspases in apoptosis was first demonstrated in 
1990 (Yuan and Horvitz, 1990; Yuan, 1995). Then the first apoptotic 
substrate of caspases was identified in 1994 (Lazebnik et al., 1994). Within 
less than seven years, more than three thousand publications treating of 
caspases appeared and many of the essential features of caspases were 
revealed. Nonetheless, the role of caspases in the death pathway remains 
unclear. Recent studies have suggested that under certain circumstances 
cells can activate caspases without undergoing apoptosis (Boise and 
Thompson, 1997; Wang and Lenardo, 2000). Conversely, even though 
caspase inhibitors usually rescue cells from apoptosis (Villa, Kaufmann et al., 
1997), cell death can occur in response to proapoptotic stimuli in the 
presence of these inhibitors (Xiang, Chao et al., 1996; McCarthy, Whyte et al., 
1997; Lavoie, Nguyen et al., 1998). 
Careful examination revealed that cells dying in the presence of 
caspase inhibitors display membrane blebbing and cell surface alternations 
but no dramatic changes in nuclear morphology (McCarthy et al., 1997). 
This observation suggests that certain cytoplasmic hallmarks of apoptosis 
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may be triggered by enzymes other than caspases, but that nuclear events 
require caspase activity. Consistent with this view, cells from caspase-3-null 
mice (Woo, Hakem et al., 1998) have been reported to display plasma 
membrane changes and cleavage of the nuclear protein poly (ADP-ribose)
polymerase (PARP) when undergoing apoptosis, but not the chromatin 
condensation and DNA cleavage that are characteristic of apoptosis (Wyllie, 
1980). 
The preceding observations suggest that caspases play a role in 
certain apoptotic events, particularly those occurring in the nucleus. 
However, it is not known whether caspases have an executive role in 
initiation of the apoptotic pathway and leave the work of actually 
disassembling the cell to other downstream factors, or whether they are 
workhorses whose cleavage of key substrates drives cellular disassembly. 
Support for an executive role comes from the observation that expression of 
the caspase cleavage product of the actin-binding protein GAS2 triggers 
cytoskeletal changes similar to those seen in apoptosis (Brancolini, Benedetti 
et al., 1995). Likewise, caspase cleavage of ICAD/DFF45 (inhibitor of 
caspase-activated DNase/DNA fragmentation factor) releases the nuclease 
CAD/DFF40, allowing it to degrade genomic DNA (Liu et al., 1997; Enari et 
al., 1998; Sakahira et al., 1998). Thus, certain products of caspase cleavage 
play important downstream roles in apoptotic events. On the other hand, 
numerous important structural and nonstructural proteins are also directly 
cleaved by caspases (Cohen, 1997; Nicholson and Thornberry, 1997; Porter, 
Ng et al., 1997; Villa et al., 1997), supporting the alternative hypothesis that 
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caspase do the bulk of work of cutting the cell apart themselves (Martin and 
Green, 1995). 
The aim of the present study was to prepare extracts from cells at 
various stages of the apoptotic pathway in order to further evaluate caspase 
involvement in nuclear disassembly. Interestingly, extracts prepared from 
morphologically normal cells in the latent phase (S/M extracts) and those 
prepared from overtly apoptotic cells ("execution phase extracts") induced 
similar apoptotic events in exogenous nuclei but exhibited fundamental 
biochemical differences. In particular, apoptotic events in S/M extracts were 
abolished by caspase inhibitors as previously reported (Lazebnik et al., 1994); 
whereas the same events in execution phase extracts were not affected by the 
inhibitors. Further examination revealed that execution phase extracts 
contain at least two caspase-activated factors required for nuclear 
disassembly, one of which appears to be the nuclease CAD. These 
experiments not only support the view that caspases act in an executive role 
in nuclear apoptosis by activating downstream factors that disassemble 
nuclei, but also suggest that activation of the downstream factors (rather 
than the caspases) accompanies the transition between the latent and 
execution phases of apoptosis. 

2.2 Materials and Methods 
2.2.1 Cell treatment and preparation of extracts 
Chicken DU249 cells were presynchronized in S phase with 
aphidicolin for 12 hr, released from the block for 6 hr, and synchronized in 
mitosis with nocodazole for 3 hr as described previously (Wood and 
Earnshaw, 1990; Lazebnik et al., 1993). DU249 cells start to undergo 
apoptosis asynchronously during and after the aphidicolin treatment, 
presumably as a result of the cell cycle disruption. E/X ('execution" phase) 
extracts were prepared from the floating cells (mostly apoptotic) obtained 
from the flasks just before the addition of nocodazole. S/M extracts were 
prepared from floating cells (>60% mitotic) obtained from the same flasks by 
selective detachment after the nocodazole treatment. After harvesting of 
cells for S/M extract production, cells for the preparation of C/D 
("condemned" phase) extracts were obtained from the attached (interphase) 
cells by rinsing the same flasks with PBS-EDTA and trypsinization. Large 
scale "roller S/M' extract was prepared as described above for S/M extract 
except that cells were grown in roller bottles. 
In each case, the cells were then washed with KPM buffer (50 mM 
Pipes-KOH, H 7.0,50 mM KC1, 10 mM EGTA, 2 mM M902,  20 pM 
cytochalasin B (Sigma), 1 mM DTT, 0.1 mM PMSF, 1 pg/ml each 
chymostatin, leupeptin, antipain, pepstatin A) (Wood and Earnshaw, 1990) 
and centrifuged in a small glass Dounce homogenizer. The cells were 
subjected to several cycles of freezing and thawing and further disrupted by 
grinding during each thawing cycle. The cell lysate was then centrifuged at 
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139,000 x g for 2 hr, yielding clear cytosolic extracts. The protein 
concentration of each extract was measured by the Bradford assay 
(Bradford, 1976). Extract concentrations ranged between 12 and 18 mg/mi. 
2.2.2 Time course of caspase activation 
DU249 cells were subjected to the synchrony procedure used in 
preparation of S/M extracts. At the indicated times (0, 5, 10, 15, 20 hr) 
following the addition of aphidicolin, both floating and attached cells were 
harvested from two T150 flasks (the former by shake-off, the latter by 
trypsinization). Cells were washed with MDB buffer (10 mM Pipes-KOH, 
H 7.0,50 mM NaCl, 5 mM EGTA, 2 mM MgC12, 1 mM DTT) (Wood and 
Earnshaw, 1990) and the number of cells of each sample was counted using 
a hemacytometer. The ratio of interphase, mitotic, and apoptotic cells in 
each sample was determined by examination of the nuclear morphology 
after cells (n > 400 for each time point) were fixed in methanol-acetic acid 
(3:1) for several min at room temperature and stained with 0.5 jig/ml 4,6-
diamidino-2-phenylindole (DAPI; Calbiochem). Cells were lysed by the 
freeze / thaw / grinding protocol described above. Lysates (the 
supernatants following centrifugation at 13,000 x g for 15 min at 4°C) were 
affinity labeled with zEK(bio)D-aomk as described below. 
2.2.3 In vitro apoptosis reaction 
Apoptotic and control extracts were preincubated at 37°C for 15 mm 
with 100 jiM caspase inhibitors (YVAD-cmk or DEVD-fmk) or diluent. HeLa 

nuclei prepared as previously described (Wood and Earnshaw, 1990; 
Lazebnik et al., 1993) were then added (up to 1.0 x 106  nuclei/ 10 p1 of 
extract) and incubated at 37°C for up to 2 hr in the presence of an ATP 
regeneration system (Wood and Earnshaw, 1990; Lazebnik et al., 1993). 
Nuclei were either stained with DAPI to observe chromatin condensation, 
solubilized in SDS-sample buffer for analysis of protein cleavage, or lysed 
for analysis of DNA ladder formation (see chapter 2.2.7). 
2.2.4 Caspase labeling 
Stock solutions (10 mM in DMSO) of caspase inhibitors (YVAD-cmk 
or DEVD-fmk from Calbiochem) were diluted immediately before use with 
MDB buffer. Extracts were preincubated at 37°C for 15 min with 100 pM 
YVAD-cmk or DEVD-fmk or diluent. After Z-.EK(bio)D-aomk (Martins, 
Kottke et al., 1997)that binds to the catalytic site of caspases was added to a 
final concentration of 1 pM from a 100X stock solution in DMSO, extracts 
were incubated at 37°C for 15 mm. Labelled proteins were subjected to 
conventional 16% SDS-PAGE (Laemmli, 1970), transferred to nitrocellulose 
membrane, probed with peroxidase-coupled streptavidin, and visualized by 
ECL (Amersham Corp.). Since the catalytic site exist in large subunit, it is 
possible to recognize different caspases by the size of large subunit (Fig 8, 9). 
2.2.5 Fluogenic assays of caspases (Performed by the laboratory of Scott 
Kaufmanns using extracts prepared by me.) 
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DEVD-AFC cleavage activity was determined by a slight modification 
of previously described methods (Martins et al., 1997). Extracts were 
preincubated with caspase inhibitors or diluent for 15 min at 37°C. Samples 
containing 20-30 ig  of various fractions or 25 ig of cytosolic protein 
(estimated by the Bradford assay) from etoposide-treated K562 leukemia 
cells (a positive control) were diluted to 50 p1 with buffer A (25 mM HEPES 
(pH 7.5), 5 mM MgC12, 5 mM EDTA, 1 mM EGTA supplemented 
immediately before use with 1 mM PMSF, 1 mM DTT, 10 pg/ml pepstatin 
A, and 10 pg/ml leupeptmn), mixed with 225 p1 freshly prepared buffer B (25 
mM HEPES (pH 7.5), 0.1% (w/v) CHAPS, 10 mM DTT, 100 U/ml aprotinin, 
1 mM PMSF) containing 100 pM DEVD-AFC (Enzyme System Products, 
Dublin, CA), and incubated for 4 hr at 37°C. Reactions were terminated by 
addition of 1.225 ml ice cold buffer B. Fluorescence was measured in a 
Sequoia-Turner spectrofluorometer using an excitation wavelength of 360 
nm and emission wavelength of 475 nm. After subtraction of fluorescence in 
blank samples (lacking protein), amounts of the liberated fluorophore were 
determined by comparison to a standard curve containing 0-1500 pmoles of 
7-amino-4-trifluoromethylcoumarin. Control experiments indicated that 
product release was linear with respect to incubation time and extract 
protein under the conditions utilized. 
2.2.6 PARP and lamin cleavage 
After HeLa nuclei (5 x 105 per loading) were incubated in extract for 2 
hr at 37°C, the reaction was stopped by the addition of sample buffer. 
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Samples were boiled at 95°C for 5 mm, sonicated briefly, subjected to 10% 
conventional SDS-PAGE (Laemmli, 1970; Wood and Earnshaw, 1990; 
Lazebnik et al., 1993), and transferred to nitrocellulose. PAR]? and its 89 kDa 
cleavage product were detected with the C-2-10 monoclonal antibody 
(Lamarre, Talbot et al., 1988). Lamins A/C and their cleavage product were 
detected with a rabbit polyclonal antibody recognizing the N-terminus of 
the protein (gift of Larry Gerace). Bound antibody was detected by ECL. 
2.2.7 DNA ladder formation 
HeLa nuclei (5x 105 per loading) were incubated for 1-2 hr in extract, 
centrifuged, and lysed in DNA lysis buffer (50 mM Tris:HC1 pH 8.0, 10 mM 
EDTA, 0.5% Sarcosyl, 0.5 mg/ml proteinase K) at 50°C for 1 hr. DNA was 
treated with RNase at 50°C for 1 hr, phenol /chloroform extracted, ethanol-
precipitated overnight at -70°C, resuspended in TE, and loaded onto 1% 
agarose gels containing 0.5 pg/ml ethidium bromide. 
2.2.8 Plasmid DNA digestion assay 
Extracts (18 -36 pg protein in 10 p1 of KPM buffer) supplemented with 
an ATP regeneration system (Wood and Earnshaw, 1990) and 100 pM 
DEVD-fmk (or diluent) were incubated at 37°C for 15 mm. Following 
addition of 160 ng purified GST-ICAD (Sakahira et al., 1998), incubation was 
continued for an additional 10 min at 37°C. Upon addition of substrate 
(pBluescript - 1.2 Vg), incubation was continued for 30 mm. at 37°C. DNA 
extraction and electrophoresis were then performed as above. Southern 
43 
_; 	 - 
blotting best saw the results of the preincubation assay (Fig. 11). DNA 
agarose gels were denatured for 30 min with denaturing buffer (1.5 M NaCl, 
0.5 M NaOH), neutralized for 30 min with neutralizing buffer (0.5 M 
Tris:HC1 pH 7.5, 1.5 M NaCl, 0.001 M EDTA), and transferred to nylon 
membrane (Hybond-N -- Amersham corp.) with 20 X SSC buffer. The nylon 
membrane was UV crosslinked and hybridized (Church and Gilbert, 1984) 
with a pBluescript probe that was labeled with 32P using the Megaprimer 
system (Amersham). The film was exposed for 1 hr at -80°C with an 
intensifying screen. 
2.2.9 Electron Microscopy (Steps after fixation were performed by Carol 
Cooke) 
Isolated HeLa cell nuclei incubated in extract or MDB buffer were 
centrifuged, washed with MDB buffer, placed on adhesion slides 
(Marienfeld) for 5 min and fixed for 30 min with 2% glutaraldehyde in 
Dulbecco's PBS pH 7.4. After fixation the nuclei were washed in 0.1 M 
cacodylate buffer, and postfixed with 4% 0s04 in 0.1 M sodium cacodylate 
pH 7.4 for 30 mm. Prestaining was done with 3% uranyl acetate in H20  for 
1 hr. The nuclei were dehydrated in ethanol (30%-100%) and embedded in 
Araldite resin (Agar). Gold sections were cut with a Reichert microtome and 
placed on copper grids. Images were photographed on a Philips CM100 
Biotwin electron microscope. 
2.2.10 Expression and purification of double mutant His6-ICAD 
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The method used for mutation was the PCR-based megaprimer 
strategy (Seraphin and Kandels-Lewis, 1996). Caspases absolutely require 
aspartic acid at the cleavage site, and mutation from D to E produces a 
caspase-uncleavable mutant. Primer 1 (T7 primer), primer 2 (5-
GCCCTGCTCTCAGGCTCATC-3), and primer 3 (5•- 
CAGCTCTGCACATGGGATGTC-3) were used to generate the DEPD117E 
mutation in the ICAD cDNA in pBluescript. Primer 4 (5-
CTGCTGTCAGAAGAGGACCTC-3), primer 5 (5-
GCCGACGCCTGTcTCAACTGC-3), and primer 6 (T3 primer) were used to 
generate the DAVD224E mutation in ICAD. Pirmers 2 and 5 contain the 
mutated sequences which are underlined. A second mutation in primer 2 
(A) was introduced for selection with a restriction enzyme and did not 
change the amino acids. Each single mutant was digested with Eco47 III 
(NEB) and Xba I (NEB) then ligated to generate double mutant ICAD in 
pBluescript. This double mutant ICAD was digested with Spe I, blunt-
ended with T4 DNA polymerase (NEB) plus 100 pM dNTPs, and digested 
with Kpn I (NEB). The resulting fragment was ligated into pRSET B 
(Invitrogen) that had been digested with Hind III, blunt-ended with T4 DNA 
polymerase, and digested with Kpn I. Double mutant ICAD in pRSET B was 
transformed into E. coli BL21 (DE3)Lys S cells. Transformed cells were 
grown to 0D600 = 0.5-0.7 and protein expression was induced with IPTG (1 
mM) for 3-4 hr. Cells were collected by centrifugation at 5000 x g for 10 mm 
and frozen at -80°C. The cell pellet was thawed on ice for 15 min and 
resuspended in lysis buffer (50 mM NaH2PO4 pH7.5, 300 mM NaCl, 10 mM 
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imidazole). Lysozyme was added to 1 mg/ml and the suspension was 
incubated on ice for 30 mm, sonicated on ice until 80% of the cells were 
disrupted, and then centrifuged at 4000 x g for 20 min at 4°C. The 
supernatant was incubated on a rotating mixer for 1 hr at 4°C with 0.5 ml of 
Ni-agarose (Qiagen) that had been pre-equilibrated with lysis buffer. The 
resin was then loaded onto a polyprep chromatography column (Bio-rad) 
and washed twice with 4 ml of wash buffer (50 mM NaH2PO4 pH7.5, 300 
mM NaCl, 20 mM imidazole). Protein was eluted four times with 0.5 ml of 
elution buffer (50 mM NaH2PO4 pH7.5, 300 mM NaCl, 250 mM imidazole). 
All samples were subjected to SDS-PAGE and examined by Coomassie blue 
staining. The eluted protein was dialyzed for at least 3 hr against two 
changes of CAD buffer (10 mM Hepes pH 7.4,50 mM NaCl, 5 mM EGTA, 2 
mM M902,  1 mM DTT), aliquoted, and frozen in N2(1). 
2.2.11 Expression and purification of His6-ICAD/CAD 
To express active CAD in E. coli, we constructed a bicistronic 
expression vector in which His6-ICAD was expressed upstream of CAD. In 
addition to the N-terminal histidine tag, the ICAD open reading frame was 
engineered to change the stop codon to TAA, and to insert a Shine-Delgarno 
sequence (GGAAT) downstream of the stop codon. The wild-type ICAD 
cDNA in pBluescript was digested with Spe I, blunt-ended with T4 DNA 
polymerase, and digested with Kpn I. The resulting fragment was ligated 
into pRSET B that had been digested with Hind III, blunt-ended with T4 




cDNA was extracted from the full length CAD cDNA in pBluescript by PCR 
using Vent polymerase (NEB) with primer 7 (5-
GGAATTCATGTGCGCGGTGCTCCG-3) and primer 8 (5-
GCGAAGCTTTCACTAGCGCTTCCGAG-3). The PCR product was 
digested with Eco RI and Hind Ill and the resulting fragment was ligated 
into pBluescript. 
To create the C-terminus of ICAD (from the Bsm I site at nucleotide 
909) engineering in a TAA stop codon and Shine-Delgarno sequence, primer 
9 (5'-GGAAGATCTGCATTCACTCAGGAATC-3) and primer 10 (5-
GGAATTCCTCCTTACGAGGAGTCTCGTTTG-3) were used with Vent 
polymerase. The PCR product was digested with Bgl TI (NEB) and Eco RI 
and ligated into pRSETB that had been digested with Bgl II and Eco RI. The 
CAD coding sequence in pBluescript was digested with Eco RI and Hind III 
and ligated into pRSET B containing the newly modified C-terminus of 
ICAD with the Shine-Delgarno sequence. This intermediate was then 
digested with Nhe I and Bsm I, and into it was inserted the His-tagged 
amino-terminal portion of ICAD, obtained from ICAD in pRSETB that had 
likewise been digested with Nhe I and Bsm I. This bicistronic vector His6- 
ICAD/CAD in pRSET B was transformed into E. coli BL21 (DE3)Lys S cells. 
Protein was expressed and purified by nickel chelate chromatography as 
described above for double mutant ICAD. The dialyzed ICAD/CAD 
protein was either frozen directly in N2(l)  or was frozen following addition 
of glycerol to 40%. 
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2.2.12 In vitro apoptosis with purified CAD 
50 pl reactions contained various combinations of the following 
reagents added sequentially (see legend to Fig. 12): 10 p1 ICAD/CAD 
protein (stored in CAD buffer plus 40% glycerol), 5 pl caspase-3, an ATP 
regeneration system (final conc. 0.8 mM ATP, 4.5 mM creatine phosphate, 
22.5 pg/rnl creatine kinase), DEVD-fmk (final conc. 300 pM), double mutant 
ICAD protein (2 pg), and CAD buffer as needed to make up the final 
volume. ICAD/CAD complexes were preincubated with caspase-3 at room 
temperature (approx. 25°C) for 30 min to cleave wild-type ICAD and release 
active CAD. At the end of this preincubation, diluent, DEVD-fmk or double 
mutant ICAD were added (defined as t = 0); and the mixture was divided 
into three aliquots to assay various apoptotic events. To examine ICAD 
cleavage during the preincubation, a 10 p1 aliquot was mixed with sample 
buffer, boiled, resolved by SDS-PAGE, transferred to nitrocellulose 
membranes, and probed with ICAD antibody (chapter 3), which was 
detected by ECL (Amersham). To assay CAD activity against a plasmid 
DNA substrate, a 6 p1 aliquot was supplemented with 0.35 pg pBluescript, 
BSA (final conc. 1 mg/ml) and 4 p1 of CAD buffer. This mixture was further 
incubated at 37°C for 30 mm, extracted with phenol-chloroform, and 
analyzed on a 1% agarose gel containing ethidium bromide. To examine the 
ability of the active CAD to induce apoptotic events, HeLa nuclei (1.3 x 106 
per sample) in 10 p1 CAD buffer were combined with the remaining 34 p1 
and incubated at 37°C for 2 hr. At the end of this incubation, 1 pl of the 
reaction mixture was stained with DAPI so that nuclear morphology could 

be examined by fluorescence microscopy (> 100 nuclei counted per slide). 
The remaining HeLa nuclei in 43 i.il of reaction mixture were centrifuged and 
prepared for agarose gel electrophoresis as described above. 

2.3 Results 
2.3.1 Extracts from three different stages of apoptosis. 
The apoptotic pathway can be conceptually divided into at least three 
stages (Fig. 8A). Upon receipt of a proapoptotic signal, cells enter a 
"condemned" stage: the death program is initiated, but cells can be rescued 
by various survival factors. Once cells pass a "point of no return", they are 
in the "committed" stage and can no longer be rescued. During both of these 
stages, preapoptotic cells appear morphologically normal. Eventually, 
committed cells undergo an abrupt transition into apoptotic execution, a 
period lasting 5 mm - 1 hr. during which cellular disassembly and death 
occur. It is not known where along this pathway caspases are activated and 
at what point the caspases activate other downstream factors that act during 
disassembly of the cell. 
It was previously noted that active caspases could be detected in 
extracts from etoposide-treated HL-60 cells several hours before the bulk of 
the cells in the culture exhibited an overtly apoptotic morphology (Martins 
et al., 1997). In order to study this phenomenon in greater detail, chicken 
DU249 cells were collected at various times after subjecting cultures to a 
synchronization protocol (Fig. 8B) shown previously to induce an apoptotic 
response in this cell line (Lazebnik et al., 1993). Floating cells obtained 10-15 
hr after the addition of aphidicolin were largely (-S  50%) apoptotic and 
contained high levels of active caspases, as detected by reactivity with the 
affinity-labeling reagent zEK(biotin)D-aomk (Martins et al., 1997) (Fig. 8 
C,D). Floating cells harvested following a change of medium and a two 
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hour treatment with nocodazole to induce a mitotic block, were 
predominantly (> 60 %) mitotic, with only 10 - 20 % of apoptotic cells. 
Despite the normal appearance of these cells, extracts prepared from them 
also contained high levels of active caspases. Cells that remained attached 
throughout the protocol were almost entirely in interphase, and extracts 
prepared from them lacked caspases detectable with zEK(biotin)D-aomk 
(Fig. 8D, left), although low levels of caspase activity were detectable when 
more sensitive assays were used (see below). 
The results of this experiment suggested that it might be possible to 
use a similar protocol to prepare extracts sequentially from the same flasks 
of cells at different stages of apoptosis (see Fig. 9A). C/D ("condemned" 
phase) extracts were prepared from the morphologically normal attached 
cells that did not enter mitosis or apoptosis during the synchrony procedure. 
Previous studies have indicated that these cells ultimately undergo 
apoptosis if left in culture (Lazebnik et al., 1993). S/M ("committed' phase) 
extracts (Lazebnik et al., 1993) were prepared from morphologically normal 
mitotic cells at the conclusion of the synchrony procedure. Because these 
cells are destined to rapidly undergo apoptosis if left in culture (Lazebnik et 
al., 1993), we postulate that S/M extracts reproduce events from the 
committed stage of apoptosis. E/X ("execution" phase) extracts were 
prepared from cells that were frankly apoptotic after a 12 hr exposure to 
aphidicolin followed by a 6 hr recovery period in medium. (Note that 
nonadherant cells were discarded at the end of the aphidicolin treatment, so 
these cells must have entered apoptosis during the 6 hr recovery period). 
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To examine the spectrum of active caspases during the three stages of 
apoptosis, extracts were assayed for their ability to cleave DEVD-AFC, for 
affinity labeling with z-EK(bio)D-aomk (Martins et al., 1997), and for the 
ability to cleave known caspase substrates in added nuclei. Collectively, 
these assays detect all known caspases. DEVD-AFC contains the preferred 
cleavage site of caspases-3 and 7 (Duan, Orth et al., 1996; Talanian, Quinlan 
et al., 1997) but is also cleaved by caspases-1, -2, -4, -6, -8 and -10 
(Fernandes-Alnemri, Litwack et al., 1995; Fernandes-Alnemri, Takahashi et 
al., 1995; Boldin, Goncharov et al., 1996; Fernandes-Alnemri, Armstrong et al., 
1996; Srinivasula, Fernandes-Alnemri et al., 1996; Talanian et al., 1997). z-
EK(bio)D-aomk covalently modifies all caspases tested to date (Martins et al., 
1997) and can detect over 30 active caspase species in apoptotic human 
leukemia cells. PARP is a documented substrate of caspases-3, -7, -8, and -9 
(Fernandes-Alnemri et al., 1995; Fernandes-Alnemri et al., 1995; Nicholson, 
Ali et al., 1995; Tewari, Quan et al., 1995; Duan et al., 1996; Muzio, 
Chinnaiyan et al., 1996), while lamin A is a substrate of caspase-6 (Takahashi, 
Alnemri et al., 1996). Application of these assays to C/D ("condemned" 
phase) extracts revealed low but detectable levels of active caspases (125-
fold less than S/M or FIX extracts in the DEVD-AFC assay, Fig. 9B) and 
some ability to cleave PARP (Fig. 9D, lane C/D), but no evidence of z-
EK(biotin)D-aomk labeling or lamin cleavage, suggesting that the latter 
assays are less sensitive. In contrast, S/M and E/X extracts contained high 
levels of active caspases that cleaved DEVD-AFC as well as PARP and lamin 
A (Fig. 9 B, D); and both had a similar pattern of active caspases following 
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affinity-labeling with z-EK(bio)D-aomk (Fig. 9C). These correspond 
primarily to active forms of caspases-3 and -6 (Faleiro, Kobayashi et al., 1997; 
Martins et al., 1997). All caspase activity detectable in these assays was 
quantitatively inactivated by treatment with YVAD-cmk (Fig. 9 C, D) or 
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Figure 8. Panel A: Diagram of apoptosis as a three stage process, with the 
latent phase being subdivided into condemned and committed stages. 
Panel B: The protocol used for harvesting of samples for examination of 
caspase activation. After addition of the aphidicolin, floating and attached 
cells were collected separately at every 5 hr. The relation between activation 
of caspases and nuclear morphology were compared in panel B and C. 
Panel C: The cells harvested as in panel B were scored for their nuclear 
morphology, based on DAPI staining (n>400/sample). Panel D: Affinity 
labeling of active caspases in whole cell lysates prepared from cells 
harvested as in panel B. Left panel, attached cells. Right panel, floating 
cells. The left most lane shows the profile of active caspases in S/M extract. 
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Figure 9. Apoptotic extracts contain active caspases that are functionally 
inactivated by specific inhibitors. Panel A: Protocol used to prepare C/D 
("condemned" phase), S/M ("committed phase") and E/X ("execution 
phase") extracts. Panel B: Quantitative analysis of DEVD-AFC cleavage 
activity in the various extracts. DEVD-fmk treatment of S/M and E/X 
extracts reduces caspase activity by at least 250- and 150- fold, respectively. 
Note the low but non-zero level of caspase activity in the C/D extracts. 
(Experiments in this panel were performed by the laboratory of Scott 
Kaufmann using extracts prepared by me.) Panel C: Several active caspases 
were labeled with zEK(biotin)D-aomk in S/M and E/X extracts. This 
labeling was completely blocked by prior incubation of extracts with YVAD-
cmk and DEVD-fmk (both at 100 1iM). Panel D: PARP and Lamin A/C 
cleavage by caspases in the cell-free extracts is abolished following caspase 
inactivation with YVAD-cmk and DEVD-fmk. Note that low levels of 




2.3.2 Differences in dependence of S/M and E/X extracts on ongoing 
caspase activity. 
C/D extracts ("condemned" phase) were unable to induce 
internucleosomal DNA fragmentation and apoptotic morphological changes 
in exogenous nuclei in spite of the weak caspase activity (Fig. 10 A, B). In 
contrast, S/M ("committed" phase) and E/X ("execution" phase) extracts 
showed strong caspase activity and nuclease activity and induced hallmark 
biochemical and morphological changes of apoptosis such as nuclear and 
chromatin condensation and DNA ladder formation in added nuclei. 
Further studies focused on these latter two extracts. 
Despite the similarities of the S/M and E/X extracts in terms of 
caspase activity (Fig. 9) and effects on exogenous nuclei (Fig. 10A,B), the two 
extracts displayed strikingly different properties following inhibition of the 
endogenous caspase activity. Pretreatment of S/M extracts with DEVD-fmk 
or YVAD-cmk prior to addition of nuclei not only inhibited caspase activity 
(Fig. 9 B-D), but also completely abolished their ability to produce 
internucleosomal DNA fragmentation (Fig. 10A) and induce morphological 
apoptotic changes (Fig. lOB). In striking contrast, E/X extracts that had been 
pretreated with caspase inhibitors continued to strongly induce 
internucleosomal DNA degradation (Fig. bA), chromatin condensation and 
fragmentation of added nuclei (shown both by light and electron microscopy 
- Fig. 10 B, C) despite a lack of detectable caspase activity (Fig. 9 B-D). My 
criteria of "non-apoptosis" and "apoptosis" in in vitro apoptosis is based on 
DAPI-stained nuclear morphologies, which are shown in figure 10D. 
Figure 10. Caspase inhibitors block apoptosis in S/M but not E/X extracts. 
Panel A. Inhibition of caspases blocks nuclease activity in S/M ("committed 
phase") extracts but not El X ("execution phase") extracts. As expected, Cl D 
("condemned" phase) extracts lack detectable nuclease activity. 
Experiments shown in Fig. 14 confirm that the nuclease activity is inhibitable 
by the specific CAD inhibitor ICAD I DFF45 (Enari et al. 1998; Liu, Zou et al. 
1997). B- buffer control. Panel B. Inhibition of caspases abolishes 
morphological apoptosis in vitro in S/M extracts but not EIX extracts. 
Nuclei shown in panel B were selected at random. Bar - 5 pm. Panel C. 
Morphological changes characteristic of apoptosis occur in E/X extracts 
independent of caspase activity: confirmation of apoptotic morphology by 
electron microscopy. Arrows indicate regions of condensed chromatin. Bar 
- 1 pm. Panel D. Criterian of "non-apoptotic" and "apoptotic" in nuclear 
morphology stained by DAPI. Apoptosis was defined by chromatin 
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2.3.3 Comparison of CAD activation in S/M and E/X extracts. 
Because the results presented in Figs. 9 and 10 suggest that the 
program of nuclear disassembly -- one of the distinguishing features of 
apoptotic cell death under physiological conditions (Wyllie, 1980; Wyllie, 
Kerr et al., 1980)-- is initiated by caspase activity but does not require the 
ongoing participation of caspases for its successful execution, we next 
turned our attention to caspase-activated downstream activities that might 
participate in nuclear disassembly. One of these activities is CAD/CPAN, 
the caspase-activated deoxyribonuclease recently identified in murine and 
human cells undergoing apoptosis (Enari et al., 1998; Halenbeck et al., 1998). 
Both S/M and E/X extracts contain an endogenous DNase activity that 
degrades added plasmid DNA (Fig. hA lanes 1, 4). Addition of 160 ng of 
murine ICAD to the extracts abolished this DNase activity (lanes 2, 5), 
indicating that this activity is functionally homologous to CAD. 
Even though CAD-like activity could be inhibited by ICAD in both 
S/M and E/X extracts, this activity appeared to be regulated differently in 
the two extracts. DEVD-fmk pretreatment abolished CAD-like activity in 
S/M ("condemned phase") extracts (Fig. hA lanes 1, 3), but had no effect on 
CAD activity in E/X ("execution phase") extracts (Fig. hA lanes 4, 6). There 
are at least two potential explanations for this difference. First, active CAD 
might be unstable in S/M extracts, and might therefore require a constant 
source of caspase activity in order to continue to generate active enzyme 
from CAD/ICAD complexes. Second, despite the presence of high levels of 
endogenous caspases in S/M extracts, the CAD in these extracts might 

initially be largely in the form of inactive CAD/ICAD complexes. Active 
CAD might be released from these complexes by caspase activity during the 
incubation with DNA substrates. 
To distinguish between these possibilities, S/M and E/X extracts 
were incubated at 30°C for various times in order to allow cleavage of 
endogenous ICAD by endogenous caspases before adding DNA in the 
presence or absence of DEVD-fmk (see the experimental protocol in Fig. 
11B). This experiment indicated that CAD activity was initially low in S/M 
extracts but increased gradually with incubation at 30°C (Fig. 11C lanes 1-5). 
Once activated, CAD was stable in the presence of DEVD-fmk (lanes 1-5'). 
In contrast, CAD was fully active at all times in E/X extracts in the presence 
and absence of DEVD-fmk (Fig. liD). Collectively, these results indicate 
that CAD is present but inactive in extracts prepared from "committed" 
stage cells, and is activated in equivalent extracts prepared from execution 
phase cells. In addition, this result confirms that the apoptotic activities 
present in S/M extracts are not due solely to the presence of low levels of 
contaminating apoptotic cells, since these cells would be expected to have 
high levels of active CAD. 
59 
Figure 11. Differences in the activity of the CAD-like nuclease in SI M and 
E/X extracts. Panel A: CAD-like nuclease in S/M extracts is sensitive to 
DEVD-fmk, whilst that in FIX extracts is not. Apoptotic extracts cleave a 
plasmid substrate at 37°C (lanes 1, 4). The nuclease responsible is inhibited 
by purified murine GST-ICAD (lanes 2, 5), and therefore is functionally 
related to murine CAD (Enari et al., 1998). In S/ M extracts, but not E / X 
extracts, the nuclease is abolished by addition of DEVD-fmk together with 
the plasmid DNA (lanes 3, 6). Panel B: Diagram of experimental protocol 
designed to test whether the CAD-like enzyme is active in both S/M and 
E/ X extracts prior to the incubation with DNA. S / M and FIX extracts were 
preincubated for various length of time at 30°C. Then after addition of 
plasmid (substrate of CAD-like enzyme), the extracts was further incubated 
for 30 min at 37°C in the presence or absence of DEVD-fmk. Then Results is 
shown in panel C. Panel C: In SI M extracts, the CAD-like activity increases 
during pre-incubation of the extract at 30°C prior to addition of the plasmid 
DNA (lanes 1-5). This activity is now insensitive to the addition of DE\TD-
fmk at the time of plasmid addition (lanes V - 5'). Bracket labeled 'Frags" 
indicates the products of CAD-like enzyme. Panel D: In contrast, 
preincubation has no effect on the cleavage of plasmid substrate by E/ X 
extracts (lanes 1-5), which is likewise resistant to inhibition with DEVD-fink 
(lanes 1'-5'). Lane D - added plasmid DNA alone. Bracket labeled 'Frags" 
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2.3.4 CAD alone is capable of inducing apoptotic morphology in added 
nuclei. 
Collectively, the results presented in Figs. 10 and 11 suggest that CAD 
might be a major factor that acts downstream of caspases to induce changes 
in nuclear structure during apoptotic execution. To examine this possibility 
in greater detail, we exposed isolated nuclei to partly purified cloned murine 
CAD. Active CAD was expressed in E. coli using a bicistronic vector, which 
ensured that the CAD was translated in the presence of an excess of ICAD 
(Enari et al., 1998). The resulting CAD/ICAD complex was purified by 
nickel chelate chromatography and then tested for activity against plasmid 
and nuclear substrates according to the experimental protocol shown in Fig. 
12A. Results obtained with the plasmid substrate are shown in Fig. 12B. 
The CAD/ICAD complex purified from E. coli became activated following a 
preincubation of 30 min at 25°C either in the absence (Fig. 12B, lane 4) or 
presence (lane 6) of purified recombinant caspase-3. We assume that 
activation in the absence of added caspase is due to the presence of 
contaminating protease activity from the E. coli lysate. Addition of double 
mutant ICAD (Sakahira et al., 1998) at the start of the preincubation blocked 
CAD activation in both the absence (lane 5) and presence (lane 7) of caspase-
3. Double mutant ICAD also blocked CAD activity if added at the end of the 
preincubation (lane 8). In contrast, DEVD-fmk blocked CAD activation if 
added at the start of the preincubation (lane 9) but had no effect if added 
after cleavage of ICAD (lane 10). 
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The results obtained with the plasmid substrate were exactly 
duplicated when we examined the ability of bacterially expressed CAD to 
induce DNA ladders and morphological changes in HeLa nuclei (Fig. 12 B, 
Q. These morphological changes were confirmed by electron microscopy, 
where condensed chromatin domains could be seen to be closely to the 
nuclear envelope (Fig. 13). When CAD was fully active, as detected using 
either plasmid or nuclear substrates, the enzyme strongly induced 
condensation of chromatin at the periphery of added nuclei (Fig. 12 
lanes/panels 4 and 6). Higher levels of CAD induced the complete 
disassembly of nuclei into apoptotic bodies (data not shown); however, 
under these conditions nucleosomal ladders were no longer seen (the DNA 
was fully degraded). Interestingly, the addition of DEVD-fmk at time T=O 
slightly inhibited the morphological apoptosis (Fig. 12 panel 10), although 
examples of fully apoptotic nuclei could still be seen. It is important to note 
that caspase-3 alone was unable to induce either DNA cleavage or apoptotic 
morphology in added nuclei (lanes/panel 3). 
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Figure 12. Bacterially expressed CAD is capable of inducing apoptotic 
morphology in added nuclei in the absence of apoptotic extract. Panel A: 
Diagram of the experimental protocol. After CAD was activated during a 
preincubation with purified caspase-3 at 25°C, substrates were added and 
incubated for various times with the active enzyme at 37°C. Panel B: Effects 
of various incubations on CAD nuclease activity using either a purified 
plasmid substrate (pBluescript - upper panels) or added nuclei (lower 
panels). The morphology of the nuclei in these same incubations is shown in 
Panel C, where the panel numbers refer to lanes in Panel B. Nuclei in buffer 
at time 0 (panel 0). Buffer and caspase-3 do not possess nuclease activity or 
induce apoptotic morphology in added nuclei (lanes/ panels 2, 3). 
Preincubation of CAD alone induces nuclease activity and apoptotic 
morphology (lane/ panel 4), presumably due to the presence of a 
contaminating protease. ICAD is cleaved during this preincubation (data 
not shown). This spontaneous activation of CAD is not observed if non-
cleavable ICAD is present from the start of the preincubation (lane/ panel 5). 
Preincubation of CAD with caspase-3 induces nuclease activity and 
apoptotic morphology (lane/ panel 6). This activity is not observed if non-
cleavable ICAD is present either from the start of the preincubation, or if it is 
added at the end of the preincubation together with the substrate nuclei 
(lanes/ panels 7, 8). Addition of DEVD-fink to the preincubation blocks 
CAD activation, but has no effect on nuclease activity or induction of 
apoptotic morphology if added once the preincubation is complete 
(lanes/ panels 9, 10). The induction of apoptotic morphology by CAD in the 
presence of DEVD-fnk was slightly, but reproducibly, reduced (panel 10). 
These results demonstrate that CAD can induce nuclear apoptosis in the 
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Figure 13. Induction of apoptotic morphology in HeLa nuclei by bacterially 
expressed CAD: analysis by electron microscopy. Nuclei treated as shown 
in Figure 12B, lane/ panel 6 were embedded in plastic, thin sectioned, and 
examined in the electron microscope. Regions of condensed chromatin are 
seen to abut the nuclear envelope, and often protrude as though beginning 
to bud outwards through the envelope. These images are indistinguishable 
from previously published images of nuclei treated with complete apoptotic 
extract (Lazebnik et al., 1993). Bar — 1 im. 
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2.3.5 Evidence for a nuclear disassembly factor distinct from CAD. 
To determine whether the CAD-like enzyme was the sole activity 
downstream of caspases that drives nuclear disassembly in these extracts, 
S/M and E/X extracts were treated with ICAD prior to addition of 
exogenous nuclei. Although addition of excess ICAD abolished production 
of a nucleosomal ladder in nuclei added to S/M and E/X extracts (Fig. 14A 
lanes 3-5 and 9 - 11), ICAD did not block the ability of the extracts to induce 
chromatin condensation and nuclear fragmentation (Fig. 1413, panels 3, 4, 5, 
9, 10, 11). The ability of the extracts to induce morphological changes in the 
presence of ICAD was even more striking when the number of nuclei in the 
incubation was reduced -4-fold (Fig. 14C). These observations indicate that 
CAD-like activity is not essential for apoptotic morphological changes in 
nuclei added to either S/M or E/X extracts. 
Interestingly, simultaneous inhibition of both ICAD and caspases did 
block the induction of apoptotic morphology by E/X extracts (Fig. 14B 
panels 13, 14; Fig. 14C, panel d). Moreover, addition of purified caspase-3 
and caspase-6, the major active caspases in cytosol (Faleiro et al., 1997; 
Martins et al., 1997) and nuclei (Martins et al., 1997; Martins, Mesner et al., 
1997), failed to induce apoptotic morphological changes in purified nuclei 
(identical to Fig. 12, panel 5). These observations appear to rule out the 
possibility that caspases themselves are capable of inducing chromatin 
condensation by acting alone on endogenous nuclear substrates. When 
coupled with these results, the observation in Fig. 14C, panel d, not only 
suggests that there is a second chromatin condensation factor present in the 
It 

extracts, but also raises the possibility that ongoing caspase activity is 
required for activity of this factor. 
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Figure 14. Induction of apoptotic morphology in cell extracts is not blocked 
by inhibition of the CAD-like nuclease. Panel A: Induction of nucleosomal 
ladders in added nuclei by S/M extract is sensitive to ICAD and DEVD-fmk 
(lanes 3-8). Induction of nucleosomal ladders in added nuclei by E/X extract 
is sensitive only to ICAD (lanes 9-14). (DEVD-fmk added: none - lanes 1-5, 
9-11; 100 jiM - lanes 6-8,12-14. ICAD added: none - lanes 3,6,9,12; 160 ng - 
lanes 4,7,10,13; 320 ng - lanes 5, 8, 11, 14.) Panel B: Both S/M and E/X 
extracts can induce apoptotic events under conditions where the CAD-like 
nuclease is inhibited, provided that they retain active caspases (panels 3, 4, 5, 
9, 10, 11). E/X extracts, which normally induce apoptosis in the absence of 
caspase activity (panel 12), are unable to do so if ICAD is added along with 
DEVD-fmk (panels 13, 14). Panel numbers refer to the gel lanes in panel A. 
These images come from the same incubations shown in panel A. Time-
lapse microscopy analysis reveals that the "C"-shaped nuclei in panels 3, 4, 
5, 9, 10 and 11 are apoptotic nuclei in which the nuclear envelope has 
ruptured following collapse of the chromatin against the nuclear periphery. 
Panel C: E/X extracts can fully induce apoptotic morphology in the absence 
of CAD-like activity, but this requires ongoing caspase activity. In a 
different experiment from those shown in panels A and B, the number of 
nuclei per microliter of extract was reduced. This gives a stronger induction 
of apoptotic morphology (compare panel with B, panel 9), even when 
caspases (panel b) or CAD are inhibited (panel c). Extracts produce a range 
of morphologies in added nuclei. As in the experiment of panels A, B, 
simultaneous inhibition of both CAD and caspases abolishes morphological 
apoptosis in the extracts (panel d). These images were selected from images 
taken at random. 
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2.4 Discussion 
The experiments described above led to a number of novel 
observations: 1) It is possible to prepare cell-free extracts specific for the 
latent and execution phases of apoptosis. 2) These extracts, both of which 
contain active caspases and induce apoptosis in substrate nuclei, exhibit 
significant biochemical and functional differences that are best explained if 
the transition from the latent to the execution phase of apoptosis is 
accompanied by a transition from caspase-dependent to caspase-
independent mechanisms of nuclear disassembly. 3) One aspect of this 
transition appears to involve activation of a CAD-like nuclease, which is 
initially latent in S/M extracts but is fully active in E/X extracts. 4) Murine 
CAD can induce an apoptotic morphology in isolated nuclei. 5) In addition 
to CAD, apoptotic extracts contain a second activity that can also induce 
apoptotic chromatin condensation in added nuclei in the absence of DNA 
fragmentation. Each of these points is discussed in greater detail below. 
At present there is no accepted biochemical marker to rigorously 
distinguish between the condemned and committed stages of the latent 
phase. Here, latent phase cells are defined as those that have received a 
proapoptotic stimulus but look morphologically normal. Condemned cells 
are operationally defined as those latent phase cells that yield extracts that 
lack significant caspase activity and do not induce apoptosis in substrate 
nuclei. Committed stage cells are defined operationally as those latent phase 
cells that yield extracts that contain high levels of active caspases together 
with low levels of active CAD and that strongly induce apoptosis in 

substrate nuclei. As expected, these cells contain only low levels of 
fragmented DNA themselves. Both of these latent phase populations are 
readily distinguishable from overtly apoptotic cells, which have detached 
from the substratum and have sustained internucleosomal DNA 
degradation in response to a proapoptotic stimulus. The various extracts 
prepared from these three operationally defined cell populations turned out 
to have remarkably distinct biochemical and functional characteristics. 
The most significant difference was the finding that induction of 
apoptotic events by 'committed' stage extracts is dependent on ongoing 
caspase activity, whereas induction of apoptotic events by "execution" phase 
extracts is independent of ongoing caspase activity. This observation is best 
explained by a model in which caspases activate downstream factors that are 
responsible for condensation of the chromatin during apoptosis. Such a 
model predicts that if it would be possible to purify the active caspases from 
apoptotic cells away from the downstream factors, then the caspases on their 
own should be insufficient to induce apoptotic events in substrate nuclei. It 
is shown that mixtures of purified caspases-3 and -6 are also unable to 
induce apoptotic morphology in purified nuclei. Thus, although recent 
experiments indicate that caspase-3 is essential for nuclear apoptosis 
(Janicke, Sprengart et al., 1998; Woo et al., 1998), this study indicates that this 
enzyme is likely to function by activating downstream factors rather than 
directly disassembling the nucleus itself. 
One such downstream factor has recently been identified in murine 
cell extracts. CAD, the caspase-activated DNase (Enari et al., 1998), interacts 
_0 k m 	 It 	 MVM 	 ;WPI ~*~. Aar! 
with an inhibitory subunit termed ICAD/DFF45 (Liu et al., 1997; Sakahira et 
al., 1998) to form an inactive complex that is thought to be sequestered in the 
cytoplasm. Caspase cleavage of ICAD is proposed to cause the release and 
subsequent nuclear translocation of CAD, leading to digestion of the 
chromatin (Sakahira et al., 1998). Here, it is shown that both S/M and E/X 
extracts from chicken DU249 cells contain a nuclease similar or identical to 
CAD, as defined by its ability to be quantitatively inhibited by exogenous 
purified murine ICAD. The fact that ICAD of mouse origin inhibits the 
apoptotic nuclease in avian (chicken) cell extracts suggests that the CAD 
nuclease and its interactions with ICAD are widely conserved in phylogeny. 
Because the same cohort of caspases is present and active in the S/M 
and E/X extracts, the transition from the latent to the execution phase of 
apoptosis may not hinge upon caspase action alone. Instead the transition 
might involve activation of downstream factors. The CAD-like nuclease 
appears to be largely inactive in freshly prepared S/M extracts, becoming 
active only as the extracts are incubated at 30 or 37°C. This activation 
presumably reflects the cleavage of ICAD/DFF45 by caspases, since CAD 
activation is blocked by caspase inhibitors. In contrast, the CAD-like 
nuclease activity appears to be fully active in freshly prepared E/X extracts. 
Collectively, these observations suggest that caspase activation occurs 
during the latent phase of apoptosis, whereas CAD activation accompanies 
the transition from the latent to execution phase of apoptosis. One 
implication of this conclusion is that cells might simultaneously contain 
active caspases and inactive complexes of ICAD/DFF bound to CAD and 
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possibly other downstream factors. This would be possible if caspases were 
segregated from their downstream targets such as ICAD/DFF - possibly by 
being sequestered in a different cellular compartment. The onset of 
apoptotic execution might then be triggered not by activation of the 
caspases, but by a change in the localization of either caspases or targets. An 
alternative explanation of our data, that caspases are inactive in the cells 
from which S/M extracts are made and become activated during 
preparation of the extract (Zapata, Takahashi et al., 1998), is unlikely for two 
reasons. First, it was previously demonstrated that caspase activity in 
similar extracts prepared from latent phase HL-60 cells was paralleled by 
cleavage of PARP and procaspase-3 in vivo (Martins et al., 1997). Second, the 
caspase-3 activation observed during extract preparation in the Zapata study 
was explained by the detergent-induced release of granzyme B from 
cytoplasmic vesicles (Zapata et al., 1998). In this study, detergents were 
avoided during extract preparation; and cells lacking granzyme B were 
utilized. 
In support of the notion that caspases and their targets might be 
segregated during the latent phase, it was noted that procaspases have 
largely been observed in the cytoplasm (Duan, Chinnaiyan et al., 1996; 
Krajewska, Wang et al., 1997; Mancini, Nicholson et al., 1998), microsomes 
(Ng, Nguyen et al., 1997; Zhivotovsky, Samali et al., 1999; Nakagawa, Zhu et 
al., 2000), or mitochondria (Mancini et al., 1998; Susin, Lorenzo et al., 1999), 
whereas subcellular fractionation studies have revealed significant levels of 
active caspases within the nucleus (Martins et al., 1997; Martins et al., 1997). 
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An additional study has indicated that interference with nuclear transport 
renders cells resistant to Fas-mediated apoptosis (Yasuhara et al., 1997). 
Moreover, functional nuclear transport is necessary for acinus to induce 
chromatin condensation, whilst acinus itself is a nuclear protein in 
nonapoptotic cells and requires caspase-3 and an unknown protease to be 
activated (Sahara et al., 1999). 
In this study a novel vector has been developed to coordinately 
express CAD and ICAD in E. coli, and partially purified CAD was prepared 
to demonstrate that CAD can induce an apoptotic morphology in isolated 
nuclei, as confirmed by both light and electron microscopy. This reaction 
does not require ongoing caspase activity. This result is consistent with 
earlier observations indicating that addition of micrococcal nuclease to 
isolated nuclei can cause clumping of chromatin (Arends, Morris et al., 1990), 
although the pattern of condensation seen with CAD more closely resembles 
that seen in apoptotic cells. However, CAD does not appear to be the only 
factor downstream of caspases that is capable of inducing apoptotic nuclear 
changes. Addition of purified ICAD to either S/M or E/X extracts abolished 
all detectable DNase activity against both chromosomal and plasmid DNA 
substrates, but did not abolish the ability of those extracts to induce an 
apoptotic morphology in substrate nuclei. This observation is consistent 
with previous reports that morphologically normal apoptosis can occur in 
the absence of internucleosomal DNA fragmentation in vivo (Ucker, 
Obermiller et al., 1992; Oberhammer, Wilson et al., 1993; Oberhammer, 
Hochegger et al., 1994; Sakahira et al., 1998). At present, the nature of the 
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second downstream factor(s) that promotes apoptotic chromatin 
condensation is unknown. Although two recent studies suggest that serine 
(Shimizu and Pommier, 1997) or cysteine proteases (Vaux, Wilhelm et al., 
1997) may be involved, the fact that apoptotic morphological changes can be 
detected in the presence of DEVD-fmk as well as a battery of serine, cysteine, 
and acid protease inhibitors (see METHODS) suggest that the chromatin 
condensing activity might not be a protease. On the other hand, 
simultaneous addition of both DEVD-fmk and ICAD to E/X extracts 
abolished the induction of apoptotic morphology in substrate nuclei. This 
result suggests that the morphogenic factor might either bind to ICAD or be 
regulated by other molecules that interact with ICAD. 
In summary, the experiments reported here demonstrate that it is 
possible to use cell-free extracts for a biochemical and functional dissection 
of the sequential phases of the apoptotic pathway. This study reveals that 
the transition from the latent to the execution phase of apoptosis appears to 
be accompanied by a change from caspase-dependent to caspase-
independent mechanisms. Since the discovery that caspases are capable of 
cleaving abundant nuclear proteins like PARP (Lazebnik et al., 1994) and the 
lamins (Lazebnik et al., 1995; Orth, Chinnaiyan et al., 1996; Rao, Perez et al., 
1996; Takahashi et al., 1996) and the absence of nuclear apoptosis in caspase-
3-null cells (Janicke et al., 1998; Woo et al., 1998), we and others had widely 
assumed that caspases are directly responsible for nuclear disassembly. The 
inability of purified caspases to produce apoptotic morphological changes in 
isolated nuclei, coupled with the inability of caspase inhibitors to abolish the 
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induction of these morphological changes by E/X extracts, argues that 
caspases are unlikely to be workhorses that are solely responsible for nuclear 
disassembly. Instead, the present results provide support for a view in 
which caspases play an executive role in nuclear disassembly by activating 
factors that in turn disassemble the nucleus. At least one of the downstream 
activities is a CAD-like nuclease; but another downstream activity required 




3. CAD and ICAD localization: The CAD/ICAD complex is 
nuclear in nonapoptotic cells 
3.1 Introduction 
One aspect of the regulation of apoptotic execution that has recently 
attracted considerable study is the movement of apoptotic factors from one 
intracellular compartment to another. The best studied example of this 
involves movement of factors, including cytochrome c, AIF and caspases 
from the mitochondrial intermembrane space into the cytosol at the onset of 
apoptotic execution (Liu et al., 1996; Susin, Zamzami et al., 1996; Susin et al., 
1999). Less well understood is the requirement for nuclear transport of 
proteins, which is essential for the onset of apoptotic execution following the 
induction of apoptosis by Fas/CD95 (Yasuhara et al., 1997). The recently 
discovered protein acinus, which is activated by caspase-3 and an unknown 
protease, requires nuclear transport to induce chromatin condensation 
(Sahara et al., 1999). Originally it was claimed that the apoptotic nuclease 
CAD/CPAN/ DFF40 which is also activated by caspase-3 indirectly is the 
essential factor to be transported into nucleus (Enari et al., 1998; Halenbeck et 
al., 1998; Liu et al., 1998; Mukae et al., 1998). However, the identity of 
essential factors that must enter the nucleus is not yet firmly established. 
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In healthy cells, CAD/CPAN/DFF40 exists in a complex with its 
inhibitory chaperone ICAD-L/DFF-45. ICAD-L, after functioning as a 
folding chaperone for CAD during translation (Enari et al., 1998), then 
remains bound to the nuclease, keeping it in inactive form. The absolute 
requirement for ICAD-L as a folding chaperone is revealed by the 
phenotype of DFF-45 knockout mice, whose cells undergo apoptosis in the 
absence of detectable DNA cleavage despite the continued presence of CAD 
(Zhang et al., 1998). At the onset of apoptosis, caspases with specificities 
characteristic of caspases -3 and -7 cleave ICAD-L at two sites (Liu et al., 
1997; Sakahira et al., 1998). This relieves the inhibition of CAD and initiates 
the fragmentation of the chromosomal DNA during apoptosis (Sakahira et 
al., 1998). CAD activation is observed after diverse apoptotic stimuli in a 
variety of cultured cells (Mcllroy et al., 1999) as well as in animals, where 
CAD may play a role after traumatic brain injury (Zhang, Raghupathi et al., 
1999). 
The location of CAD/CPAN/DFF40 in healthy cells remains 
controversial. In the original descriptions, CAD was predicted to have a 
nuclear localization signal (NLS) on its C-terminus but no obvious NLS was 
noted within DFF45/ICAD-L (Enari et al., 1998). It was therefore suggested 
that ICAD might complex with nascent CAD on the ribosome, first helping 
it to fold, and then restraining it in the cytoplasm by occluding the CAD 
NLS. This latter activity was proposed to function similarly to the retention 
of NF-KB in the cytoplasm by 1KB (Enari et al., 1998). As is the case for 
IKB:NFicB, it was proposed that cleavage of ICAD releases CAD, thereby 
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enabling it enter the nucleus and attack the cellular DNA (Sakahira et al., 
1998). 
In the present study, this hypothesis for the role of ICAD in 
regulation of CAD has been examined. Two different approaches have been 
used to localize ICAD-L in cultured cells. First, it was demonstrated that a 
GFP:ICAD-L fusion protein is nuclear in transfected human, pig and chicken 
cells. Second, an antibody to murine ICAD was prepared. Subcellular 
fractionation and immunoblotting experiments with this antibody showed 
that the endogenous protein is likewise concentrated in cell nuclei. Next the 
mechanism of ICAD-L entry into the nucleus was examined, in particular 
whether ICAD-L enters the nucleus as a consequence of the function of an 
NLS that was not recognized in previous studies, or whether the protein 
must enter the nucleus in a complex with another NLS-bearing protein or 
proteins. The data presented here clearly indicate that the C-terminus of 
ICAD-L functions as an autonomous NLS that is able to direct the entry of a 
GFP fusion protein into the nucleus. 
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3.2 Materials and Methods 
3.2.1 Materials 
Reagents were obtained from the following suppliers: antipain, 
chymostatin, pepstain A, PMSF, isopropyl 3-D thiogalactopyranoside 
(IPTG), etoposide, and 4,4-diamidino-2-phenylindole (DAPI) were from 
Sigma; staurosporine and leupeptin were from Calbiochem; Hybond-C 
membrane, horseradish perixidase conjugated anti-mouse, anti-human, and 
anti-rabbit antibodies, and enhanced chemiluminescence (ECL) reagents 
were from Amersham Corp.; Super Signal Ultra chemiluminescence 
reagents were from Pierce; Ni-NTA agarose from Qiagen. All restriction 
enzymes were from New England Biolabs. Monoclonal antibody to GFP 
was a gift of I. Davis (ICMB Edinburgh). Monoclonal antibody to tubulin 
was a gift of L. Binder (Northwestern University, Chicago. IL). Human 
autoantibody to DNA topoisomerase I has been described previously (Shero, 
Bordwell et al., 1986). 
3.2.2 Expression and purification of His6-ICAD and antigen preparation 
The ICAD cDNA in pBluescript (Stratagene) was digested with Spe I, 
blunt-ended with T4 DNA polymerase (NEB) plus 100 pM dNTPs, and 
digested with Kpn I (NEB). The resulting fragment was ligated into pRSET 
B (Invitrogen) that had been digested with Hind III, blunt-ended with T4 
DNA polymerase, and digested with Kpn I. ICAD in pRSET B was 
transformed into E. coli BL21(DE3)Lys S cells. Transformed cells were 
grown to 0D600 = 0.5 - 0.7 and protein expression was induced with IPTG (1 

mM) for 3-4 hr. Cells were collected by centrifugation at 5000 x g  for 10 mm 
and frozen at -80°C. The cell pellet was thawed on ice for 15 min and 
resuspended in sonication buffer (50 mM NaH2PO4 pH 7.5; 300 mM NaCl; 
10 mM imidazole). Lysozyme was added to 1 mg/ml and the suspension 
was incubated on ice for 30 mm; sonicated on ice until 80% of the cells were 
disrupted and then centrifuged at 4000 x g for 20 min at 4°C. The 
supernatant fraction was incubated on a rotating mixer for 1 hr at 4°C with 
0.5 ml of Ni-agarose that had been pre-equilibrated with sonication buffer 
then loaded onto a polyprep chromatography column (Bio-rad). The 
column was washed with 4 ml of wash buffer (50 mM NaH2PO4 pH7.5; 300 
mM NaCl; 20 mM imidazole) twice. Protein was eluted with 0.5 ml of 
elution buffer (50 mM NaH2PO4 pH7.5; 300 mM NaCl; 250 mM imidazole) 
four times. All samples were subjected to SDS-PAGE and examined by 
Coomassie Blue staining. For antigen preparation, purified ICAD was 
subjected to SDS-PAGE, then the gel was washed in distilled water three 
times for 10 min each, stained with aqueous Coomassie Blue (0.1%) for 1 hr 
and rinsed with water until the induced protein band became obvious. The 
band was excised, frozen at -80°C, and then ground to a fine powder under 
N20) with a mortar and pestle. This powder was resuspended in PBS buffer 
and used to immunise two rabbits at the Scottish Antibody Production Unit 
(Now Diagnostics Scotland) (Carluke, Lanarkshire). 
3.2.3 Construction of clones 
3.2.3.1 Construction of GFP:ICAD-0 331  
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The ICAD cDNA in pBluescript (Stratagene) was digested with Hind 
III, blunt-ended with T4 DNA polymerase (New England Biolabs) plus 100 
3iM dNTPs, and digested with Xba I (New England Biolabs). The resulting 
fragment was ligated into a vector containing enhanced GFP-with a flexible 
linker (gift of Larry M. Karnitz, Mayo Research Foundation, Rochester, MN) 
in pCDNA3 (Invitrogen) that had been digested with Not I (New England 
Biolabs), blunt-ended with T4 DNA polymerase and digested with Xba I. 
3.2.3.2 Construction of GFP:ICAD-L1311  
The C-terminus of ICAD-L lacking 20 amino acids was obtained by 
PCR using primer (5'-CTGCTGTCAGAAGAGGACCTC-3) and primer (5'-
GCCCAAGCTTCTAGAATTCTTATGCTGATAG-3'), then digested with 
Hinc II and Hind III. The resulting fragment was ligated into vector pRSET 
A (Invitrogen) containing full length ICAD-L1331  that had been digested 
with Hinc II and Hind III. Next, pRSET A ICAD-L1311  was digested with 
Xho I and Xba I and the resulting fragment was ligated into vector pCDNA 
GFP:ICAD-L (4.2.3.1) that had been digested with Xho I and Xba I. 
3.2.3.3 Construction of GFP:ICAD-S1265  
The C-terminus of ICAD-S was obtained by PCR using primer (5'-
CTGCTGTCAGAAGAGGACCTC-3') and primer (5-
TAGGGCCCTTAGTTCTTGCCCACCTCCAAATCCTG-3'), then digested 

with Xcm I and Apa I. The resulting fragment was ligated into a vector 
pCDNA GFP:ICAD-L that had been digested with Xcm I and Apa I. 
3.2.3.4 Construction of GFP:ICAD-S1261  
The C-terminus of ICAD-S1261  lacking 4 amino acids was obtained 
by PCR using primer (5-CTGCTGTCAGAAGAGGACCTC-3') and primer 
(5'-GCCCAAGCTTCTAGAATTCTTACTCCAAATC-3'), then digested with 
Hinc II and Hind III. The resulting fragment was ligated into vector pRSET 
A ICAD-L (Invitrogen) that had been digested with Hinc II and Hind III. 
Next, this pRSET A ICAD-S1261  was digested with Xho I and Xba I. The 
resulting fragment was ligated into a vector pCDNA GFP:ICAD-L that had 
been digested with Xho I and Xba I. 
3.2.3.5 Construction of Zeo GFP:ICAD-L, Zeo GFP:ICAD-0 311, Zeo 
GFP:ICAD-S, and Zeo GFP:ICAD-S1261  
GFP:ICAD-L, GFP:ICAD-L1311, GFP:ICAD-S, and GFP:ICAD-S1261  
in pCDNA3 (Invitrogen) were digested with Hind III and Apa I. The 
resulting fragments were ligated into vector pZeo SV2 (Invitrogen) that 
had been digested with Hind III and Apa I. 
3.2.3.6 Construction of Zeo GFP:CAD 
CAD in pBluescript KS (Stratagene) was digested with Not I and Xho 
I. The resulting fragment was ligated into vector pCDNA3 GFP linearised 
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by digestion of the multiple cloning sites (MCS) with Not I and Xho I. This 
GFP:CAD was digested with Hind III and ligated into vector pZeo SV2+ that 
had been digested with Hind III. 
3.2.3.7 Construction of pCDNA3 GFP with MCS 
pBluescript KS was digested with Not I and Apa I. The resulting 
fragment, a part of multiple cloning site (MCS), was ligated into pCDNA3 
(Invitrogen) containing enhanced GFP with a flexible linker (gift of Larry M. 
Karnitz, Mayo Research Foundation, Rochester, MN) that had been digested 
with Not I and Apa I. 
3.2.3.8 Construction of pCDNA3 GFP:ICAD-L312331 from ICAD-L 
The C-terminal 20 amino acids of ICAD-L was obtained by PCR using 
primer (5-CATAGCGGCCGCAGGAGGAGCCCAC-3) and primer (5'-
GCACCTTCCAGGGTCAAG-3'), then digested with Not I and Apa I. The 
resulting fragment was ligated into pCDNA3 GFP linearised by digestion of 
the MCS with Not I and Apa I. 
3.2.4 Subcellular fractionation 
HeLa cells were maintained in RPMI 1640 medium containing 5% 
(v/v) calf serum. Cells were collected by trypsinization and centrifuged at 
1400 x g for 5 min at room temperature. Cell pellets were washed once in 
PBS, once in nuclei solution that is very hypotonic (10 mM Pipes pH 7.0, 10 
mM KC1, 1.5 mM M902,  1 mM DTT, 100pM PMSF, 10 pM cytochalasin B, 

plus 1 pM each of antipain, chymostatin, pepstatin A, and leupeptin) and 
resuspended into 200 p1 of nuclei solution. This suspension was incubated 
on ice with occasional agitation, and then lysed by passage through a 21G 
needle. The lysate was fractionated into crude nuclei and cytosol by 
centrifugation at 2400 x g for 10 min at 4°C. The supernatant and pellet were 
immediately resuspended into SDS sample buffer and boiled for 5 min and 
subjected to SDS-PAGE (Laemmli, 1970). 
3.2.5 Induction of apoptosis 
Apoptosis was induced in cells 20-24 hr after they were 
electroporated either with a construct expressing GFP-ICAD or in the 
absence of added DNA (mock transfection). Cells were either treated with 
68 pM etoposide for 1 hr and kept in drug-free media for a subsequent 6-7 hr 
or treated with 1 pM staurosporine for 16-24 hr. To examine GFP-ICAD 
cleavage, both floating cells and attached cells were collected, resuspended 
into sample buffer and subjected to SDS-PAGE. 
3.2.6 Microscopy 
Chicken DU249 cells and LLCPK cells were cultured in RPMI 1640 
medium containing 10% (v/v) fetal bovine serum. HeLa cells were cultured 
in RPMI 1640 medium containing 5% (v/v) calf serum. After 
electroporation with various constructs (Mackay, Eckley et al., 1993), cells 
were grown on coverslips overnight. These coverslips were rinsed with 
PBS, fixed in a 4% formaldehyde solution for 5 mm, stained with DAPI (2 

ig/m1) for 5 mm, rinsed with PBS, and mounted with Vectashield (Vector). 
Images were acquired on a Zeiss Axioplan II epifluorescence microscope 
equipped with a Princeton Instruments Micromax cooled CCD camera, 
driven by IF Lab Spectrum software. 

3.3 Results 
3.3.1 ICAD-L/DFF45 is nuclear in growing cells 
The initial evidence that ICAD-L/DFF45 is a nuclear protein in a 
variety of cell types was obtained when we constructed a fusion protein in 
which the A. victoria green fluorescent protein (GFP) attached to the N-
terminus of murine ICAD-L. Although GFP-ICAD-L expressed in E. coli was 
relatively insoluble, this protein was able to inhibit the CAD-mediated 
cleavage of plasmid DNA, indicating that this molecule remains competent 
to interact with CAD. Following transient transfection, this GFP-ICAD-L 
fusion protein was detected solely in the nucleus of healthy human, pig and 
chicken cells (Fig. 15). The GFP-ICAD-L fusion protein was excluded from 
nucleoli. Otherwise this protein showed a relatively homogeneous 
distribution throughout the nucleus. GFP on its own does not target to the 
nucleus (Fig. 20). 
Although the nuclear localization of GFP-ICAD-L fusion protein was 
extremely reproducible, being nuclear in all transfected cells, it was 
nevertheless important to demonstrate that these results reflect the 
distribution of the endogenous ICAD/DFF, particularly since both ICAD 
and DFF were originally isolated from cytoplasmic lysates (Liu et al., 1997; 
Enari et al., 1998). We therefore subcloned murine ICAD-L into a vector that 
expressed the protein in E. coli as a fusion with a hexa-histidine tag (His6). 
This protein was expressed in E. coli, purified to homogeneity by nickel 
chelate chromatography, and used to immunise two rabbits. The resultant 
sera recognized both murine and human ICAD in immunoblots (Fig. 16). 

The specificity of one of these ICAD antisera is shown in figure 16A. 
The serum recognized a single polypeptide of approximately 45 kDa in 
nuclei isolated from HeLa cells (lane n). As expected (Sakahira et al., 1998), 
this endogenous polypeptide was cleaved when untransfected cells were 
induced to undergo apoptosis in the presence of 1 1iM staurosporine (data 
not shown). When nuclei were isolated from HeLa cells transfected with 
GFP-ICAD-L, the antibody recognized both the endogenous human 
ICAD/DFF, as well as the 75 kDa GFP-ICAD-L fusion protein (lane n'). The 
antiserum did not recognise any polypeptides in a clarified cytosolic fraction 
prepared by sedimentation of a post-nuclear supernatant at 85,000 x g for 1 
hr. (lane c). Unfortunately this antiserum did not give a distinct signal 
above background by indirect immunofluorescence. 
The localization of endogenous ICAD-L in nuclei was confirmed in 
subsequent experiments in which HeLa cells were lysed and subjected to a 
single centrifugation at 2,400 x g  for 10 mm (Fig. 16B). This process is 
sufficient to fractionate cells into a crude nuclear pellet and cytosolic 
supernatant. The efficacy of this fractionation was confirmed by 
immunoblotting with antibodies to the nuclear protein DNA topoisomerase 
I and the cytoplasmic J3 -tubulin. As expected, topoisomerase I was found 
predominantly in nuclei (lane n), with a small proportion of the protein 
being found in the crude cytosol (lane c). This cytosolic material may arise 
from low levels of nuclear breakage during cell lysis. When cells were 
fractionated by this method, 13 -tubulin was found solely in the cytosol. 

The distribution of ICAD-L in two independent fractionation 
experiments is also shown in figure 16B. In both experiments, the 
endogenous ICAD-L was found to be predominantly nuclear, with a trace 
amount of the antigen being detected in the crude cytosol. Given the 
presence of low levels of topoisomerase Tin the cytoplasm in these 
experiments, it is likely that some or all of the cytoplasmic ICAD-L is 
derived from nuclear breakage. This would be consistent with the absence 
of detectable ICAD-L in clarified cytosol (Fig. 16A). However, the presence 
of a small pool of cytoplasmic ICAD-L cannot be excluded by these 
experiments. Presumably ICAD/DFF was isolated from cytosol in previous 
experiments because the protein leaked from nuclei during extract 
preparation (Liu et at., 1997; Sakahira et at., 1998). 
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Figure 15. GFP-ICAD-L is a nuclear protein. Aequoria victoria green 
fluorescent protein (GFP) was fused in frame to N-terminus of murine ICAD 
and expressed by transient transfection in (A) human (HeLa), (B) pig 
(LLCPK) and (C) chicken (DU249) cells. The expressed protein was 
observed solely in cell nuclei. Panels A-C - phase contrast. Panels A' - C' -
GFP  fluorescence. Panels A" - C'T - DNA stained with DAPI. 
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Figure 16. Subcellular fractionation confirms that ICAD-L is a nuclear 
protein. (A) Confirmation of the specificity of the ICAD antibody. Anti-
ICAD recognizes endogenous human ICAD in a crude nuclear fraction 
prepared by centrifugation of HeLa whole cell extract at 2,400 x g  for 10 mm 
(lane n). ICAD is not detected in clarified cytosol (85,000 x g, 1 hr - lane c). 
Anti-ICAD recognizes GFP-ICAD-L in a similar fractionation of transfected 
cells (lane n'). (B) Subcellular fractionation confirms that ICAD is highly 
enriched in nuclei of HeLa cells and detected at only trace amounts in crude 
cytosol (lysates were centrifuged 2,400 x g  for 10 min yielding nuclei, lane n, 
and cytosol, lane c). (C) GFP-ICAD-L is cleaved in transfected cells 
following induction of apoptosis by exposure of cells to staurosporine. 
Mock transfected cells (lanes 1, 2) or cells transfected with a construct 
expressing GFP-ICAD-L (lanes 3, 4) were cultured as normal (lanes 1, 3) or 
exposed to 1 pM staurosporine for 24 hr (lanes 2, 4), then lysed and 
subjected to SDS-PAGE and immunoblotting. Detection was with a 
monoclonal antibody to GFP (gift of Ilan Davis). 

3.3.2 GFP-ICAD-L can remain associated with DNA in apoptotic cells. 
Current models of ICAD/DFF function assume that the protein is 
cytoplasmic, and experiments reveal that the protein is destroyed at the 
onset of apoptotic execution (Liu et al., 1997; Sakahira et al., 1998). Since it is 
shown that endogenous and GFP-fusion ICAD-L/DFF 45 is predominantly 
nuclear, it has to be confirmed that the fusion protein is in fact processed 
normally during apoptosis. In addition the fate of the GFP moiety during 
apoptosis was examined. If GFP remains intact during apoptosis, then the 
GFP derived from GFP-ICAD-L might serve as a marker of nuclear integrity 
during apoptotic execution. 
In order to follow the fate of GFP-ICAD-L during apoptosis, HeLa 
cultures transfected with constructs expressing the chimeric protein were 
induced to enter apoptosis by exposure to either etoposide or staurosporine. 
Six hrs after a one hr exposure to 68 pM etoposide - 10% of transfected HeLa 
cells had an apoptotic morphology. Following exposure to 1 PM 
staurosporine for 24 hr, all cells had an abnormal morphology, with the 
majority of these cells looking clearly apoptotic. Following induction of 
apoptosis, cells were harvested, lysed by passage through a needle, and a 
crude nuclear fraction prepared by centrifugation at 2,400 x g for 10 mm. 
The integrity of the GFP-ICAD-L in this fraction was followed by 
immunoblotting with a monoclonal antibody to GFP (gift of Ilan Davis). 
These experiments revealed that GFP-ICAD-L is cleaved as expected in 
apoptotic HeLa cells (Fig. 16C). GFP is not degraded, at least during the 
early stages of apoptotic execution. This experiment shows that although 
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the chimeric protein is predominantly located in the cell nucleus, it remains 
accessible to the caspases that target ICAD during apoptosis. 
The fate of the GFP moiety derived from GFP-ICAD-L following 
induction of apoptosis in HeLa cells was followed by fluorescence 
microscopy. In many apoptotic cells (class 1), GFP remained in close 
association with the chromatin, both in condensed and non-condensed 
regions (Fig. 17A). In other apoptotic cells (class 2), much of the GFP signal 
appeared to be no longer associated with the DNA (Fig. 17C). Both classes 
of cells could be seen to have at least two types of cytoplasmic blebs, some 
which contained both DNA and GFP, and others that were negative for 
both. The difference in the localization of GFP may be due to the cleavage of 
GFP-ICAD-L protein by caspases. 
Because GFP expressed on its own is distributed evenly throughout 
the cytoplasm of transfected cells (Rizzuto, Brini et al., 1995), the 
fluorescence signal would be expected to diffuse relatively freely following 
caspase cleavage of the ICAD-L. Therefore, since GFP-ICAD-L is completely 
cleaved in these apoptotic cells (Fig. 16), this suggests that the nuclear 
envelope is likely to remain intact in those cells where the GFP stayed in 
close association with the condensed chromatin. This is consistent with the 
observation of apparently intact nuclear envelopes in apoptotic cells 
examined by electron microscopy (Wyllie et al., 1980). Cells with a more 
widespread distribution of GFP are likely to represent those in which 
apoptotic execution was accompanied by a loss of nuclear envelope 
integrity. Blebs in these cells that lack detectable GFP (arrows, Fig. 17C) may 
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have formed and been sealed off prior to the loss of nuclear envelope 
integrity. In other studies, we directly observed lysis of the nuclear 
envelope in time-lapse movies of late stage apoptotic HeLa cells expressing a 
GFP-lamin A chimera. 
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Figure 17. Distribution of the GFP-L moiety of GFP-ICAD-L fusion protein 
in apoptotic HeLa cells. Cells transiently transfected with a construct 
expressing GFP-ICAD-L were exposed to (A, B) etoposide or (C) 
staurosporine to induce apoptosis. The expressed protein was observed 
either in association with the DNA, or in certain cases throughout the entire 
cytoplasm. In the case where the GFP was cytoplasmic, not all prominent 
surface blebs were observed to contain the GFP fragment (arrows in Panel 
Q. Panels A-C - phase contrast. Panels A' - C' - GFP fluorescence. Panels 
A" - C" - DNA stained with DAPI. 
93 
3.3.3 The C-terminus determines the nuclear localization of ICAD-
L/DFF45 
In order to investigate the mechanisms underlying the subcellular 
localization of ICAD-L and ICAD-S, we constructed fusion proteins between 
murine ICAD and the Aequoria victoria green fluorescent protein (GFP). 
Following transient transfection, GFP:ICAD-L fusion protein was detected 
solely in the nucleus of healthy human epithelial and chicken hepatoma cells 
(Fig. 18, panels A). In contrast, a GFP:ICAD-S fusion protein was located 
diffusely throughout the cell (Fig. 18, panels B). 
The transcripts encoding ICAD-L/DFF45 and ICAD-S/DFF35 arise 
by alternative splicing of a single precursor transcript (Sakahira et al., 1998). 
The two proteins are identical except for their C-terminal regions, in which 
the seventy C-terminal residues of ICAD-L are replaced by four different 
residues in ICAD-S. It therefore appeared likely that the different 
localization of ICAD-L and ICAD-S might be due to the differing C-termini 
of these proteins. Two hypotheses can explain the differential localization of 
the two proteins. First, a nuclear localization signal might be present in the 
seventy residues of ICAD-L that are missing from ICAD-S. Second, the four 
different amino acids at the C-terminus of ICAD-S might function as part of 
a cytoplasmic retention or nuclear export signal. 
To test the latter hypothesis, we constructed a GFP:ICAD-S fusion 
that lacks the four novel C-terminal amino acids (GFP:ICAD-S 261). When 
expressed by transient transfection, GFP:ICAD-S1261  was distributed 
diffusely throughout the cell, appearing indistinguishable from the 

GFP:ICAD-S protein (Fig. 18, panels Q. This indicated that the C-terminus 
of ICAD-S does not specify the cytoplasmic localization of this protein. It 
therefore seemed much more likely that the C-terminal region of ICAD-L 
contains a nuclear localization signal (NLS). 
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Figure 18. The C-terminal 20 aa of ICAD-L is required for localization of 
the protein in cell nuclei. Aequoria victoria green fluorescent protein (GFP) 
was fused in frame to N-terminus of murine ICAD-L, ICAD-S and CAD and 
expressed by transient transfection in human (HeLa) cells. (panels A) The 
expressed GFP:ICAD-L1331  (full length ICAD-L) was solely observed in 
nuclei. In contrast, GFP:ICAD-S1265 (full length ICAD-S) (panels B), 
GFP:ICAD-S1261  (panels C), and GFP:ICAD-L1311  (panels D) were all 
found to be distributed throughout the cell in both nucleus and cytoplasm. 
(panels E) GFP:CAD was highly concentrated in nuclei. Panels A-E - phase 
contrast; Panels A'-E' - detection of GFP fluorescence; Panels A" - E" - DAPI 
fluorescence of cellular DNA. Bar 10 tim 
3.3.4 Identification of a nuclear localization signal at the C-terminus of 
ICAD-L 
The nuclear localization of ICAD-L/DFF45 could be explained by the 
protein having its own nuclear localization signal or by an interaction with 
other proteins such as CAD/CPAN/DFF40. We suspected that the nuclear 
localization of ICAD-L was unlikely to be due to the protein being 
transported into the nucleus in a complex with a carrier protein such as 
CAD, since the GFP:ICAD-L protein was detected almost solely in the 
nucleus, even in cells where the transfected protein was highly 
overexpressed. 
Previous descriptions of the sequence of ICAD-L/DFF45 have yet to 
describe a putative nuclear localization signal within the molecule. 
Nonetheless, upon examination of the ICAD-L deduced amino acid 
sequence we noticed a cluster of basic residues in the C-terminal twenty 
amino acids that might function as a bipartite nuclear localization signal 
(Fig. 19) (Robbins, Dilworth et al., 1991). To test the possibility that this 
region functions as a nuclear localization sequence, we constructed a fusion 
protein between GFP and ICAD-L from which this twenty amino acids had 
been removed (GFP:ICAD-L1311). Following transient transfection, 
GFP:ICAD-L1311  was localized diffusely throughout the cell, thus 
confirming that this region of ICAD-L is essential for the nuclear localization 
of the protein (Fig. 18, Panels D). It is worth noting that these twenty amino 
acids do not include the region which has been proposed to be necessary for 
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interaction between ICAD and CAD (Cu et al., 1999; Inohara, Koseki et al., 
1999). 
To confirm that the C-terminal twenty amino acids of ICAD-L 
possesses autonomous NLS function, we constructed a vector encoding a 
fusion between GFP and this twenty amino acid peptide (GFP:ICAD-L312 
331). In control experiments, GFP on its own did not target to the nucleus 
(Fig. 20 panels B). However, following transient transfection, GFP:ICAD- 
L312331  was predominantly nuclear (Fig. 20 panels A). This result strongly 
supports the hypothesis that ICAD-L localizes in the nucleus due to the 





Figure 19. A possible bipartite NLS in the C-terminal 20 amino acid 
residues of JCAD-L is conserved between mouse and human. Basic residues 
are shadowed. 
.r 	 : 
Figure 20. The C-terminal 20 aa of ICAD-L functions as an autonomous 
nuclear localization sequence capable of targeting GFP to the cell nucleus. 
Aequoria victoria green fluorescent protein (GFP) was fused in frame to a 
peptide comprising the C-terminal 20 amino acids from murine ICAD-L and 
expressed by transient transfection in HeLa cells. (panels A) The expressed 
GFP:ICAD-L312331  was highly concentrated in nuclei. (panels B) GFP 
expressed on its own is distributed throughout the cell in both nucleus and 
cytoplasm. Panels A, B - phase contrast; Panels A', B' - detection of GFP 
fluorescence; Panels A", B" - DAPI fluorescence of cellular DNA. Bar 10 im 
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3.3.5 CAD is also a nuclear protein 
It has been proposed that CAD/CPAN/DFF40 exists as a one to one 
complex with ICAD-L/DFF45 in healthy cells (Liu et al., 1997; Enari et al., 
1998), although it has not proven possible to detect significant complexes 
between CAD and ICAD-S/DFF35 in cells (Sakahira et al., 1999). 
Furthermore, it has been claimed that CAD contains a nuclear localization 
signal near its C-terminus (CAD: amino acid residues 331-345) (Enari et al., 
1998). To confirm the localization of CAD within cells, a plasmid encoding a 
GFP: CAD fusion protein was constructed. Following transient transfection, 
this fusion protein was detected almost solely in the nucleus of human 
epithelial and chicken hepatoma cells (Fig. 18, panels E). To exclude the 
possibility that the nuclear localization of GFP:CAD was due to its 
overexpression and failure to form a complex with ICAD, plasmids 
expressing GFP:CAD plus HA-tagged ICAD-L were co-transfected into 
HeLa cells. Both proteins were highly concentrated in the nucleus of human 
epithelial cells (data not shown). In addition, endogenous CAD was 
detected in the nuclear fraction following subcellular fractionation and 




The CAD:ICAD-L complex is stored within nuclei 
The locations of ICAD-L/DFF45 and CAD/CPAN/DFF40 in cells 
have been remained controversial, with the original claims that these 
proteins are located in the cytoplasm (Enari et al., 1998). However, this and 
other people's studies have shown that expressed exogenous ICAD and 
CAD are in the nucleus (Liu et al., 1998; Samejima and Earnshaw, 1998; 
Samejima and Earnshaw, 2000). In general, studies that have examined the 
location of expressed ICAD-L/DFF45 and CAD/CPAN/DFF40 in 
transfected cells have found the protein in the nucleus (Liu et al., 1998; 
Samejima and Earnshaw, 1998), whilst subcellular fractionation studies have 
found and ICAD-L/DFF45 to be cytoplasmic to a greater or lesser extent 
(Sabol, Li et al., 1998; Zhang et al., 1999; Zhivotovsky et al., 1999). However, 
subcellular fractionation in the present study using HeLa cells found the 
endogenous ICAD-L/DFF45 protein to be predominantly nuclear when 
steps were taken to minimize leakage from nuclei (Samejima and Earnshaw, 
1998). Apart from methodological differences, it is, of course, possible that 
the localization of these proteins could vary between differing cell types. To 
clarify this issue, we examined the sequence of ICAD-L and found a putative 
nuclear localization signal on its C-terminus that had not been predicted 
previously. The data presented here confirmed that both CAD and its 
inhibitory chaperone ICAD-L possess autonomous nuclear localization 
sequences. We also showed that ICAD-L/DFF45 was primarily located in 
apoptotic HeLa nuclei. 
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Cells contain two forms of ICAD:ICAD-L and ICAD-S, which differ at 
their C-termini. Because the region of ICAD-L that is missing from ICAD-S 
contains a bipartite NLS, these two splice forms occupy very different 
cellular locations. ICAD-S is found in both the nucleus and cytoplasm, 
whereas TCAD-L is almost exclusively nuclear. Interestingly, these two 
forms of ICAD are functionally distinct (Cu et al., 1999; Sakahira et al., 1999). 
Whether ICAD-S has a distinct function in the cytoplasm is not currently 
known, nor is it known whether the cytoplasmic pool of ICAD-S is 
associated with CAD. All in all, current results are consistent with models in 
which the primary location of CAD in proliferating cells is nuclear, making 
it unlikely that regulation of CAD entry into the nucleus is a critical factor in 
the control of the onset of apoptotic execution. 
Studies using a model for the induction of apoptosis by Fas/CD95 
showed previously that nuclear transport of proteins is essential for cells to 
enter apoptotic execution (Yasuhara et al., 1997). The results presented here 
suggest that activated CAD is unlikely to be the key factor that must 
translocate into the nucleus since CAD localizes already in the nucleus as an 
inactive complex. Interestingly the recently identified Drosophila CAD 
homologue, dCAD/Drep-4 does not have its own NLS. When incubated 
with nuclei, recombinant dCAD/Drep-4 does not cause DNA cleavage in 
nuclei despite its DNase activity against naked DNA (Yokoyama et al., 2000). 
It will be very interesting to determine the activation and translocation 
mechanism of dCAD/Drep-4 in vivo. 
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The nature of the critical translocating factor in the Fas/CD95 
experiment is unknown (Yasuhara et al., 1997). Likely candidates include 
apoptosis inducing factor AIF (Susin et al., 1999), acinus (Sahara et al., 1999), 
and in view of the results described here, activated caspase-3 and possibly 
caspase-7, since these enzymes appear to be responsible for the activation of 
CAD in cells (Janicke et al., 1998; Mitamura, Ikawa et al., 1998; Tang and 
Kidd, 1998; Zheng, Schlosser et al., 1998; Liu et al., 1999; Wolf et al., 1999). 
The intracellular localization and translocation of caspases during apoptosis 
is still under investigation, however, we previously reported the detection of 
an activity comigrating with activated caspase-3 in the nucleus by activity 
labeling and two-dimensional gel analysis (Martins et al., 1997). It has 
recently been reported that following cleavage of procaspase-3, which exists 
primarily in the cytoplasm and mitochondria (Mancini et al., 1998; Samali, 
Zhivotovsky et al., 1998), active caspase-3 is found in the nuclear, 
mitochondrial, and cytosolic fractions (Chandler, Cohen et al., 1998; 
Zhivotovsky et al., 1999). In contrast, caspase-7 shifts quantitatively from the 
cytosol to the microsomal fraction following activation (Zhivotovsky et al., 
1999). 
What is the role of ICAD-S? 
The levels of expression of ICAD-L/DFF-45 and ICAD-S/DFF35 are 
similar at least in mouse WR19L and human Jurkat I lymphoma cells 
(Sakahira et al., 1999). It has been suggested that ICAD-S might function as a 
safety device to prevent the mistaken activation of CAD in healthy cells (Cu 
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et al., 1999). Promoter analysis of the murine ICAD and CAD genes suggests 
that expression of these genes is regulated by different mechanisms (Kawane 
et al., 1999). Alternative splicing of the ICAD pre-mRNA could serve as a 
mechanism to regulate the level of ICAD-L in response to the expression 
level of functional CAD. Changes in the efficiency of alternative splicing of 
the ICAD pre-mRNA would alter the ratio of ICAD-L to ICAD-S without 
necessitating changes in the transcription of the gene. 
Although ICAD-S/DFF35 cannot act as a folding chaperone to enable 
the synthesis of functional CAD/CPAN/DFF40, it can bind to active 
CAD/DFF40 and inhibit its nuclease activity in vitro (Gu et al., 1999; 
Sakahira et al., 1999). This is because amino acid residues 101-180 of 
DFF35/45 mediate the binding to DFF40 while residues 23-100 are 
implicated in the inhibition of the nuclease in vitro (Gu et al., 1999). Despite 
the fact that ICAD-S can inhibit CAD in cells (Sakahira et al., 1998; Cu et al., 
1999), ICAD-S exists primarily in free form in vivo (Sakahira et al., 1999). The 
data from this study suggest that this may be because much of ICAD-S is 
cytoplasmic whilst CAD is nuclear. Whether ICAD-S has a distinct 
cytoplasmic function in addition to interaction with CAD is not currently 
known. Recently a Drosophila ICAD-L/DFF45 homologue, Drep-1 /dICAD 
was identified (Inohara and Nunez, 1999; Mukae et al., 2000). Drosophila 
has apparently only the long-form of ICAD, suggesting the possibility that 
ICAD-S may not have an essential role. However, a preliminary yeast two 
hybrid study suggested an association of ICAD with cytoskeletal 
components, possibly indicative of unknown functions for ICAD in the 
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4. DNA topoisomerase IIc interacts with CAD nuclease and is 
involved in chromatin condensation during apoptotic execution 
4.1 Introduction 
DNA topoisomerase II (topo II) is an enzyme which catalyzes DNA 
topological transformations by transiently cleaving double strand DNA. 
One of the major cellular functions of topo II, is to prevent excessive 
supercoiling of intracellular DNA, which can occur during replication, 
transcription, recombination, chromosome condensation or sister chromatid 
segregation. Moreover, it has been known for over ten years that topo II is 
one of the major components of the metaphase chromosome scaffold 
(Earnshaw, Halligan et al., 1985; Mirkovitch, Gasser et al., 1987). Thus topo II 
is essential for remodelling of the chromatin structure during the normal cell 
cycle. In eukaryotes, topo ha is a homodimer of a 170 kDa subunit. 
Vertebrates also express a second type of topo II, topo 1113, a 180 kDa protein. 
Although they exhibit some differences in cell cycle regulated expression 
level and localization (Zini, Martelli et al., 1992; Adachi, Miyaike et al., 1997; 
Warburton and Earnshaw, 1997; McPherson and Goldenberg, 1998), the 
functional difference between a and 13 is largely unknown. 
It has been shown that apoptotic degradation of genomic DNA in 
mammalian cells starts by excision of large DNA fragments ranging in size 
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from 50 kilobases to more than 300 kilobases (Oberhammer et al., 1993). It 
was suggested that the above fragments could represent chromosomal DNA 
loops. A role of topo IT for the generation of these fragments during 
apoptotic execution has been controversial (Lagarkova, Iarovaia et al., 1995; 
Beere, Chresta et al., 1996; McPherson and Goldenberg, 1998; Li et al., 1999). 
Previous studies in our lab had raised the possibility that topo IIa 
might have a role in chromatin condensation during apoptotic execution. 
We found that the topo II( level in chick erythroblasts drops drastically 
during development. The extent of chromatin condensation of chicken 
erythrocyte nuclei incubated in S/M extracts correlates with the level of 
endogenous topo IT present in the added nuclei (Wood and Earnshaw, 1990). 
In chapter 2, it is demonstrated that our E/X extracts contain another 
factor(s) apart from CAD which is responsible for chromatin condensation. 
It was suspected that topo II might be one such factor. In this study, the 
function of topo II during apoptotic execution was investigated using both 
biochemical approaches and highly specific topo IT inhibitors (Gorbsky, 
1994) which interfere with the catalytic activity of the topoisomerase, but do 
not trap the cleavable complex. 

4.2 Materials and Methods 
4.2.1 Preparation of apoptotic extracts and in vitro apoptosis reaction 
Apoptotic (E/X) extracts were prepared from chicken DU249 cells as 
described (chapters 1.5 and 2.2.1). The in vitro apoptosis reaction was 
performed as described (chapter 2.2.3) with the following exceptions. For 
certain experiments, the HeLa nuclei were preincubated for 30 min at 37°C 
with either a topo II inhibitor ICRF-187 (50 mg/ml, gift of Dr. A. Imondi, 
Pharmacia) or diluent. For CAD inhibition, E/X extracts were preincubated 
with ICAD-L or CAD buffer (10 mM HEPES, pH 7.4,50 mM NaCl, 5 mM 
EGTA, 2 mM MgCl2,  1 mM DTT) for 15 min at 37°C. For caspase inhibition, 
E/X extracts were preincubated with DEVD-fmk (100 pM, Calbiochem) or 
diluent for 15 min at 37°C. In certain experiments 1.5 pg of purified human 
topo IIcL (corresponding to a -4x higher-than-physiological level of 1.7 x 106 
molecules per nucleus) was added to the incubation (human topo II was 
prepared from baculovirus infected insect cells.). Nuclei were subsequently 
stained with DAPI to observe chromatin condensation. 
4.2.2 Construction of clones and bacterial expression of cloned proteins 
4.2.2.1 Construction of clones 
For construction of intein-I CAD, mouse full length ICAD-L (Enari et 
al., 1998) (gift of S. Nagata, Osaka) was cloned into the Nco 1/Sma I cloning 
sites of pTYB4 (New England Biolabs Inc.). GST-CAD was prepared by 
cloning full length murine CAD into the pGEX 4T-1 (Pharmacia Biotech) Eco 
RI and Xho I cloning site. To make the plasmid encoding the GST-CAD 
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His6-ICAD combination, GST-CAD/His6-I CAD, His64CAD in pRSET B 
(chapter 3.2.2) was obtained by PCR with primer (5'-
TGAGACGTCTAATACGACTCAC-3') and primer (5'-
GTCGACGTCAGCAAAAAACCCC-3') and cloned into the Aat II site of 
pGEX 4T-1 containing GST-CAD. To make the Zeo:His:HA vector, first a 
His6 tag was constructed by ligation of oligos (5'-
CTAGCATGCATCATCATCATCATCACCGCGGA-3') and (5'-
AGCTTCCGCGGTGATGATGATGATGATGCATG-3'). The resulting 
fragment was ligated into vector pZeo SV2 (Invitrogen) that had been 
digested with Nhe I and Hind III. The HA tag in pBluescript KS 
(Stratagene) was digested with Sac II and blunt-ended with T4 DNA 
polymerase plus 100 pM dNTPs, and digested with Eco RI. The resulting 
fragment was ligated into vector pZeo His that had been digested with Kpn 
I and blunt-ended with T4 DNA polymerase plus 100 pM dNTPs, and 
digested with Eco RI. To make Zeo:His:HA:CAD and Zeo:His:IIA:GFP, the 
CAD ORF was obtained by PCR from a plasmid containing the full-length 
CAD cDNA (gift of S. Nagata), cloned into pBluescript KS (Stratagene) and 
digested with Eco RI and Xho I. GFP was obtained by PCR using primer T7 
and primer (5-CCGCTCGAGTTACTTGTACAGC-3') from an enhanced 
GFP: lamin A in pCDNA 3 (gift of Larry M. Karnitz, Mayo Research 
Foundation, Rochester, MN), then digested with Eco RI and Xho I. The 
resulting fragments were ligated into vector Zeo:His:HA that had been 
digested with Eco RI and Xho I. 
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4.2.2.2 Expression and Purification of GST-ICAD, GST-CAD, GST-
CAD/His6-ICAD, and GST 
Plasmids encoding GST-ICAD, GST-CAD, GST-CAD/His6-ICAD, 
GST-BubRl, GST-hAIRK2 and GST alone transformed into E. coli 
BL21(DE3)Lys S cells were grown to 0D600 = 0.5-0.7, and protein expression 
was induced with IPTG (0.3-0.5 mM) for 3-5 hr. Cells were collected by 
centrifugation at 5,000 g for 10 min and frozen at -80°C. 
GST-CAD/His6-ICAD was first purified with 0.5 ml of Ni-agarose 
(Qiagen, Catswirth, CA) as described previously for the purification of His6-
ICAD protein (chapter 3.2.2). Protein eluted from Ni-agarose column was 
diluted 20-fold into GST wash buffer (PBS, 5 mM EDTA, 5 mM DTT, 1% 
Triton), and then purified a second time over glutathione sepharose as 
described below. 
Pellets of E. coli expressing GST-ICAD, GST-CAD, or GST were 
thawed on ice and resuspended in lysis buffer (PBS, 5 mM EDTA, 5 mM 
DTT) with lysozyme (final conc. lmg/ml) and incubated on ice for 30 mm. 
After sonication, Triton X-100 was added to 1% and the lysate was 
centrifuged at 4,000 x g for 20 mm. The supernatant was mixed with 
Glutathione Sepharose 4B (Pharmacia Biotech) which had been equilibrated 
with PBS and incubated on a rotating mixer for 1 hr at 4°C. The sepharose 
beads were washed in batch 3 times with wash buffer. GST-ICAD and GST 
were eluted with elution buffer 1 (10 mM glutathione, 50 mM Tris:HC1 (pH 
8.0)). GST-CAD, and GST-CAD/His-ICAD were eluted with elution buffer 
2 (20 mM glutathione, 100 mM Tris:HC1 (pH 8.0), 120 mM NaCl). The eluted 
111 

proteins were dialyzed for at least 3 hr against two changes of CAD buffer 
(10 mM HEPES, pH 7.4,50 mM NaCl, 5 mM EGTA, 2 mM MgCl2, 1 mM 
DTT), aliquoted, and frozen in N2(1). 
Intein-ICAD encoded by pTYB4/ICAD-L was expressed in E. coli 
strain ER2566 and purified using the IMPACTTM T7 system (New England 
Biolabs Inc.) following the manufacturer's instructions. Intein-ICAD bound 
to chitin beads was left at 4°C overnight in Cleavage Buffer (20 mM 
Tris:HC1, pH 8.0,50 mM NaCl, 0.1 mM EDTA, 30 mM DTT). The protein 
was eluted with Cleavage Buffer without DTT. The eluted protein was 
dialyzed for at least 3 hr against two changes of CAD buffer, aliquoted and 
frozen in N2(1). 
4.2.3 Binding of topo ha to GST- fusion proteins in vitro 
125 ng of purified topo ha and 53.3 ng of purified PARP (in PBS + 5 
mM DTT, 10 mM EDTA and 1% Triton X-100) were incubated with 
glutathione sepharose beads either alone, or with bound GST, GST-ICAD-L, 
GST-CAD, GST-cBubRl or GST-hAIRK2. The bound fraction was resolved 
by SDS-PAGE (10% gel), and topo ha was detected by immunoblotting with 
monoclonal antibody Ki-S1. PARP was detected by immunoblottirtg with 
monoclonal antibody C2-10- 
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4.2.4 Immunoprecipitation of HA-tagged CAD and GFP from stable cell 
lines (Steps after establishment of stable cell lines were performed by 
Stefanie Kandels-Lewis) 
Stable lines of MSB-1 chicken lymphoblastoid cells expressing 
His:HA:CAD and His:HA:GFP were obtained by electroporation with 
Zeo:His:HA:CAD and Zeo:His:HA:GFP (310 V 975 pF (BioRad Gene-Pulser 
with 0.4 mm cuvettes)), selected with 400 ig/ml Zeosin (Invitrogen) and 
confirmed by immunoblotting with anti HA tag antibody. For 
immunoprecipitation, cells were harvested, washed twice with PBS/EDTA 
and lysed by sonication for 5 seconds at setting 4 (max) with microtip in IPP 
150 (10 mM Tris:HC1 pH 8.0, 150 mM NaCl, 0.1% NP-40), and insoluble 
material removed by centrifugation for 5 min at 8161 x C at 4°C. HA-
conjugated proteins were immunoadsorbed using mAb 12CA5 preloaded 
onto Affi-Prep Protein A Support beads (BioRad). After incubation for 1 hr 
at 4°C the beads were washed 3 times for 5 min with 25 bed volumes of 
either IPP150, IPP200 (200 mM NaCl) or IPP300 (300 mM NaC1). Bound 
proteins were subjected to SDS-PAGE in 10 % Prosieve 50 Acrylamide gels 
(FMC, Rockland, Maine USA), transferred to Hybond C nitrocellulose 
(Amersham), and detected by ECL. Detection of topo lla was with Rabbit C 
(Hoffmann, Heck et al., 1989) at a 1:1000 dilution. Detection of HA-CAD 
was with mouse mAB 12CA5 diluted 1:1000. 
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4.2.5 Kinetoplast minicircie decatenation assay (GST-fusion proteins were 
prepared by Kumiko Samejima. The assay was performed in the 
laboratory of Prof. Neil Osheroff.) 
0.3 pg of kinetoplast DNA was incubated with 10 nM purified human 
topo llcL plus 10 nM of GST:CAD, GST:ICAD, GST:CAD + GST:ICAD, or 
GST alone for 10 min at 37 °C. The reaction was stopped by addition of 
DNA loading buffer, heated at 65°C for 10 mm, loaded onto a 1% agarose 
gel containing 0.5 mg/ml ethidium bromide and run at 90V for 2 hr (Fig 
23B), and the minicircies released by decatenation were quantified. No 
detectable intact minicircies were released in incubations with GST-CAD or 
GST-CAD + His-ICAD-L in the absence of topo llc. Under these conditions, 




4.3.1 Topo ha has a role in chromatin condensation during apoptosis 
HeLa nuclei incubated in E/X extracts underwent chromatin 
condensation in two stages: condensation against the nuclear rim was 
followed by the formation of discrete apoptotic bodies (Fig. 21B). The rim-
condensation also occurred when caspase activity was inhibited with the 
peptide fluoromethylketone inhibitor DEVD-fmk (Fig. 21C -see also chapter 
2 Fig. 10). Strikingly, simultaneous inhibition of caspase and topo II activity 
completely abolished apoptotic chromatin condensation (Fig. 21E). This 
inhibition of apoptotic chromatin condensation was unlikely to arise from 
global changes in the accessibility of chromatin to condensation factors, 
since simultaneous inhibition of caspases and topo II had no effect on the 
ability of CAD nuclease to cleave the nuclear DNA to an oligonucleosomal 
ladder (performed by Francoise Durriu and data not shown). 
The abolition of apoptotic chromatin condensation following 
simultaneous inhibition of topo II and caspases was seen with the highly 
specific topo II inhibitor, ICRF-187, suggesting that the effect is due to action 
of the drug on topo II(Gorbsky, 1994). In a further control, apoptotic 
chromatin condensation was restored when highly purified human topo ha 
was added to nuclei in E/X extract in the presence of the topo II and caspase 
inhibitors (Fig. 21F). Topo ha alone had no effect on the morphology of 
nuclei in buffer after 2 hr (Fig. 21J). 
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Simultaneous inhibition of caspases and CAD (by addition of the 
ICAD-L) also blocked chromatin condensation in E/X extracts (Fig. 21H). 
This confirmed our previous results suggesting that CAD and caspases act 
in parallel pathways of apoptotic chromatin condensation (chapter 2.3.5). 
Surprisingly, this inhibition of chromatin condensation could be partially 
reversed upon addition of purified human topo II( (Fig 211). 
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Figure 21. Topo ha is required for apoptotic chromatin condensation in the 
absence of caspase activity. Isolated HeLa cell nuclei were preincubated 
either with diluent alone (A-C) or 50 zg/ml ICRF-187 (D-F). The nuclei 
were then added to buffer (A) or apoptotic EIX extract (chapter 2) (B-I) and 
further incubated for 2 hr at 37°C. (D) -Inhibition of topo ha did not inhibit 
apoptotic chromatin condensation. (E) - Inhibition of topo IJcz plus caspases 
(with 100 pM DEVD-fmk) abolished chromatin condensation. (F) - This 
block was reversed if 1.5 ig (4.5 pM) purified human topo ha was added at 
the start of the 37°C incubation. (G) Inhibition of CAD with 160 ng of DM-
ICAD-L does not block apoptotic chromatin condensation (H) Simultaneous 
inhibition of CAD plus caspases blocks morphological apoptosis; (I) 
Simultaneous inhibition of CAD plus caspases - rescue of apoptotic 
morphology with 1.5 ig added topo ha. (J) Purified human topo ha (1.5 ig 
= 4.5 pM) did not induce chromatin condensation in nuclei in buffer. The 
panels below each micrograph indicate the percentage of apoptotic cells 
scored in the microscope. Green panels were interpreted as a normal 
morphology. Red panels were interpreted as showing an apoptotic 
morphology. These images were selected from images taken at random. 
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4.3.2 Interaction between topo 1hz and CAD 
Physical interactions between topo ha and CAD were readily 
detected both in vitro and in vivo. Purified topo ha bound quantitatively to 
GST-CAD on glutathione sepharose, but not to GST alone, GST:ICAD-L, 
GST:BubRl, GST:AIRK2, GST:13 tubulin (not shown), or the sepharose alone 
(Fig. 22A). As a control, purified PARP added to the mix did not bind to any 
protein (Fig. 22A). Similar topo 1hz binding was also observed with Intein-
CAD (not shown). 
To confirm that topo ha can bind CAD in cell extracts, we made 
stable sublines of chicken MSB-1 cells expressing His-HA-GFP or very low 
levels of His-HA-CAD. Lysates were prepared, and the expressed CAD was 
immunoprecipitated using anti-HA antibody. These immunoprecipitates 
reproducibly contained topo 1hz, which was not seen in control 
immunoprecipitates of the much more highly expressed control protein, 
His-HA-GFP (Fig. 2213). This demonstrates that CAD can interact with topo 
ha in cell extracts. It is not surprising that only a fraction of topo 1hz was 
bound to CAD, as topo ha is very abundant in MSB-1 cells, and thus is 
presumably present in a vast excess over CAD. 
Importantly, the interaction between topo ila and CAD appears to be 
functionally significant. In a quantitative assay for DNA decatenation, 
purified GST-CAD either on its own or as a complex with His-tagged ICAD-
L, stimulated the decatenation activity of topo ha two to three fold, whilst 
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buffer, GST or GST-ICAD-L had no effect (Fig. 23A). It is important to note 
that under these conditions the CAD is enzymatically inactive, and does not 
interfere with the topo H assay (which measures the release of intact 
minicircles from kinetoplast networks (Fig. 23B). In other experiments, we 
could not detect an effect of topo II inhibition or addition on nuclease 
activity of CAD against nuclear chromatin (data not shown). 
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Figure 22. Physical interaction between topo IIo and CAD in vitro and in 
vivo. (A) Human topo ila 125ng/100pi binds in vitro to GST-CAD, but not 
to GST, GST-ICAD-L, GST-cBubRl or GST-hAIRK2: PARP 53.3ng/lOOpl 
tested as a control does not bind any of these proteins. The Coomassie Blue-
stained gel shows the relative amount of each protein on the beads. (B) A 
subfraction of endogenous topo Ha associates with tagged CAD in vivo. 
HA-tagged proteins were immunoprecipitated from stable transfectants 
expressing His-HA-CAD or His-HA-GFP and subjected to SDS-PAGE. Left 
- blot with anti-topo ha showing the input and unbound fractions 
(equivalent to 8 x 105 cells), and the fractions bound to the beads (5x106 cells 
for His-HA-CAD and 1 x106 cells for His-HA-GFP). Right - blot with anti-
HA showing the input and unbound fractions (equivalent to 8 x 105 cells for 
His-HA-CAD and 1.6 x105 cells for His-HA-GFP). We estimate that His-
HA-GFP is expressed roughly 25-100- fold more abundantly than His-HA-
CAD in these cells. 
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Figure 23. Functional interaction between topo ha and CAD in vitro. (A) 
GST-CAD stimulates topo Ha activity measured using a kinetoplast 
minicircie decatenation assay. The error bars represent standard errors of 
the mean for two independent assays. (B) The kinetoplast minicircie 
decatenation assay. (top) Experimental. All samples contained: 5 nM k-
DNA, 1 mM ATP, and 10 riM topo Ill (except for "-Topo II") in 50 mM Tris, 
pH 7.9, 100 mM KC1, 10 mM MgCl2, 0.5 mM NaEDTA, pH 8.0,2.5% 
glycerol. The positions of the kinetoplast network (substrate), released 
minicircies (topo II reaction product) and linear DNA (product of cleavage 
by CAD) are indicated. Less than 3% of the kinetoplast DNA minicircles are 
cleaved. Since decatenation is determined by quantitating released DNA 
minicircies (and not by disappearance of the k-DNA substrate), any CAD-
mediated DNA cleavage would deplete the topoisomerase II decatenation 
substrate and thus decrease (not increase) observed levels of decatenation. 
(bottom) Controls. This experiment is the same as in the upper panel, 
except that topo II was omitted from all GST, GST-CAD, GST-CAD/J-Ijs-
ICAD, and CST-ICAD samples. That is, the only sample that contained topo 
This "Topo II control." 
A 	 decatenation (%) 
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4.3.3 Topo IIc and GFP-CAD colocalize in healthy cell nuclei. 
It is widely accepted that topo IIcx is nuclear (Adachi et al., 1997), and 
that CAD must be nuclear during apoptotic execution (Enari et al., 1998). 
However the location of CAD in non-apoptotic cells has been much more 
controversial. Initial biochemical fractionation results that identified first 
DFF (Liu et al., 1997), and then CAD/ICAD (Enari et al., 1998) were obtained 
using cytoplasmic extracts. However, these experiments did not take special 
steps to minimize leakage of soluble proteins from nuclei during extract 
preparation. The first evidence suggesting that the CAD/ICAD complex 
might be nuclear came with the observation that exogenous ICAD is nuclear 
when expressed in a variety of cell types (chapter 3) (Liu et al., 1998). In 
addition, our subcellular fractionation experiments confirmed that 
endogenous ICAD is predominantly nuclear (chapter 3). Consistent with 
this localization, we have recently identified an autonomous NLS at the C-
terminus of ICAD-L (chapter 3). In the present study we have addressed the 
localization of the CAD nuclease itself. 
GFP-CAD is exclusively nuclear when expressed at low-to-moderate 
levels in cultured cells (Fig. 24A, panel 2 - see also chapter 3 Fig. 18E). The 
expressed protein is distributed throughout the nucleus in a micropunctate 
pattern that largely follows the distribution of the DNA. Endogenous topo 
ha has a similar distribution in interphase cell nuclei (Fig. 24A, panel 3), and 
in a merged image (Fig. 24A, panel 4), the CAD and topo ha signals 
superimpose as a yellow signal distributed throughout the nucleus. In order 
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to confirm the nuclear localization of endogenous CAD, we prepared a 
rabbit antiserum to cloned murine CAD and used this in subcellular 
fractionation experiments (Fig. 24B). These results reveal that a substantial 
portion of the CAD is found in the nuclear fraction. Although we cannot 
exclude the possibility that a portion of CAD is normally resident in the 
cytoplasm, our results reveal that much of this protein is nuclear, and would 












Figure 24. (A) Topo IIcx and GFP-CAD colocalize in healthy cell nuclei. 
Chicken DU249 cells were transfected with constructs expressing GFP-CAD 
and then stained for endogenous topo ha. The two proteins were 
distributed throughout the nuclei in an overlapping micropunctate pattern. 
The image shown is a single deconvolved optical section obtained with a 
DeltaVision microscope. (microscopy by Bill Earnshaw) (B) A significant 
portion of endogenous CAD is nuclear. HeLa S3 cells were fractionated into 
nucleus and cytoplasm (chapter 3.2.4) and immunoblotted with rabbit 
antibody raised against murine CAD, mouse anti-tubulin, and human 
autoantibody against topo I. 
124 
4.4 Discussion 
The experiments described above provide the first evidence that topo 
ha has a role in chromatin condensation during apoptosis. They show that 
simultaneous inhibition of either caspase plus topo II or caspases plus CAD 
blocked chromatin condensation in E/X extracts. This inhibition was 
reversed by the addition of purified topo ha. The rescue by purified topo 
ha in the presence of the ICRF-187 inhibitor raises the possibility that topo 
ha could be functioning in a non-enzymatic role, either as a structural or 
targeting factor, as has been proposed for its role in mitotic chromosome 
condensation (Adachi, Luke et al., 1991). The suprising result that addition 
of purified topo ha can reverse the effect of the simultaneous inhibition of 
caspases plus CAD suggests that topo ha acts downstream of CAD or 
promotes condensation in a pathway parallel to the CAD pathway. 
However, it was also possible that the added topo ha might interfere with 
the interaction between CAD and the exogenous ICAD added to these 
reactions as a CAD inhibitor. 
These results might be explained if CAD and topo II functionally 
interact in cells. The present study showed that topo ha and CAD 
physically interact in vitro and in vivo. Functional interaction between CAD 
and topo II was shown by an in vitro assay. Co-localization of topo II and 
CAD in the nucleus was shown by the experiment with GFP:CAD and a cell 
fractionation assay. All these results strongly suggest that CAD and topo II 
125 

functionally interact in normal cells, and presumably, in apoptotic cells to 
induce chromatin condensation. 
The results presented in this chapter reveal that the control of 
apoptotic chromatin condensation is likely to be complex. The results are 
consistent with models in which CAD and topo ha act in independent 
pathways in E/X extracts, but both have their activities modulated by 
caspases. Recent results have identified several other molecules that appear 
to be able to induce apoptotic chromatin condensation in nuclei. These 
include the mitochondrial flavoprotein AIF (apoptosis-inducing factor) 
(Susin et al., 1999), L-DNase II (Torriglia, Perani et al., 1998) and acinus 
(Sahara et al., 1999). The experiments reported here suggest that in the 
absence of caspases, none of these activities is sufficient to induce apoptotic 
chromatin condensation unless either CAD or topo ha is also present and 
functional. It is possible that AIF and Acinus might function in the same 
pathways as CAD or topo ha during apoptotic chromatin condensation. 
Although a role for topo ha in apoptotic execution has been 
controversial (Lagarkova et al., 1995; Beere et al., 1996), a recent study clearly 
demonstrated an involvement of the enzyme in the generation of reversible 
high molecular weight DNA fragments following oxidative stress (Li et al., 
1999). In addition, a more recent study has shown that topo ha can 
stimulate the activity of CAD against a naked DNA substrate approximately 
8-fold, although the cleavage of chromatin substrates was essentially 
unaffected (Widlak et al., 2000). A direct interaction such as demonstrated 
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here between topo II( and CAD might result in targeting of CAD to sites 
occupied by topo IIo at the base of chromosomal loop domains. At those 
sites, CAD might initially stimulate the activity of topo ha, and then 
subsequently, upon cleavage of ICAD-L by caspases, CAD might commence 
the wholesale digestion of the DNA that is characteristic of apoptotic 
execution, possibly being further stimulated by interactions with topo ha. 
The present results predict that CAD cleavage might initiate at or near topo 




Purpose of this study 
One of the hallmarks of apoptosis is the dramatic changes of nuclear 
morphology that occur during apoptotic execution. However, the 
mechanisms underlying these changes are not understood. In this study, 
chromatin condensation and DNA fragmentation were used to assay nuclear 
disassembly. The goal of this study was to elucidate the biochemical 
mechanism of the changes in nuclear morphology. The initial aim was to 
clarify whether caspases drive nuclear disassembly directly or whether 
caspases play an executive role, activating downstream factors which induce 
nuclear disassembly. 
Further characterization of the cell free system 
A revision of the protocol for preparing S/M extracts revealed that it 
is possible to prepare a variety of extracts which represent different stages of 
apoptosis (C/D, S/M and E/X extracts) from cells in the same culture. Both 
S/M and E/X extracts, which represent the committed and execution 
phases, respectively, were found to induce apoptosis in isolated nuclei. 
However, they showed strikingly different effects when a caspase-inhibitor 
was added to the extracts: S/M extracts required caspase activity to induce 




These data demonstrated that caspase-activated downstream factors 
are responsible for chromatin condensation during apoptotic execution 
rather than caspases themselves (chapter 2). It was also found that PARP 
and lamin cleavage by caspases are dispensable for chromatin condensation, 
at least in an in vitro system. 
In addition, it was shown that internucleosomal DNA cleavage and 
chromatin condensation are independent during apoptosis as addition of 
ICAD protein to E/X extracts inhibited DNA fragmentation but not 
chromatin condensation. Interestingly, simultaneous inhibition of topo II 
and caspases abolished chromatin condensation activity of E/X extract, 
however, DNA fragmentation was not suppressed. 
CAD is a nuclear protein 
Since inappropriate activation of CAD is potentially harmful for cells, 
the protein must be carefully regulated. One mechanism regulating 
apoptotic pathways could involve translocation of key factors such as 
cytochrome c, AIF, Bid, and caspases between subcellular compartments. 
Moreover, it was reported that translocation of unknown factors is necessary 
for nuclear disassembly in Fas-mediated apoptosis (Yasuhara et al., 1997). 
Here I tested the hypothesis that CAD/ICAD is sequestered within the 
cytoplasm of living cells and then, after liberation of CAD by caspase 
mediated cleavage of ICAD, CAD translocates into the nucleus where it 
induces apoptosis. The data presented in chapter 3 demonstrated that the 
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CAD/ICAD complex is nuclear in healthy cells. Thus CAD cannot be the 
factor which is transported into the nucleus at the onset of apoptosis. 
Caspase-3 is known to cleave nuclear proteins such as ICAD and 
PARP during apoptosis (Lazebnik et al., 1994; Liu et al., 1997). Interestingly, 
in this study nuclei incubated with caspases did not exhibit chromatin 
condensation although PARP and lamins were cleaved. This suggests either 
that extensive DNA fragmentation is needed to induce chromatin 
condensation when nuclei are incubated with recombinant CAD; or that the 
physiological level of CAD in nucleus may be insufficient to induce 
chromatin condensation (the caspases would have been expected to activate 
nuclear CAD); or, interestingly, that an additional co-factor(s) may be 
required. 
CAD and topo II are chromatin condensation factors 
I demonstrated that E/X extracts contain at least two factors capable 
of inducing chromatin condensation. One such factor is CAD (chapter 2). 
CAD induces both chromatin condensation and internucleosomal DNA 
cleavage. The other is topo II, which interacts with CAD (chapter 4). The 
activities of both CAD and topo II are modulated by caspases. CAD and 
topo II appear to work in parallel during apoptotic chromatin condensation 
(chapter 4) and preliminary evidence suggests that AIF and topo II might 
work on the same pathway (data not shown). 
Other proteins, including AIF, acinus, and L-DNase II were 
previously reported as chromatin condensation factors (chapter 1.4). 
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However, it is shown here that none of these factors is sufficient to induce 
chromatin condensation under conditions in which caspases plus CAD or 
caspases plus topo II are inhibited (chapter 4). 
Final remark 
The results presented in this thesis contributed to the identification of 
two components, CAD and topo II, involved in the mechanics of apoptotic 
execution. I believe that basic apoptosis research such as this will further 
our understanding of biological functions which will ultimately contribute 




This study showed that caspase-activated downstream factors are 
responsible for chromatin condensation during apoptotic execution. E/X 
extracts appear to contain at least two such factors: CAD and topo II. Initial 
characterization of these two factors revealed that both CAD and topo II 
locate in the nucleus and interact with each other in non-apoptotic cells but 
work in parallel during apoptotic chromatin condensation, suggesting that 
more than one pathway exists. In addition, using an in vitro system it was 
shown that PAR]? and lamin cleavage by caspases were dispensable for 
chromatin condensation. Furthermore, internucleosomal DNA cleavage is 
unnecessary for nuclear apoptosis and chromatin condensation. 
Although these results and the identification of several chromatin 
condensation factors, including CAD and topo II, greatly contributed to the 
understanding of the mechanism of chromatin condensation in apoptosis, 
many questions still remain. It is not known whether any of these proteins 
work in the same pathway. The regulation of these factors is largely 
unknown. Furthermore, nothing is known about how these factors change 
the state of chromatin. It is not clear whether any component that is 
involved in mitotic chromatin condensation also functions in apoptotic 
chromatin condensation, other than topo II. 
In my future studies, I would like to focus on the following points. 
The first aim is to identify the relationships between the known chromatin 
condensation factors. Preliminary results have suggested AIF and topo II 
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might work in the same pathway. The second aim is to investigate the 
mechanism of the chromatin condensation activity of CAD. This might be 
independent from its nuclease activity. The third aim is to identify factors 
which are involved in either CAD regulation or chromatin condensation 
directly. The final aim is to clarify the state of histone phosphorylation and 
chromatin condensation. Each project is discussed in more detail below. 
A combination of genetic and biochemical approaches will be suitable 
for these projects. As a genetic approach, cell lines will be prepared in 
which a gene of interest such as CAD or topo II, is knocked out. To knock-
out genes, the chicken DT40 B cell lymphoma line has a number of 
advantages: efficient gene targeting, stable genotype, double/triple and 
conditional knock-outs are possible, and the small genome size of the 
chicken allows greater ease for obtaining a true gene, rather than a pseudo 
gene. In addition, cytosolic extracts and nuclei can be prepared for in vitro 
experiments from these cells and cytological analysis is possible. 
Cell lines deficient in a chromatin condensation factor will be useful 
to identify other factors which operate in the same pathway. The CAD 
knock-out will be prepared in DT40 cells. A human conditional topo II 
knock-out has been prepared in HT1 080 cells (gift of Andy Porter) and these 
cells will be used to look at topo II function. In addition, microinjection of 
recombinant AIF into nuclei of topo II null cells will give us clear answer if 
topo II works upstream or downstream of AIF. In the latter case, chromatin 
condensation against the nuclear periphery would be suppressed in the topo 
II null cells. Since addition of inhibitors to living cells is difficult to control 
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in terms of specificity and dose dependency, knock-out cells may produce 
more reliable data. 
Secondly, CAD knock-out cells will be useful to confirm in vivo 
whether CAD has separate functions in chromatin condensation and DNA 
cleavage. It may be possible to identify the catalytic site of CAD nuclease 
either from the crystal structure or computer modeling, comparing the 
sequence with those of other known nucleases. Mutation of crucial amino 
acids located in the catalytic site might create an inactive nuclease but one 
still capable of inducing chromatin condensation. In addition, replacing the 
endogenous gene with a GFP-fusion CAD gene under its endogenous 
promoter may avoid problems accompanied with overexpression and make 
it possible to follow the localization of functional CAD in living and 
apoptotic cells under the microscope. 
Third, taking advantage of chicken lymphoblast stable MSB-1 cell 
lines which constitutively over-expresses 6xHis and HA tagged mouse 
ICAD and/or CAD, biochemical analysis will be performed to identify 
proteins that are bound to CAD and ICAD in vivo. Such proteins might be 
involved in the regulation of CAD/ICAD or in the chromatin condensation 
working downstream of CAD. CIDE proteins which share CIDE-N/CAD 
domain and interact with CAD/ICAD in vitro are expected to be isolated 
from this approach. It is reported that overexpression of CIDE-A protein in 
cells induces apoptosis (Inohara et al., 1998) and mitochondrial localization 
and dimerization are required for CIDE-B to induce apoptosis (Chen, Guo et 
al., 2000), however, the molecular mechanisms are not known. The CAD 
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null cell line will be useful to investigate whether the apoptosis-inducing 
activity of CIDE protein depends on CAD. 
Lastly it may be worthwhile investigating the relationship between 
the state of histone phosphorylation and apoptotic chromatin condensation. 
Histone H3 phosphorylation is known to be involved in chromatin 
remodeling in mitotic cells. Furthermore, it was recently reported that 
histone H2B and/or H2AX are phosphorylated in apoptotic cells (Ajiro, 
2000; Rogakou, Nieves-Neira et al., 2000). Phosphorylation of histone H2B 
and/or H2AX might be involved in apoptotic chromatin condensation. 
Genetic approaches and specific antibodies which recognize only the 
phosphorylated form of histones will be useful for this project. Histone 
genes are clustered - usually 6 genes exist for each histone in case of chicken. 
One Japanese group has created a DT40 cell line in which about half of 
histone gene clusters are removed. Amazingly, the cell line is still alive. If 
the remaining histone H2B or H2AX gene can be replaced with the non-
phosphorylatable form of the histone and apoptotic chromatin condensation 
is suppressed, this would mean that specific phosphorylation is a key factor 
of apoptotic chromatin condensation. Even if this is not the case, the specific 
histone phosphorylation of H2B and/or H2AX might be useful as an assay 
for initial DNA cleavage during apoptosis. 
I believe that these approaches will reveal the mechanisms of nuclear 
disassembly during apoptosis in the near future. Furthermore, it will be 
interesting and important to determine whether a failure of chromatin 
condensation and fragmentation underlies apoptosis-related human 
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disorders, taking into account that chromosome condensation and nuclear 
fragmentation are supposed to facilitate the engulfment and digestion by 
neighbouring cells or macrophages. In addition, since the initial DNA 
cleavage during apoptosis is supposed to release chromatin loops, these 
studies of apoptosis may also help us to understand the chromatin structure 
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Abstract. We have compared cytoplasmic extracts 
from chicken DU249 cells at various stages along the 
apoptotic pathway. Extracts from morphologically nor-
mal "committed stage" cells induce apoptotic morphol-
ogy and DNA cleavage in substrate nuclei but require 
ongoing caspase activity to do so. In contrast, extracts 
from frankly apoptotic cells induce apoptotic events in 
added nuclei in a caspase-independent manner. Bio-
chemical fractionation of these extracts reveals that a 
column fraction enriched in endogenous active 
caspases is unable to induce DNA fragmentation or 
chromatin condensation in substrate nuclei, whereas a 
caspase-depleted fraction induces both changes. Fur-
ther characterization of the "execution phase" extracts 
revealed the presence of an ICAD/DFF45 (inhibitor of 
caspase-activated DNase/DNA fragmentation factor)- 
inhihitable nuclease resembling CAD, plus another ac-
tivity that was required for the apoptotic chromatin 
condensation. Despite the presence of active caspases, 
committed stage extracts lacked these downstream ac-
tivities, suggesting that the caspases and downstream fac-
tors are segregated from one another in vivo during the 
latent phase. These observations not only indicate that 
caspases act in an executive fashion, serving to activate 
downstream factors that disassemble the nucleus rather 
than disassembling it themselves, but they also suggest 
that activation of the downstream factors (rather than 
the caspases) is the critical event that occurs at the tran-
sition from the latent to active phase of apoptosis. 
Key words: apoptosis • caspases • CAD • ICAD 
DFF 
POPTOSIS is a cellular disassembly pathway that is ac- 
tivated by members of a distinct family of cysteine 
proteases called caspases (Cohen, 1997; Nicholson 
and Thornberry, 1997; Villa et al., 1997; Cryns and Yuan, 
1998). Genetic analyses show clearly that caspases such as 
CED-3 and caspase-3 are essential for apoptotic death 
(Yuan and Horvitz, 1990; Kuida et al., 1996; Woo et al., 
1998). Nonetheless, the role of these enzymes in the death 
pathway remains unclear. One recent study has suggested 
that cells can activate caspases without undergoing apop-
tosis (Boise and Thompson, 1997). Conversely, even 
though caspase inhibitors usually rescue cells from apop-
tosis (for review see Villa et al., 1997), cell death can occur 
in response to proapoptotic stimuli in the presence of 
these inhibitors (Xiang et al., 1996; McCarthy et al., 1997; 
Lavoie et al., 1998). 
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Careful examination has revealed that cells dying in the 
presence of caspase inhibitors display membrane blebbing 
and cell surface alterations but no changes in nuclear mor-
phology (McCarthy et al., 1997). This observation suggests 
that certain cytoplasmic hallmarks of apoptosis may be 
triggered by enzymes other than caspases, but that nuclear 
events require caspase activity. Consistent with this view, 
cells from caspase-3—null mice (Woo et al., 1998) have 
been reported to display plasma membrane changes and 
cleavage of the nuclear protein poly (AD P-ribose) poly-
merase (PARP)t when undergoing apoptosis, but not the 
chromatin condensation and DNA cleavage that are char-
acteristic of apoptosis (Wyllie et al., 1980). 
Although the preceding observations suggest that cas- 
1. Abbreviations used in this paper: CAD, caspase-activated DNase; CID 
extract, nonapoptotic extract from cells in the condemned phase; DAPI, 
4,6-diamidino-2-phenylindole; DFF, DNA fragmentation factor; E/X ex-
tract, apoptotic extract from execution phase cells; Fr-2 and Fr-3, fractions 
2 and 3 from heparin—agarose chromatography of S/M extract; ICAD, in-
hibitor of CAD; S/M extract, proapoptotic extract from committed phase 
cells; PARP, poly(ADP-ribose) polymerase. 
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pases play a role in certain apoptotic events, particularly 
those occurring in the nucleus, it is not known whether 
caspases function in an executive role to initiate the apop-
totic pathway and leave the work of actually disassembling 
the cell to other downstream factors, or whether they are 
workhorses whose cleavage of key substrates drives cellu-
lar disassembly. Support for an executive role comes from 
the observation that expression of the caspase cleavage 
product of the actin-binding protein GAS2 triggers cytoskel-
etal changes similar to those seen in apoptosis (Brancolini 
el al., 1995). Likewise, caspase cleavage of ICAD/DFF (in-
hibitor of caspase-activated DNase/DNA fragmentation 
factor) releases the nuclease CAD, presumably allowing it 
to enter the nucleus and degrade genomic DNA (Liu et 
at., 1997; Enari et al., 1998; Sakahira et al., 1998). Thus, 
certain products of caspase cleavage play important down-
stream roles in apoptotic events. On the other hand, nu-
merous important structural and nonstructural proteins 
are also directly cleaved by caspases (Cohen, 1997; Nichol-
son and Thornberry, 1997; Porter et al., 1997; Villa et al., 
1997), supporting the alternative hypothesis that caspases 
do the bulk of the work of cutting the cell apart themselves 
(Martin and Green, 1995). 
Current understanding of caspase function has been fa-
cilitated by the development of cell-free systems for the 
study of apoptosis (Lazebnik et at., 1993; Solary et al., 
1993; Newmeyer et al., 1994; Enari et al., 1995a; Martin et 
al., 1995; Schlegel et at., 1995; Liu et al., 1996). One such 
system uses extracts from DU249 chicken hepatoma cells 
that become committed to apoptosis after perturbation of 
the cell cycle (Lazebnik et at., 1993). Highly concentrated 
cytosolic extracts prepared from these morphologically 
normal cells (S/M extracts) reproduce all of the biochemi-
cal features of apoptosis in substrate nuclei (Lazebnik et 
at., 1993), including genome digestion (Wyllie et al., 1980; 
Lazebnik et al., 1993); cleavage of a subset of nuclear pro-
teins, including PARP and lamins (Kaufmann, 1989; 
Ucker et at., 1992a; Lazebnik et al., 1994,1995); chromatin 
condensation; and nuclear fragmentation into apoptotic 
bodies (Lazebnik et al., 1993). This entire program of apop-
totic events is inhibited in vitro by caspase inhibitors (La-
zebnik et al., 1994) or millimolar concentrations of Zn2 
(Lazebnik et al., 1993) just as in intact cells. Although nu-
clei are used as the substrate in these studies, the extracts 
themselves are derived from the cytoplasm of the DU249 
cells (Lazebnik et at., 1993), thus supporting the view that 
cytoplasmic factors and events have an essential role in the 
apoptotic pathway (Jacobson et al., 1994; Schulze-Osthoff 
et al., 1994; Nakajima et al., 1995; Martin et al., 1996; Kroe-
mer, 1997). 
The aim of the present study was to extend this ap-
proach by preparing extracts from cells at various stages of 
the apoptotic pathway to further evaluate caspase involve-
ment in nuclear disassembly. Interestingly, extracts pre-
pared from morphologically normal cells in the latent 
phase (S/M extracts) and those prepared from frankly 
apoptotic cells (execution phase extracts) induced similar 
apoptotic events in exogenous nuclei but exhibited funda-
mental biochemical differences. In particular, apoptotic 
events in the S/M extracts were abolished by caspase in-
hibitors as previously reported (Lazebnik et al., 1994), 
whereas the same events in execution phase extracts were  
not. Further examination revealed that execution phase 
extracts contain at least two caspase-activated factors re-
quired for nuclear disassembly, one of which appears to be 
the nuclease CAD. These experiments not only support 
the view that caspases act in an executive role in nuclear 
apoptosis by activating downstream factors that disassem-
ble nuclei but also suggest that activation of the down-
stream factors (rather than the caspases) accompanies the 
transition between the latent and execution phases of apop-
tosis. 
Materials and Methods 
Cell Treatment and Preparation of Extracts 
Chicken DU249 cells were presynchronized in S phase with aphidicolin 
for 12 h, released from the block for 6 h, and synchronized in mitosis with 
nocodazole for 3 h as described previously (Wood and Earnshaw. 1990; 
Lazebnik et al., 1993). DU249 cells start to undergo apoptosis asynchro-
nously during and after the aphidicolin treatment, presumably as a result 
of the cell cycle disruption. Execution phase (EIX) extracts were prepared 
from the floating cells (mostly apoptotic) obtained from the flasks just be-
fore the addition of nocodazole. S/M extracts were prepared from floating 
cells (>60% mitotic) obtained from the same flasks by selective detach-
ment after the nocodazole treatment. After harvesting of cells for S/M ex-
tract production, cells for the preparation of condemned phase (C/D) ex-
tracts were obtained from the attached (interphase) cells by rinsing the 
same flasks with PBS-EDTA and trypsinizstlon. Large scale "roller S/M" 
extract was prepared as described above for S/M extract except that cells 
were grown in roller bottles. 
In each case, the cells were then washed with KPM buffer (50 mM 
Pipes-KOH. pH 7.0,50mM KCI, 10 mM EGTA, 2mM MgCl2, 20 p.M cy-
tochalasin B [Sigma Chemical Co., St. Louis, MO], 1 mM D'F1', 0.1 mM 
PMSF, I p.g/ml each chymostatin, leupeptin, antipain. pepstatin A) 
(Wood and Earnshaw, 1990) and centrifuged in a small glass Dounce ho-
mogenizer. The cells were subjected to several cycles of freezing and 
thawing and further disrupted by grinding during each thawing cycle. The 
cell lysate was then centrifuged at 139,000g for 2 h, yielding clear cytosolic 
extracts. Protein concentration of each extract was measured by the Brad-
ford assay (Bradford, 1976). Extract concentrations ranged between 12 
and 18 mg/ml. 
Time Course of Caspase Activation 
DU249 cells were subjected to the synchrony procedure used in prepara-
tion of S/M extracts. At the indicated times (0, 5, 10. 15, and 20 h) after the 
addition of aphidicolin, both floating and attached cells were harvested 
from two T150 flasks (the former by shake-off, the latter by trypsiniza-
tion). Cells were washed with MOB buffer, and the number of cells in 
each sample was counted using a hemacytometer. The ratio of interphase, 
mitotic, and apoptotic cells in each sample was determined by examina-
tion of the nuclear morphology after cells (n > 400 for each time point) 
were fixed in methanol/acetic acid (3:1) and stained with 0.5 p.g/ml 4,6-dia-
midino-2-phenylindole (DAPI; Calbiochem. La Jolla. CA). Cells were 
lysed by the freeze/thaw/grinding protocol described above. Lysates (the 
supernatants after centrifugation at 13,000 g for 15 min at 4CC) were affin-
ity labeled with z-EK(biotin)D-aomk as described below. 
Fractionation of SIM Extracts with 
Heparin—Agarose Resin 
Roller S/M extract (typically 7 mg of protein) prepared in KPM buffer 
containing 60 mM KCI was mixed with 360 p.1 of heparin—agarose resin 
(HiTrapHeparin; Pharmacis Biotech, Piscataway, NJ), which was pre-
equilibrated with KPM buffer. This mixture was rotated at 4C for I h and 
centrifuged in a rnicrocentrifuge at 5.000 rpm for 5 mm, and the superna-
tant was recovered (fraction 1; data not shown). Three cycles of absorp-
tion with heparin-agarose were needed to completely absorb all DNase 
activities from S/M extracts. After extensive washing of the resin with KPM 
buffer containing 60 mM KCI, bound proteins were eluted first with 450 p.1 
of KPM containing 0.2 M KCI (fraction 2), and subsequently with 450 p.1 
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of KPM containing 0.6 M KCI (fraction 3). The eluted fractions were de-
salted and concentrated to 4-8 mg/ml protein by centrifugation using UI-
trafree-0.5 filters (5K cut; Millipore. Bedford. MA). 
In Vitro Apoptosis Reaction 
Apoptotic and control extracts were preincubated at 37°C for 15 min with 
100 p.M caspase inhibitors (YVAD-cmk or DEVD-fmk) or diluent. HeLa 
nuclei prepared as previously described (Wood and Earnshaw, 1990; La-
zebnik et al.. 1993) were then added (up to 1.0 X 106  nucleil10 p.l of ex-
tract) and incubated at 37°C for up to 2 h in the presence of an ATP regen-
eration system (Wood and Earnshaw, 1990; Lazebnik ci al., 1993). Nuclei 
were either stained with DAPI to observe chromatin condensation, solu-
bilized in SDS-sample buffer for analysis of protein cleavage, or lysed for 
analysis of DNA ladder formation. 
Caspase Labeling and Fluorogenic Assays 
Labeling. Stock solutions (10 mM in DMSO) of caspase inhibitors 
(YVAD-cmk or DEVD-fmk from Calbiochem) were diluted immediately 
before use with MDB buffer (Wood and Earnshaw, 1990). Extracts were 
preincubated at 37°C for 15 min with 100 1sM YVAD-cmk or DEVD-fmk 
or diluent. After Z-EK(bio)D-aomk (Martins et al., 1997a) was added to a 
final concentration of 1 p.M from a 100X stock solution in DMSO, ex-
tracts were incubated at 37°C for 15 mm. Labeled proteins were subjected 
to conventional 16% SDS-PAGE (Laemmli, 1970), transferred to nitro-
cellulose membrane, probed with peroxidase-coupled streptavidin, and vi-
sualized by ECL (Amersham Corp., Arlington Heights, IL). 
Fluorogenic Assays. DEVD-AFC cleavage activity was determined by a 
slight modification of previously described methods (Martins et al., 
1997a). Extracts were preincubated with caspase inhibitors or diluent for 
15 min at 37°C. Samples containing 20-30 p.g of various fractions or 25 p.g 
of cytosolic protein (estimated by the Bradford assay) from etoposide-
treated K562 leukemia cells (a positive control) were diluted to 50 0 with 
buffer A (25 mM 1-lepes, p1-1  7.5.5 mM MgCl2, 5 mM EDTA. 1 mM EGTA 
supplemented immediately before use with 1 mM PMSF, 1 mM DTT, 10 
p.g/ml pepstatin A, and 10 jig/ml leupeptin), mixed with 225 ld freshly pre-
pared buffer B (25 mM l-lepes. p1-I 7.5, 0.1% [wt/vol] CHAPS, 10 mM 
DTT, 100 U/mI aprotinin. 1 mM PMSF) containing 100 p.M DEVD-AFC 
(Enzyme System Products, Dublin. CA), and incubated for 4 h at 37°C. 
Reactions were terminated by addition of 1.225 ml ice-cold buffer B. Fluo-
rescence was measured in a Sequoia-Turner spectrofluorometer using an 
excitation wavelength of 360 nm and emission wavelength of 475 nm. After 
subtraction of fluorescence in blank samples (lacking protein), amounts of 
the liberated fluorophore were determined by comparison to a standard 
curve containing 0-1.500 pmol of 7-amino4-trifluoromethylcoumarin. 
Control experiments indicated that product release was linear with re-
spect to incubation time and extract protein under the conditions used. 
Protein and DNA Gel Electrophoresis 
PARP and Lamin Cleavage. After HeLa nuclei (5 >< 105 per loading) were 
incubated in extract for 2 h at 37°C, the reaction was stopped by the addi-
tion of sample buffer. Samples were boiled at 95°C for 5 mm, sonicated 
briefly, subjected to 10% conventional SDS-PAGE (Laemmli, 1970; 
Wood and Earnshaw, 1990; Lazebnik et al., 1993), and transferred to ni-
trocellulose. PARP and its 89-kD cleavage product were detected with the 
C-2-10 monoclonal antibody (Lamarre et al., 1988). Lamins A/C and their 
cleavage product were detected with a rabbit polyclonal antibody recog-
nizing the NH, terminus of the protein (gift of Larry Gerace). Bound anti-
body was detected by ECL. 
DNA Ladder Formation. HeLa nuclei (5 x 10 per loading) were incu-
bated for 1-2 h in extract, centrifuged, and lysed in DNA lysis buffer (50 
mM Tris-HCI, pH 8.0, 10 mM EDTA, 0.5% Sarcosyl. 0.5 mg/ml protein-
ase K) at 50°C for 1 h. DNA was treated with RNase at 50°C for 1 h, phe-
nol/chloroform extracted, ethanol-precipitated overnight at -70°C, resus-
pended in TE, and loaded onto 1% agarose gels containing 0.5 Jig/ml 
ethidium bromide. 
Plasmid DNA Digestion Assay. Extracts (18-36 p.g protein in 10 p.1 of 
KPM buffer) supplemented with an ATP regeneration system (Wood and 
Earnshaw, 1990) and 100 p.M DEVD-fmk (or diluent) were incubated at 
37°C for 15 mm. After addition of 160 ng purified glutathione-S-trans-
ferase-ICAD (GST-ICAD) (Sakahira et at., 1998), incubation was contin-
ued for an additional 10 min at 37°C. Upon addition of substrate (pBlue-
script, 1.2 p.g), incubation was continued for 30 min at 37°C. DNA 
extraction and electrophoresis were then performed as above. The results  
of the preincubation assay (Fig. 5) were best seen by Southern blotting. 
DNA agarose gels were denatured for 30 min with denaturing buffer (1.5 
M NaCl, 0.5 M NaOH), neutralized for 30 min with neutralizing buffer 
(0.5 M Tris-HCI, pH 7.5. 1.5 M NaCI. 1 mM EDTA), and transferred to 
nylon membrane (Hybond-N; Amersham Corp.) with 20X SSC buffer. 
The nylon membrane was UV cross-linked and hybridized (Church and 
Gilbert, 1984) with a pBluescript probe that was labeled with 32P using the 
megaprimer system (Amersham Corp.). The film was exposed for 1 h at 
-80°C with an intensifying screen. 
Pulsed-Field Gel Electrophoresis. HeLa nuclei (5 X 10) were incubated 
with each fraction (10 p.1) for the specified time and embedded in 1.5% 
low melting agarose (Sea Plaque GTG agarose, FMK). Gel blocks were 
soaked in nuclei lysis buffer (10 mM Tris-HCI, pH 9.5, 500 mM EDTA, 1 
mg/ml proteinaae K, 1% sarkosyl) for 20 h at 50°C and then stored in TE 
buffer at 4°C. Blocks were transferred into the wells of an agarose gel and 
sealed in place by the addition of a small volume of agarose. Contour-
clamped homogeneous (CHEF) electrophoresis was performed using a 
CHEF system purchased from Bio-Rad Laboratories Ltd. (Watford, En-
gland) with a model 200/2.0 power supply and a Pulsewave 760 switcher. 
Horizontal gels (1% agarose; Sigma Chemical Co.) were run at 14°C at 
200 V for 20 h with a pulse ramp of 4-40 s and stained with ethidium bro-
mide. 
Electron Microscopy. Isolated HeLa cell nuclei incubated in extract or 
MDB buffer were centrifuged, washed with MDB buffer, placed on adhe-
sion slides (Marienfeld) for 5 mm, and fixed for 30 min with 2% glutaral-
dehyde in Dulbecco's PBS, pH 7.4. After fixation the nuclei were washed 
in 0.1 M cacodylate buffer, and postfixed with 4% Os04 in 0.1 M sodium 
cacodylate, p1-I 7.4, for 30 mm, Prestaining was done with 3% uranyl ace-
tate in H50 for I h. The nuclei were dehydrated in ethanol (30-100%) and 
embedded in Araldite resin (Agar). Gold sections were cut with a Rei-
chert (Vienna, Austria) microtome and placed on copper grids. Images 
were photographed on an electron microscope (model CM100 Biotwin; 
Philips Electron Optics, Mahwah, NJ). 
Expression and Purification of Double 
Mutant His6-ICAD 
The method used for mutation was the PCR-based megaprimer strategy 
(Seraphin and Kandels-Lewis, 1996). Primer I (T7 primer). primer 2 (5'-
GCCCTGCI'CTCAGGCTCATC-3'), and primer 3 (5'-CAGCTCTG-
CACATGGGATGTC-3') were used to generate the DEPD'17E mutation 
in the ICAD cDNA in pBluescript. Primer 4 (5'-C7GCFGTCAGAA-
GAGGACCTC-3'), primer 5 (5'-GCCGACGCCTGTCTCAACTGC-
3'), and primer 6 (T3 primer) were used to generate the DAVD224E muta-
tion in ICAD. Each single mutant was digested with Eco47III (New 
England Biolabs, Hitchin, UK) and XbaI (New England Biolabs) and 
then ligated to generate double mutant ICAD in pBluescript. This double 
mutant ICAD was digested with Spel, blunt-ended with T4 DNA poly-
merase (New England Biolabs) plus 100 p.M dNTPs, and digested with 
KpnI (New England Biolabs). The resulting fragment was ligated into 
pRSET B (Invitrogen. Carlsbad, CA) that had been digested with Hindlil, 
blunt-ended with T4 DNA polymerase, and digested with KpnI. Double 
mutant ICAD in pRSETB was transformed into Escherichia coil BL21 
(DE3)Lys S cells. Transformed cells were grown to OD6w = 0.5-0.7, and 
protein expression was induced with IPTG (1 mM) for 3-4 h. Cells were 
collected by centrifugation at 5,000 g for 10 min and frozen at -80°C. The 
cell pellet was thawed on ice for 15 min and resuspended in lysis buffer (50 
mM NaH2PO4 pH 7.5, 300 mM NaCl, 10 mM imidazole). Lysozyme was 
added to 1 mg/ml, and the suspension was incubated on ice for 30 mm, 
sonicated on ice until 80% of the cells were disrupted, and then centrifuged 
at 4,000 g for 20 min at 4°C. The supernatant was incubated on a rotating 
mixer for 1 h at 4°C with 0.5 ml of Ni-agarose (Qiagen. Chatsworth. CA) 
that had been preequilibrated with lysis buffer. The resin was then loaded 
Onto a polyprep chromatography column (Bio-Rad Laboratories) and 
washed twice with 4 ml of wash buffer (50 mM NaH2PO4 pH 7.5,300 mM 
NaCl, 20 mM imidazole). Protein was eluted with 2 ml of elution buffer 
(50 mM NaH2 PO4 pH 7.5,300 mM NaCl, 250 mM imidazole). All samples 
were subjected to SDS-PAGE and examined by Coomassie blue staining. 
The eluted protein was dialyzed for at least 3 h against two changes of 
CAD buffer (10 mM Hepes. pH 7.4, 50 mM NaCl, 5 mM EGTA, 2 mM 
MgCl2. 1 mM DTI'), atiquoted, and frozen in N2(l). 
Expression and Purification of His6-I CAD/CAD 
To express active CAD in E. coil, we constructed a bicistronic expression 
vector in which His6-ICAD was expressed upstream of CAD. In addition 
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to the NH,-terminal histidine tag, the ICAD open reading frame was engi-
neered to change the stop codon to TAA and to insert a Shine-Delgarno 
sequence (GGAAT) downstream of the stop codon. The wild-type ICAD 
eDNA in pBluescript was digested with Spel, blunt-ended with T4 DNA 
polymerase, and digested with Kpnl. The resulting fragment was ligated into 
pRSET B that had been digested with Hindill, blunt-ended with T4 DNA 
polymerase, and digested with Kpnl. The coding region of the CAD eDNA 
was extracted from the full-length CAD eDNA in pBluescript by PCR using 
Vent potyrnerase (New England Biolabs) with primer 7 (5'-GGAAYFCAT-
GTGCGCGGTGCTCCG-3') and primer 8 (5'-GCGAAGDVFCAC-
TAGCGcTTCCGAG-3'). The PCR product was digested with EcoRl 
and Hindlll, and the resulting fragment was ligated into pBluescript. 
To create the COOH terminus of ICAD (from the Bsml site at nucle-
otide 909) engineering in a TAA stop codon and Shine-Delgarno se-
quence, primer 9 (5'-GGAAGATCTGCATFCACTCAGGAATC-3') 
and primer 10 (5'-GGAATTCCTCCYFACGAGGAGTCTCGmG-3') 
were used with Vent polyrnerase. The PCR product was digested with 
BglIl (New England Biolabs) and EcoRl and ligated into pRSETB that 
had been digested with Bglll and EcoRl. The CAD coding sequence in 
pBluescript was digested with EcoRl and Hindlil and ligated into pRSET 
B containing the newly modified COOH terminus of ICAD with the 
Shine-Delgarno sequence. This intermediate was then digested with Nhel 
and Bsml, and into it was inserted the His-tagged NH2-terminal portion of 
ICAD, obtained from ICAD in pRSETB that had likewise been digested 
with Nhel and Bsml. This bicistronic Vector His6-ICAD/CAD in pRSET 
B was transformed into E. coli BL21 (DE3)Lys S cells. Protein was ex-
pressed and purified by nickel chelate chromatography as described above 
for double mutant ICAD. The dialyzed ICAD/CAD protein was frozen in 
N2(l) either directly or following addition of glycerol to 40%. 
In Vitro Apoptosis with Purified CAD 
50-p.l reactions contained various combinations of the following reagents 
added sequentially (see legend to Fig. 6): 10 fLI ICAD/CAD protein 
(stored in CAD buffer plus 40% glycerol), 5 p.1 caspase-3, an ATP regen-
eration system (final concentration 0.8 mM ATP, 4.5 mM creatine phos-
phate, 22.5 pg/mI creatine kinase). DEVD-fmk (final concentration 300 
p,M), double mutant ICAD protein (2 pg), and CAD buffer as needed to 
make up the final volume. ICAD/CAD complexes were preincubated 
with caspase-3 at room temperature ('-.'25°C) for 30 min to cleave wild-type 
ICAD and release active CAD. At the end of this preincubation. diluent, 
DEVD-fmk, or double mutant ICAD were added (defined as t = 0), and 
the mixture was divided into three aliquots to assay various apoptotic 
events. To examine ICAD cleavage during the preincubation, a 10-p.l ali-
quot was mixed with sample buffer, boiled, resolved by SDS-PAGE, 
transferred to nitrocellulose membranes, and probed with ICAD antibody 
(Samejima and Earnshaw, 1998), which was detected by ECL (Amersham 
Corp.). To assay CAD activity against a plasmid DNA substrate, a 6-pd al-
iquot was supplemented with 0.35 pg pBluescript, BSA (final concentra-
tion 1 mg/ml), and 4 cl of CAD buffer. This mixture was further incubated 
at 37'C for 30 mm, extracted with phenol-chloroform, and analyzed on a 
1% agarose gel containing ethidium bromide. To examine the ability of 
the active CAD to induce apoptotic events, HeLa nuclei (1.3 x 10 per 
sample) in 10 p.1 CAD buffer were combined with the remaining 34 p.1 and 
incubated at 37'C for 2 h. At the end of this incubation, I i,l of the reac-
tion mixture was stained with DAPI so that nuclear morphology could be 
examined by fluorescence microscopy (>100 nuclei counted per slide). 
The remaining HeLa nuclei in 43 p.1 of reaction mixture were centrifuged 
and prepared for agarose gel electrophoresis as described above. 
Results 
Extracts from Three Different Stages of Apoptosis 
The apoptotic pathway can be conceptually divided into at 
least three stages (Fig. I A). Upon receipt of a proapop- 
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Figure 1. (A) Diagram of apoptosis as a three 
stage process, with the latent phase being sub-
divided into condemned and committed 
stages. (B) The protocol used for harvesting 
of samples for examination of caspase activa-
tion. (C) The cells harvested at each time 
point were scored for their nuclear morphol-
ogy, based on DAPI staining. (D) Caspase ac-
tivity in whole cell lysates prepared from cells 
harvested at various times points after the ad-
dition of aphidicolin to the culture (time in 
hours shown at bottom). Left, attached cells; 
right, floating cells. The left-most lane shows 
the profile of active caspases in S/M extract. 
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totic signal, cells enter a "condemned" stage: the death 
program is initiated, but cells can be rescued by various 
survival factors. Once cells pass a point of no return, they 
are in the "committed" stage and can no longer be res-
cued. During both of these stages, preapoptotic cells ap-
pear morphologically normal. Eventually, committed cells 
undergo an abrupt transition into apoptotic execution, a 
period lasting from 5 min to I h, during which cellular dis-
assembly and death occur. It is not known where along this 
pathway caspases are activated and at what point the 
caspases activate other downstream factors that act during 
disassembly of the cell. 
We previously noted that active caspases could be de-
tected in extracts from etoposide-treated HL-60 cells sev-
eral hours before the bulk of the cells in the culture exhib-
ited an overtly apoptotic morphology (Martins et al., 
1997a). To study this phenomenon in greater detail, we 
harvested chicken DU249 cells at various times after sub-
jecting cultures to a synchronization protocol (Fig. 1 B) 
shown previously to induce an apoptotic response in this 
cell line (Lazebnik et al., 1993). Floating cells obtained 10- 
15 h after the addition of aphidicolin were largely (- 50%) 
apoptotic and contained high levels of active caspases, as 
detected by reactivity with the affinity-labeling reagent 
z-EK(hiotin)D-aomk (Martins et al., 1997a) (Fig. 1, C and 
D). Floating cells harvested after a change of medium and 
a 2-h treatment with nocodazole to induce a mitotic block 
were predominantly (>60%) mitotic, with only 10-20% of 
apoptotic cells. Despite the normal appearance of the vast 
majority of these cells, extracts prepared from them also 
contained high levels of active caspases. Cells that re-
mained attached throughout the protocol were almost en-
tirely in interphase, and extracts prepared from them 
lacked caspases detectable with z-EK(biotin)D-aornk (Fig. 
I D, left), although low levels of caspase activity were de-
tectable when more sensitive assays were used (see be-
low). 
The results of this experiment suggested that it might be 
possible to use a similar protocol to prepare extracts se-
quentially from the same flasks of cells at different stages 
of apoptosis (Fig. 2 A). CID (condemned phase) extracts 
were prepared from the morphologically normal attached 
cells that did not enter mitosis or apoptosis during the syn-
chrony procedure. Previous studies have indicated that 
these cells ultimately undergo apoptosis if left in culture 
(Lazebnik et al., 1993). S/M (committed phase) extracts 
Figure 2. Apoptotic extracts contain active caspases that are 
functionally inactivated by specific inhibitors. (A) Protocol used 
to prepare CID, S/M, and E/X extracts. (B) Quantitative analysis 
of DEVD-AFC cleavage activity in the various extracts. DEVD-
fmk treatment of S/M and E/X extracts reduces caspase activity 
by at least 250- and 150-fold, respectively. Note the low but non-
zero level of caspase activity in the C/D extracts. Fr-3 (see Fig. 4) 
has '-8% the caspase activity seen in S/M extract. Treatment of 
Fr-3 with DEVD-fmk further reduces this activity by ~!130-fold 
relative to the S/M extract. (C) Active caspases were labeled with 
zEK(biotin)D-aomk in S/M and E/X extracts. This labeling was 
completely blocked by prior incubation of extracts with YVAD-
cmk and DEVD-fmk (both at 100 riM). (D) PARP and lamin 
A/C cleavage by caspases in the cell-free extracts is abolished af- 
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ter caspase inactivation with YVAD-cmk and DEVD-fmk. Note 
that tow levels of caspases in the C/D extract cause some PARP 
cleavage but fail to cleave lamins. 
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(Lazebnik et al., 1993) were prepared from morphologi-
cally normal mitotic cells at the conclusion of the syn-
chrony procedure. Because these cells are destined to rap-
idly undergo apoptosis if left in culture (Lazebnik et al., 
1993), we postulate that S/M extracts reproduce events 
from the committed stage of apoptosis. E/X (execution 
phase) extracts were prepared from cells that were frankly 
apoptotic after a 12-h exposure to aphidicolin followed by 
a 6-h recovery period in medium. (Note that nonadherent 
cells were discarded at the end of the aphidicolin treat-
ment, so these cells must have entered apoptosis during 
the 6-h recovery period). 
To examine the spectrum of active caspases during the 
three stages of apoptosis, extracts were assayed for their 
ability to cleave DEVD-AFC, for affinity labeling with 
z-EK(hio)D-aomk (Martins et al., 1997a), and for the abil-
ity to cleave known caspase substrates in added nuclei. 
Collectively, these assays detect all known caspases. 
DEVD-AFC contains the preferred cleavage site of 
caspases-3 and -7 (Talanian et al., 1997; Duan et al., 1996b) 
but is also cleaved by caspases-1, -2, -4, -6, -8, and -10 
(Fernandes-Alnemri et al., 1995a, 1996; Boldin et al., 1996; 
Srinivasula et al., 1996; Talanian et al., 1997). z-EK(bio)D-
aomk covalently modifies all caspases tested to date (Mar-
tins et al., 1997a) and can detect over 30 active caspase 
species in apoptotic human leukemia cells (Martins, L.M., 
and W.C. Earnshaw, unpublished observations). PARP is 
a documented substrate of caspases-3, -7, -8, and -9 
(Nicholson et al., 1995; Tewari et al., 1995; Fernandes-
Alnemri et al., 1995a,b; Duan et al,, 1996b; Muzio et al, 
1996), while lamin A is a substrate of caspase-6 (Takahashi 
et al., 1996). Application of these assays to C/D extracts 
revealed low but detectable levels of active caspases (125-
fold less than S/M or E/X extracts in the DEVD-AFC as-
say; Fig. 2 B) and some ability to cleave PARP (Fig. 2 D, 
lane CID), but no evidence of z-EK(biotin)D-aomk label-
ing or lamin cleavage, suggesting that the latter assays are 
less sensitive. In contrast, S/M and E/X extracts contained 
high levels of active caspases that cleaved DEVD-AFC as 
well as PARP and lamin A (Fig. 2, B and D), and both had 
a similar pattern of active caspases after affinity-labeling 
with z-EK(bio)D-aomk (Fig. 2 C). These correspond pri-
marily to active forms of caspases-3 and -6 (Martins et al., 
1997a; Faleiro et al., 1997). All caspase activity detectable 
in these assays was quantitatively inactivated by treatment 
with YVAD-cmk (Fig. 2, C and D) or DEVD-fmk (Fig. 2, 
B—D). 
Differences in Dependence of SIM and EIX Extracts on 
Ongoing Caspase Activity 
CID extracts were unable to induce intern ucleosomal 
DNA fragmentation and apoptotic morphological changes 
in exogenous nuclei (Fig. 3, A and B). In contrast, S/M and 
Figure 3. Caspase inhibitors block apoptosis in S/M but not E/X 
extracts. (A) Inhibition of caspases blocks nuclease activity in S/M 
extracts but not E/X extracts. As expected, CID extracts lack de-
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EIX extracts induced hallmark biochemical and morpho-
logical changes of apoptosis in added nuclei. Further stud-
ies focused on these latter two extracts. 
Despite the similarities of the S/M and EIX extracts in 
terms of caspase activity (Fig. 2) and effects on exogenous 
nuclei (Fig. 3, A and B), the two extracts displayed strik-
ingly different properties after inhibition of the endoge-
nous caspase activity. Pretreatment of S/M extracts with 
DEVD-fmk or YVAD-cmk before addition of nuclei not 
only inhibited caspase activity (Fig. 2, B—D) but also com-
pletely abolished their ability to produce internucleosomal 
DNA fragmentation (Fig. 3 A) and induce morphological  
apoptotic changes (Fig. 3 B). In striking contrast, EIX ex-
tracts that had been pretreated with caspase inhibitors 
continued to strongly induce internucleosomat DNA deg-
radation (Fig. 3 A), chromatin condensation, and fragmen-
tation of added nuclei (shown both by light and electron 
microscopy; Fig. 3, B and C) despite a lack of detectable 
caspase activity (Fig. 2, B—D). 
Fractionation of Active Extracts 
Further evidence for the ability of extracts to induce nu-
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Figure 4. A fraction rich in 
endogenous caspases fails to 
induce apoptotic events in 
added nuclei. (A) Protocol 
used to prepare fractions 1-3 
by heparin-agarose chroma-
tography of roller S/M ex-
tract. (B) Active caspases 
were labeled with zEK(bi-
otin)D-aomk in roller S/M 
extract and fraction 2, but 
could not be detected in Fr-3. 
The bands in the upper por-
tion of the gel are cellular 
proteins that bind to the 
streptavidin probe. (C) PARP 
and lamin A are efficiently 
cleaved by roller S/M extract 
and by Fr-2. Fr-3 has low lev-
els of PARP cleavage activity 
that are abolished by pre-
treatment with DEVD-fmk. 
(D) Pulsed field gel electro-
phoresis. High molecular 
weight DNA fragments were 
produced in HeLa nuclei in-
cubated in roller S/M extracts 
and Fr-3 (caspase-deficient), 
but not in nuclei incubated in 
buffer or Fr-2, which contains 
high levels of active caspases. 
Lane M, DNA markers (sizes 
shown in kilobase pairs). (E) 
Conventional agarose gel 
electrophoresis. An oligonu-
cleosomal DNA ladder is 
formed in nuclei incubated in 
roller S/M extracts and Fr-3, 
but not in nuclei incubated in 
buffer or Fr-2. Lane M, DNA 
markers (sizes shown in base 
pairs). (1) Fr-3 induces very 
strong morphological apop-
tosis even when all detectable 
caspase activity is abolished 
by pretreatment with DEVD-
fmk. In contrast, Fr-2, which 
has a distribution and con-
centration of caspases essen-
tially identical to S/M extract, 
does not induce morphologi-
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was obtained through biochemical fractionation of large-
scale roller S/M extracts prepared using cells growing in 
roller bottles. These extracts appeared to functionally re-
semble a mixture of S/M and E/X extracts (i.e., were only 
partly inhibited by DEVD-fmk or YVAD-cmk). We be-
lieve that this is because a much higher percentage of apop-
totic cells was present among the committed phase cells at 
the time of harvest. When roller S/M extracts were frac-
tionated on heparin agarose (Fig. 4 A), proteins cluted 
from the column at 0.2 M KCI (fraction 2 [Fr-21) included 
many of the active endogenous caspases, as shown by their 
ability to cleave the peptide substrate DEVD-AFC (Fig. 2 
B), by activity labeling with z-EK(biotin)D-aomk (Fig. 4 
B), and by cleavage of PARP and lamin A (Fig. 4 Q. Fac-
tors eluted from the column at 0.6 M KCI (fraction 3 
[Fr-3]) were substantially depleted of caspases, and this 
fraction resembled C/D extracts in several regards. DEVD-
AFC cleavage activity in Fr-3 was reduced 13-fold relative 
to roller S/M extract (Fig. 2 B), and only trace levels of 
PARP cleavage activity were detected (compare Fig. 4 C, 
lanes Fr-3, with Fig. 2 I), lane CID). Both zEK(biotin)D-
aomk binding activity and lamin A cleaving activity were 
undetectable in Fr-3 (Fig. 4, B and Q. 
Although fraction 2 contained high levels of endoge-
nous caspase activity, it was unable to trigger either inter-
nucleosomal DNA fragmentation or morphological apop-
tosis in added nuclei. In contrast, fraction 3 was a more 
potent inducer of apoptosis than the starting roller S/M ex-
tract, inducing both high molecular weight and oligonu-
cleosomal DNA fragmentation (Fig. 4, D and E) as well as 
morphological apoptosis in substrate nuclei (Fig. 4 J). This 
activity was not due to the low levels of residual caspases 
present in fraction 3. Pretreatment with DEVD-fmk, 
which abolished all detectable caspase activity (Fig. 2 B), 
had no effect on the ability of fraction 3 to induce DNA 
fragmentation (not shown) or apoptotic morphology in 
added nuclei (Fig. 4 F). Thus, a column fraction rich in en-
dogenous apoptotic caspases (Fr-2) was unable to induce 
morphological apoptosis in isolated nuclei, while a second 
fraction prepared on the same column from the same ex-
tract (Fr-3) strongly induced apoptotic events despite be-
ing severely depleted or devoid (after inhibitor treatment) 
of detectable caspase activity. 
Comparison of CAD Activation in SIM and 
EIX Extracts 
Because the results presented in Figs. 2-4 suggest that the 
program of nuclear disassembly—one of the distinguishing 
features of apoptotic cell death under physiological condi-
tions (Wyllie et al., 1980)—is initiated by caspase activity 
Figure 5. Differences in the activity of the CAD-like nuclease in 
S/M and E/X extracts. (A) CAD-like nuclease in S/M extracts is 
sensitive to DEVD-fmk, whereas that in E/X extracts is not. Apop-
totic extracts cleave a plasmid substrate at 37°C (lanes I and 4). 
The nuclease responsible is inhibited by purified murine GST-
ICAD (lanes 2 and 5) and therefore is functionally related to 
murine CAD (Enari et al., 1998). In S/M extracts, but not E/X 
extracts, the nuclease is abolished by addition of DEVD-fmk 
together with the plasmid DNA (lanes 3 and 6). (II) Diagram of 
experimental protocol designed to test whether the CAD-like en-
zyme is active in both S/M and E/X extracts before the incubation 
with DNA. (C) In S/M extracts, the CAD-like activity increases 
during preincubation of the extract at 30°C before addition of the 
plasmid DNA (lanes 1-5). This activity is now insensitive to the 
addition of DEVD-fmk at the time of plasmid addition (lanes 1 
5). Bracket labeled "Frags" indicates the products of caspase 
cleavage. The DNA cleavage activity in lane I' may arise from 
some limited activation of CAD before all caspases were inhib-
ited since DNA and DEVD-fmk were added at the same time. 
(D) In contrast, preincubation has no effect on the cleavage of 
plasmid substrate by E/X extracts (lanes 1-5), which is likewise 
resistant to inhibition with DEVD-fmk (lanes I'—S'). Lane D, 
added plasmid DNA alone. Bracket labeled "Frags" indicates the 
products of caspase cleavage. 
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but does not require the ongoing participation of caspases 
for its successful execution, we next turned our attention 
to caspase-activated downstream activities that might par-
ticipate in nuclear disassembly. One of these activities is 
CAD/CPAN, the recently identified caspase-activated 
deoxyribonuclease identified in murine and human cells 
undergoing apoptosis (Enari et al., 1998; Halenbeck et at., 
1998). Both S/M and EIX extracts contain an endogenous 
DNase activity that degrades added plasmid DNA (Fig. 
5 A, lanes I and 4). Addition of 160 ng of murine ICAD 
to the extracts abolished this DNase activity (lanes 2 and 
5), indicating that this activity is functionally homologous 
to CAD. 
Even though CAD-like activity could be inhibited by  
ICAD in both S/M and E/X extracts, this activity appeared 
to be regulated differently in the two extracts. DEVD-fmk 
pretreatment abolished CAD-like activity in S/M extracts 
(Fig. 5 A. lanes I and 3) but had no effect on CAD activity 
in EIX extracts (Fig. 5 A. lanes 4 and 6). There are at least 
two potential explanations for this difference. First, active 
CAD might be unstable in S/M extracts and might there-
fore require a constant source of caspase activity to con-
tinue to generate active enzyme from CAD/ICAD com-
plexes. Second, despite the presence of high levels of 
endogenous caspases in S/M extracts, the CAD in these 
extracts might initially be largely in the form of inactive 
CAD/ICAD complexes. Active CAD might be released 
from these complexes by caspase activity during the incu- 
Figure 6. Bacterially expressed CAD is ca-
pable of inducing apoptotic morphology in 
added nuclei in the absence of apoptotic 
extract. (A) Diagram of the experimental 
protocol. After CAD was activated during 
a preincubation with purified caspase-3 at 
25°C, substrates were added and incubated 
for various times with the active enzyme at 
37°C. (B) Effects of various incubations on 
CAD nuclease activity using either a puri- 
fied plasmid substrate (pBluescript, upper 
panels) or added nuclei (lower panels). The 
morphology ofthe nuclei in these same in- 
cubations is shown in C, where the panel 
numbers refer to lanes in B. Buffer and 
caspase-3 do not possess nuclease activity 
or induce apoptotic morphology in added 
nuclei (lanes and panels 2 and 3). Preincu- 
bation of CAD alone induces nuclease ac- 
tivity and apoptotic morphology (lane and 
panel 4), presumably because of the pres- 
ence of a contaminating protease. ICAD is 
cleaved during this preincubation (data not 
shown). This spontaneous activation of 
CAD is not observed if noncleavable 
ICAD is present from the start of the pre-
incubation (lane and panel 5). Preincuba- 
tion of CAD with caspase-3 induces nu- 
clease activity and apoptotic morphology 
(lane and panel 6). This activity is not ob-
served if noncleavable ICAD is present ei-
ther from the start of the preincubation, or 
if it is added at the end of the preincuba- 
tion together with the substrate nuclei 
(lanes and panels 7 and 8). Addition of 
DEVD-fmk to the preincubation blocks 
CAD activation but has no effect on nu-
clease activity or induction of apoptotic 
morphology if added once the preincuba- 
tion is complete (lanes and panels 9 and 
10). The induction of apoptotic morphol- 
ogy by CAD in the presence of DEVD- 
fmk was slightly, but reproducibly, reduced 
(panel 10). These results demonstrate that 
CAD can induce nuclear apoptosis in the 
absence of caspase-3 activity. I and II at the 
right of B indicate the migration of form I 
(supercoiled) and form II (nicked circular) 
plasmid DNA. 
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bation with DNA substrates. 
To distinguish between these possibilities, we preincu-
bated S/M and EIX extracts at 30°C for various times to 
allow cleavage of endogenous ICAD by endogenous 
caspases before adding DNA in the presence or absence of 
DEVD-fmk (see the experimental protocol in Fig. 5 B). 
This experiment indicated that CAD activity was initially 
low in S/M extracts but increased gradually with incuba-
tion at 30°C (Fig. 5 C, lanes 1-5). Once activated, CAD 
was stable in the presence of DEVD-fmk (lanes 1 '-5'). In 
contrast, CAD was fully active at all times in EIX extracts 
in the presence and absence of DEVD-fmk (Fig. 5 D). 
Collectively, these results indicate that CAD is present but 
inactive in extracts prepared from committed stage cells 
and is activated in equivalent extracts prepared from exe-
cution phase cells. In addition, this result confirms that the 
apoptotic activities present in S/M extracts are not due 
solely to the presence of low levels of contaminating apop-
totic cells since these cells would be expected to have high 
levels of active CAD. 
CAD Alone Is Also Capable of Inducing Apoptotic 
Morphology in Added Nuclei 
Collectively, the results presented in Figs. 3 and 5 suggest 
that CAD might be a major factor that acts downstream of 
caspases to induce changes in nuclear structure during 
apoptotic execution. To examine this possibility in greater 
detail, we exposed isolated nuclei to partly purified cloned 
murine CAD. Active CAD was expressed in E. coli using 
a bicistronic vector, which ensured that the CAD was 
translated in the presence of an excess of ICAD (Enari et 
al., 1998). The resulting CAD/ICAD complex was purified 
by nickel chelate chromatography and then tested for ac-
tivity against plasmid and nuclear substrates according to 
the experimental protocol shown in Fig. 6 A. Results ob-
tained with the plasmid substrate are shown in Fig. 6 B. 
The CAD/ICAD complex purified from E. coli became 
activated after a preincubation of 30 min at 25°C either in 
the absence (Fig. 6 B, lane 4) or presence (lane 6) of puri-
fied recombinant caspase-3. We assume that activation in 
the absence of added caspase is due to the presence of 
contaminating protease activity from the E. coli lysate. 
Addition of double mutant ICAD (Sakahira et al., 1998) 
at the start of the preincubation blocked CAD activation 
in both the absence (lane 5) and presence (lane 7) of 
caspase-3. Double mutant ICAD also blocked CAD activ-
ity if added at the end of the preincubation (lane 8). In 
contrast, DEVD-fmk blocked CAD activation if added at 
the start of the preincubation (lane 9) but had no effect if 
added after cleavage of ICAD (lane 10). 
The results obtained with the plasmid substrate were ex-
actly duplicated when we examined the ability of bacteri-
ally expressed CAD to induce DNA ladders and inorpho-
logical changes in HeLa nuclei (Fig. 6, B and C). These 
morphological changes were confirmed by electron mi- 
croscopy, where condensed chromatin domains could be 
seen to be closely apposed to the nuclear envelope (Fig. 
7). When CAD was fully active, as detected using either 
plasmid or nuclear substrates, the enzyme strongly in- 
duced condensation of chromatin at the periphery of 
added nuclei (Fig. 6, B and C, lanes and panels 4 and 6). 
Figure 7. Induction of apoptotic morphology in HeLa nuclei by 
bacterially expressed CAD: analysis by electron microscopy. Nu-
clei treated with CAD—as shown in Fig. 6 B, lane and panel 6—
were embedded in plastic, thin sectioned, and examined in the 
electron microscope. Regions of condensed chromatin are seen 
to abut the nuclear envelope, and often protrude as though be-
ginning to bud outwards through the envelope. These images are 
indistinguishable from previously published images of nuclei 
treated with complete apoptotic extract (Lazebnik et al., 1993). 
Bar, 1 p.m. 
Higher levels of CAD induced the complete disassembly 
of nuclei into apoptotic bodies (data not shown); however, 
under these conditions nucleosomal ladders were no 
longer seen (the DNA was fully degraded). Interestingly, 
the addition of DEVD-fmk at time t = 0 slightly inhibited 
the morphological apoptosis (Fig. 6 C, panel 10), although 
examples of fully apoptotic nuclei could still be seen. It is 
important to note that caspase-3 alone was unable to in-
duce either DNA cleavage or apoptotic morphology in 
added nuclei (lane and panel 3), consistent with the results 
obtained with fraction 2 described above (Fig. 4 F). 
Evidence for a Nuclear Disassembly Factor Distinct 
from CAD 
To determine whether the CAD-like enzyme was the sole 
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Figure 8. Induction of apoptotic morphology 
in cell extracts is not blocked by inhibition of 
the CAD-like nuclease. (A) Induction of nu-
cleosomal ladders in added nuclei by S/M ex-
tract is sensitive to ICAD and DEVD-fmk 
(lanes 3-8). Induction of nucleosomal ladders 
in added nuclei by E/X extract is sensitive 
only to ICAD (lanes 9-14). (DEVD-fmk 
added: none, lanes 1-5 and 94I; 100 p.M, 
lanes 6-8 and 12-14. ICAD added: none, 
lanes 3, 6, 9, and 12; 160 ng, lanes 4, 7, 10, and 
13; 320 ng, lanes 5, 8, 11, and 14.) (B) Both 
S/M and E/X extracts can induce apoptotic 
events under conditions where the CAD-like 
nuclease is inhibited, provided that they re-
tain active caspases (panels 3-5 and 9—I1). 
E/X extracts, which normally induce apopto-
sis in the absence of caspase activity (panel 
12), are unable to do so if ICAD is added 
along with DEVD-fmk (panels 13 and 14). 
Panel numbers refer to the gel lanes in A. 
These images come from the same incuba-
tions shown in A. Time-lapse microscopy 
analysis reveals that the C-shaped nuclei in 
panels 3-5 and 9-11 are apoptotic nuclei in 
which the nuclear envelope has ruptured after 
collapse of the chromatin against the nuclear 
periphery. (C) E/X extracts can fully induce 
apoptotic morphology in the absence of 
CAD-like activity, but this requires ongoing 
caspase activity. In a different experiment 
from that shown in A and B, the number of 
nuclei per microliter of extract was reduced. 
This gives a stronger induction of apoptotic 
morphology (compare a with B. panel 9), 
even when caspases (b) or CAD are inhibited 
(c). Extracts produce a range of morphologies 
in added nuclei. As in the experiment of A 
and B, simultaneous inhibition of both CAD 
and caspases abolishes morphological apopto-
sis in the extracts (d). These images were se-
lected from images taken at random. 
activity downstream of caspases that drives nuclear disas-
sembly in these extracts, S/M and E/X extracts were 
treated with ICAD before addition of exogenous nuclei. 
Although addition of excess ICAD abolished production 
of a nucleosomal ladder in nuclei added to S/M and E/X 
extracts (Fig. 8 A, lanes 3-5 and 9-11), ICAD did not 
block the ability of the extracts to induce chromatin con-
densation and nuclear fragmentation (Fig. 8 B, panels 3-5 
and 9-11). The ability of the extracts to induce morpholog-
ical changes in the presence of ICAD was even more strik-
ing when the number of nuclei in the incubation was 
reduced approximately fourfold (Fig. 8 Q. These observa-
tions indicate that CAD-like activity is not essential for 
apoptotic morphological changes in nuclei added to either 
S/M or E/X extracts. 
Interestingly, simultaneous inhibition of both CAD and 
caspases did block the induction of apoptotic morphology 
by E/X extracts (Fig. 8 B, panels 13 and 14; Fig. 8 C, d). As 
indicated above, the caspase-rich column fraction Fr-2 
lacked the ability to induce apoptotic morphological 
changes in exogenous nuclei (Fig. 4fl. Moreover, addition 
of purified caspases-3 and -6, the major active caspases in 
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cytosol (Faleiro et al., 1997; Martins et al., 1997a) and nu-
clei (Martins et al., 1997a,b), failed to induce apoptotic 
morphological changes in purified nuclei (data not shown; 
identical to Fig. 6 C, panel 5). These observations appear 
to rule out the possibility that caspases themselves are ca-
pable of inducing chromatin condensation by acting alone 
on endogenous nuclear substrates. When coupled with 
these results, the observation in Fig. 8 C, d, not only sug-
gests that there is a second chromatin condensation factor 
present in the extracts but also raises the possibility that 
ongoing caspase activity is required for activity of this factor. 
Discussion 
The experiments described above have led to a number of 
novel observations: (a) It is possible to prepare cell-free 
extracts specific for the latent and execution phases of 
apoptosis. (b) These extracts, both of which contain active 
caspases and induce apoptosis in substrate nuclei, exhibit 
significant biochemical and functional differences that are 
best explained if the transition from the latent to the exe-
cution phase of apoptosis is accompanied by a transition 
from caspase-dependent to caspase-independent mecha-
nisms. (c) One aspect of this transition appears to involve 
activation of a CAD-like nuclease, which is initially latent 
in SIM extracts but is fully active in FIX extracts. (d) Mu-
rifle CAD can induce an apoptotic morphology in isolated 
nuclei. (e) In addition to CAD, apoptotic extracts contain 
a second activity that can also induce apoptotic chromatin 
condensation in added nuclei in the absence of DNA frag-
mentation. Each of these points is discussed in greater de-
tail below. 
At present, there is no accepted biochemical marker to 
rigorously distinguish between the condemned and com-
mitted stages of the latent phase. Here, we define latent 
phase cells as those that have received a proapoptotic 
stimulus but look morphologically normal. We then opera-
tionally define condemned cells as those that yield extracts 
that lack significant caspase activity and do not induce 
apoptosis in substrate nuclei. We operationally define 
committed stage cells as those that yield extracts that con-
tain high levels of active caspases together with low levels 
of active CAD and that strongly induce apoptosis in sub-
strate nuclei. As expected, these cells contain only low lev-
els of fragmented DNA themselves. Both of these latent 
phase populations are readily distinguishable from overtly 
apoptotic cells, which have detached from the substratum 
and have sustained intern ucleosomal DNA degradation in 
response to a proapoptotic stimulus. The various extracts 
prepared from these three operationally defined cell pop-
ulations turned out to have remarkably distinct biochemi-
cal and functional characteristics. 
The most significant difference was the finding that in-
duction of apoptotic events by committed stage extracts is 
dependent on ongoing caspase activity, whereas induction 
of apoptotic events by execution phase extracts is indepen-
dent of ongoing caspase activity. This observation is best 
explained by a model in which caspases activate down- 
stream factors that are responsible for condensation of the 
chromatin during apoptosis. Such a model predicts that if 
we were able to purify the active caspases from apoptotic 
cells away from the downstream factors, then the caspases 
on their own should be insufficient to induce apoptotic 
events in substrate nuclei. To test this hypothesis, so-called 
roller SIM extracts (large scale extracts functionally inter-
mediate between S/M and E/X extracts) were fractionated 
on heparin—agarose. The fraction eluting with 0.2 M KCI 
(Fr-2) appeared to not only encompass the entire range of 
endogenous caspases activated during apoptosis in these 
cells but was also highly active in the cleavage of caspase 
target proteins. Nonetheless, this fraction was completely 
unable to induce either DNA fragmentation or apoptotic 
morphology in substrate nuclei. We have independently 
shown that mixtures of purified caspases-3 and -6 are also 
unable to induce apoptotic morphology in purified nuclei 
(unpublished results). Thus, although recent experiments 
indicate that caspase-3 is essential for nuclear apoptosis 
(Jänicke et al., 1998; Woo et al., 1998), our experiments in-
dicate that this enzyme is likely to function by activating 
downstream factors rather than directly disassembling the 
nucleus itself. 
A subsequent 0.6 M KCI wash of the same heparin—aga-
rose column yielded a fraction (Fr-3) that is rich in down- 
stream apoptosis-promoting activities. Fr-3 strongly in-
duces DNA fragmentation and apoptotic morphology 
despite the fact that it contains only very low levels of 
caspases, similar to those seen in CID extracts (which do 
not induce apoptotic events in substrate nuclei). Further-
more, treatment of Fr-3 with caspase inhibitors (as well as 
other protease inhibitors; see Materials and Methods) had 
no effect on its apoptosis-promoting activity. Thus, this 
fraction is a potential source of downstream factors acti- 
vated during the apoptotic pathway. 
One such downstream factor has recently been identi-
fied in murine cell extracts. CAD, the caspase-activated 
DNase (Enari et al., 1998), interacts with an inhibitory 
subunit termed ICADIDFF45 (Sakahira et al., 1998; Liu et 
al., 1997) to form an inactive complex that is thought to be 
sequestered in the cytoplasm. Caspase cleavage of ICAD 
is proposed to cause the release and subsequent nuclear 
translocation of CAD, leading to digestion of the chroma-
tin (Sakahira et al., 1998). Here, we have shown that both 
SIM and E/X extracts from chicken DU249 cells contain a 
nuclease similar or identical to CAD, as defined by its abil-
ity to be quantitatively inhibited by exogenous purified 
mouse ICAD. The fact that ICAD of mouse origin inhibits 
the apoptotic nuclease in avian (chicken) cell extracts sug-
gests that the CAD nuclease and its interactions with 
ICAD are widely conserved in phylogeny. 
Because the same cohort of caspases is present and ac-
tive in the SIM and E/X extracts, the transition from the la-
tent to the execution phase of apoptosis may not hinge 
upon caspase action alone. Instead, the transition might 
involve activation of downstream factors. The CAD-like 
nuclease appears to be largely inactive in freshly prepared 
SIM extracts, becoming active only as the extracts are in-
cubated at 30 or 37°C. This activation presumably reflects 
the cleavage of ICADID FF45 by caspases since CAD acti-
vation is blocked by caspase inhibitors. In contrast, the 
CAD-like nuclease activity appears to be fully active in 
freshly prepared E/X extracts. Collectively, these observa-
tions suggest that caspase activation occurs during the la- 
tent phase of apoptosis, whereas CAD activation accom-
panies the transition from the latent to execution phase of 
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apoptosis. One implication of this conclusion is that cells 
might simultaneously contain active caspases and inactive 
complexes of ICAD/DFF bound to CAD and possibly 
other downstream factors. This would be possible if 
caspases were segregated from their downstream targets 
such as ICAD/DFF, possibly by being sequestered in a dif-
ferent cellular compartment. The onset of apoptotic exe-
cution might then be triggered not by activation of the 
caspases but by a change in the localization of either 
caspases or targets. An alternative explanation of our 
data, that caspases are inactive in the cells from which S/M 
extracts are made and become activated during prepara-
tion of the extract (Zapata et al., 1998), is unlikely for two 
reasons. First, we previously demonstrated that caspase 
activity in similar extracts prepared from latent phase HL-
60 cells was paralleled by cleavage of PARP and pro-
caspase-3 in vivo (Martins et al., 1997a). Second, the 
caspase-3 activation observed during extract preparation 
in the previous study was explained by the detergent-induced 
release of granzyme B from cytoplasmic vesicles (Zapata 
et at., 1998). In our study, detergents were avoided during 
extract preparation, and cells lacking granzyme B were 
used. 
In support of the notion that caspases and their targets 
might be segregated during the latent phase, we note that 
procaspases have largely been observed in the cytoplasm 
(Duan et al., 1996a; Krajewska et al., 1997; Mancini et al., 
1998) (Mesner, P.W., and S.H. Kaufmann, unpublished 
observations) or mitochondria (Mancini et al., 1998), 
whereas our subcellular fractionation studies have re-
vealed significant levels of active caspases within the nu-
cleus (Martins et al., 1997a,b). An additional study has in-
dicated that interference with nuclear transport renders 
cells resistant to Fas-mediated apoptosis (Yasuhara et al., 
1997). 
We have developed a novel vector to coordinately ex-
press CAD and ICAD in E. coli and have used this par- 
tially purified CAD to demonstrate that CAD can induce 
an apoptotic morphology in isolated nuclei, as confirmed 
by both light and electron microscopy. This reaction does 
not require ongoing caspase activity. This result is consis-
tent with earlier observations, indicating that addition of 
micrococcal nuclease to isolated nuclei can cause clumping 
of chromatin (Arends et al., 1990), although the pattern of 
condensation seen with CAD more closely resembles that 
seen in apoptotic cells. However, CAD does not appear to 
be the only factor downstream of caspases that is capable 
of inducing apoptotic nuclear changes. Addition of puri-
fied ICAD to either S/M or EIX extracts abolished all de-
tectable DNase activity against both chromosomal and 
plasmid DNA substrates but did not abolish the ability of 
those extracts to induce an apoptotic morphology in sub-
strate nuclei. This observation is consistent with previous 
reports that morphologically normal apoptosis can occur 
in the absence of internucleosomal DNA fragmentation in 
vivo (Ucker et al., 1992b; Oberhammer et al., 1993; Saka-
hira et at., 1998). At present, the nature of the second 
downstream factor(s) that promotes apoptotic chromatin 
condensation is unknown. Although two recent studies 
suggest that serine (Shimizu and Pommier, 1997) or cys-
teine proteases (Vaux et al., 1997) may be involved, the 
fact that we can detect apoptotic morphological changes in 
the presence of DEVD-fmk as well as a battery of serine, 
cysteine, and acid protease inhibitors (see Materials and 
Methods) suggest that the chromatin-condensing activity 
might not be a protease. On the other hand, simultaneous 
addition of both DEVD-fmk and ICAD to EIX extracts 
abolished the induction of apoptotic morphology in sub-
strate nuclei. This result suggests that the morphogenic 
factor either binds to ICAD or is regulated by other mole-
cules that interact with ICAD. 
In summary, the experiments reported here demon-
strate that it is possible to use cell-free extracts for a bio-
chemical and functional dissection of the sequential 
phases of the apoptotic pathway. Our studies reveal that 
the transition from the latent to the execution phase of 
apoptosis appears to be accompanied by a change from 
caspase-dependent to caspase-independent mechanisms. 
The discovery that caspases are capable of cleaving abun-
dant nuclear proteins like PARP (Lazebnik et al., 1994) 
and the lamins (Lazebnik et al., 1995; Takahashi et at., 
1996; Orth et al., 1996; Rao et al., 1996), along with the ob-
servation that apoptotic nuclear fragmentation is absent in 
caspase-3—null cells (Woo et at., 1998; Janicke etal., 1998), 
led us and others to previously assume that caspases are 
directly responsible for nuclear disassembly. However, the 
inability of purified caspases to produce apoptotic mor-
phological changes in isolated nuclei, coupled with the in-
ability of caspase inhibitors to abolish the induction of 
these morphological changes by EIX extracts, argues that 
caspases are unlikely to be workhorses that are solely re-
sponsible for nuclear disassembly. Instead, the present re-
sults provide support for a view in which caspases play an 
executive role in nuclear disassembly by activating factors 
that in turn disassemble the nucleus. At least one of the 
downstream activities is a CAD-like nuclease; but another 
downstream activity capable of inducing nuclear morpho-
logical changes appears to be distinct from CAD. 
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In nonapoptotic cells, the caspase-activated DNase 
AD/CPAN is associated with a regulatory subunit, 
CAD/DFF, that binds to it and blocks its enzymatic 
.ctivity. It has been proposed that a major function of 
CAD is to restrain CAD in the cytoplasm in healthy 
ells. The experiments presented here demonstrate 
hat rather than being cytoplasmic, a GFP-ICAD fu-
ion protein is nuclear in healthy human, pig, and 
hicken cells. Furthermore, immunoblots using anti-
odies to murine ICAD confirm the presence of endo-
enous ICAD and the marker protein DNA topoisomer-
se I in human nuclei, while tubulin was found solely 
11 the cytosolic fraction. Since ICAD is located in cell 
Luclei, it is unlikely that the protein functions primar.. 
Ly in the cytoplasm either as an anchor for CAD/CPAN 
r as a factor that enters the nucleus following caspase 
:leavage in order to activate resident endonucleases. 
1998 Academic Press 
INTRODUCTION 
Apoptotic execution is a cellular disassembly path-
ay in which nuclear and cytoplasmic structures are 
reatly altered, both to terminate the life of the cell and 
o favor its engulfment by other healthy cells. The 
iochemical mechanisms of apoptotic execution are 
till under intensive study, with particular attention 
musing on the role of proteases and nucleases. A great 
Leal is now known about the identity and targets of the 
aspase proteases that appear to be the driving force 
ehind the apoptotic pathway [1-3]. Paradoxically, de-
pite the fact that DNases were the first biochemical 
ictivities to be identified in apoptotic cells [41, until 
'ery recently much less has been known about the 
dentities of the DNases involved in processing of the 
enome during apoptotic execution. 
In recent years it has been suggested that apoptotic 
To whom correspondence and reprint requests should be ad-
ressed. Fax: 0131-650-7100. E-mail: bill.earnshaw@ed.ac.uk.  
cells harness one or more of the well-known digestive 
enzymes, such as DNase I or DNase II, for use in 
apoptosis [5, 61. These conclusions have been based 
upon a variety of analyses ranging from examination of 
the DNA ends produced during apoptosis [7-9] to in-
hibitor, antibody, and PCR studies looking at the ex-
pression and cellular distribution of these enzymes [5, 
61. Other studies have suggested that the apoptotic 
nuclease might be a novel enzyme, DNase y [81, or a 
well-known protein, cyclophilin, which was not previ-
ously suspected to have nuclease activity [101. Given 
the existence of these conflicting studies proposing that 
each of these different enzymes is the apoptotic nucle-
ase, it must be considered that in fact there is no single 
enzyme that fulfills this role in all cell types. Further-
more, it is important to bear in mind that DNA frag-
mentation does not appear to be a universal require-
ment in apoptosis [11-141. 
The study of DNA metabolism during apoptosis has 
recently been greatly stimulated by the discovery, pu-
rification, and cloning of a caspase-activated DNase, 
CAD, in murine cells [15]. A human homologue of this 
enzyme, termed caspase-activated nuclease (CPAN), 
has also been identified [161. These enzymes have at-
tracted considerable interest, largely because of the 
demonstration that their activity is regulated in an 
apoptosis-specific manner. CAD/CPAN is expressed in 
healthy cells, where it is held in an inactive state, 
apparently through association with a regulatory sub-
unit, which the discoverers of CAD termed ICAD [14, 
15]. ICAD had previously been identified as a cytoplas-
mic factor, DFF (DNA fragmentation factor), whose 
cleavage by caspase-3 was proposed to be responsible 
for activation of the apoptotic nuclease [17]. 
Published studies have suggested three possible 
mechanisms of ICAD/DFF function. First, it was pro-
posed that upon cleavage by caspases, DFF enters the 
cell nucleus and activates a resident nuclease [17]. 
This model is now considered somewhat less likely, 
given the observation that DFF is normally complexed 
with the nuclease CPAN. CPAN apparently corre- 
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ponds to the 40-kDa subunit originally identified as a 
Dmponent of the DFF protein [17]. It has now been 
hown that ICAD/DFF can act as a direct inhibitor of 
ie apoptotic nuclease. Binding of ICAD/DFF to CAD! 
PAN inactivates its enzymatic function [15]. Impor-
ntly, this inactivation is specific for CAD/CPAN. 
CAD does not inactivate either DNase I or DNase II in 
itro [151. A second unexpected activity of ICAD/DFF is 
s a chaperone that promotes the stable folding of 
ctive CAD/CPAN. This was shown most clearly for in 
itro transcription/translation experiments in which 
ctive CAD was produced only in the presence of ICAD 
151. However, evidence consistent with this model was 
lso obtained in baculovirus expression studies, in 
,hich it was found that active CAD could be obtained 
nly when Sf9 cells were co-infected with viruses ex-
iressing both CAD and ICAD [16]. Finally, analysis of 
he predicted polypeptide sequences of CAD and ICAD 
uggested a possible further role for ICAD. CAD, but 
LOt ICAD, has a predicted nuclear localization signal 
151. It was therefore suggested that ICAD might corn-
lex with nascent CAD on the ribosome, first helping it 
D fold and then restraining it in the cytoplasm. This 
Ater activity was proposed to function similarly to the 
etention of NFKB in the cytoplasm by 1KB [15], and it 
as proposed that cleavage of ICAD releases CAD, 
hereby enabling it to enter the nucleus and attack the 
ellular DNA [141. 
In the present study, we have performed an initial 
est of this hypothesis for the role of ICAD in regula-
ion of CAD. We have used two different approaches to 
Dcalize ICAD in cultured cells. First, we have shown 
hat a GFP—ICAD fusion protein is nuclear in trans-
ected human, pig, and chicken cells. Second, we have 
repared an antibody to murine ICAD and used this in 
mmunoblotting experiments to show that the endoge-
ous protein is likewise concentrated in cell nuclei. 
1hese observations make it unlikely that ICAD fulfills 
Ls major cellular functions in the cytoplasm. 
MATERIALS AND METHODS 
Materials. Reagents were obtained from the following suppliers: 
ntipain, chymostatin, pepstatin A, PMSF, isopropyl -D-thiogalac-
Dpyranoside (IPTG), etoposide, and 4,4-diamidino-2-phenylin-
ole(DAPI) were from Sigma; staurosporine and leupeptin were from 
albiochem; Hybond-C membranes, horseradish peroxidase-
onjugated anti-mouse, anti-human, and anti-rabbit antibodies, and 
nhanced chemiluminescence (ECL) reagents were from Amersham 
orp.; Super Signal Ultra chemiluminescence reagents were from 
'ierce; Ni-NTA agarose was from Qiagen. Monoclonal antibody to 
'FP was a gift of I. Davis (ICMB, Edinburgh). Monoclonal antibody 
D tubulin was a gift of L. Binder (Northwestern University, Chicago. 
L). Human autoantibody to DNA topoisomerase I has been de-
cribed previously [181. 
Expression and purification of His6-ICAD. The ICAD cDNA in 
Bluescript (Stratagene) was digested with SpeI, blunt-ended with 
'4 DNA polymerase (NEB) plus 100 j.LM dNTPs, and digested with 
KpnI (NEB). The resulting fragment was ligated into pRSET B 
(Invitrogen) that had been digested with HindIII, blunt-ended with 
T4 DNA polymerase, and digested with KpnI. ICAD in pRSETB was 
transformed into Escherichia coli BL21(DE3)Lys S cells. Trans-
formed cells were grown to OD600 = 0.5-0.7 and protein expression 
was induced with IPTG (1 mM) for 3-4 h. Cells were collected by 
centrifugation at 5000g for 10 min and frozen at —80°C. The cell 
pellet was thawed on ice for 15 min and resuspended in sonication 
buffer (50 mM NaH2PO4, pH 7.5; 300 mM NaCl; 10 mM imidazole). 
Lysozyme was added to 1 mg/ml and the suspension was incubated 
on ice for 30 mm, sonicated on ice until 80% of the cells were 
disrupted, and then centrifuged at 4000g for 20 min at 4°C. The 
supernatant fraction was incubated on a rotating mixer for 1 h at 4°C 
with 0.5 ml of Ni-agarose that had been preequilibrated with soni-
cation buffer and then loaded onto a polyprep chromatography col-
umn (Bio-Rad). The column was washed with 4 ml of wash buffer (50 
mM NaH2PO4, pH 7.5; 300 mM NaCl; 20 mM imidazole) twice. 
Protein was eluted with 0.5 ml of elution buffer (50 mM NaH2PO41  
pH 7.5; 300 mM NaCl; 250 mM imidazole) four times. All samples 
were subjected to SDS—PAGE and examined by Coomassie blue 
staining. For antigen preparation, purified ICAD was subjected to 
SDS—PAGE, and then the gel was washed in distilled water three 
times for 10 min each, stained with aqueous Coomassie blue (0.1%) 
for 1 h, and rinsed with water until the induced protein band became 
obvious. The band was excised, frozen at —80°C, and then ground to 
a fine powder under N2 (1) with a mortar and pestle. This powder was 
resuspended in PBS buffer and used to immunize two rabbits at the 
Scottish Antibody Production Unit (Carluke, Lanarkshire). 
Construction of GFP—ICAD. The ICAD cDNA in pBluescript 
(Stratagene) was digested with HindIII, blunt-ended with T4 DNA 
polymerase (New England Biolabs) plus 100 /LM dNTPs, and di-
gested with XbaI (New England Biolabs). The resulting fragment 
was ligated into a vector containing enhanced GFP with a flexible 
linker (gift of Larry M. Karnitz, Mayo Research Foundation, Ro-
chester, MN) in pCDNA3 (Invitrogen) that had been digested with 
NotI (New England Biolabs), blunt-ended with T4 DNA polymerase, 
and digested with XbaI. 
Subcellular fractionation. HeLa cells were maintained in RPMI 
1640 medium containing 5% (vlv) calf serum. Cells were collected by 
trypsinization and centrifuged at 1400g for 5 min at room tempera-
ture. Cell pellets washed once in PBS and once in nuclei solution (10 
mM Pipes, pH 7.0, 10 mM KC1, 1.5 mM MgCl2, 1 mM D'N', 100 AM 
PMSF, 10 AM cytochalasin B, plus 1 AM each of antipain, chymo-
statin, pepstatin A, and leupeptin) and resuspended into 200 Al of 
nuclei solution. This suspension was incubated on ice with occasional 
agitation and then lysed by passage through a 21-gauge needle. The 
lysate was fractionated into crude nuclei and cytosol by centrifuga-
tion at 2400g for 10 min at 4°C. The supernatant and pellet were 
immediately resuspended into SDS sample buffer, boiled for 5 min, 
and subjected to SDS—PAGE [19]. 
Induction of apoptosis. Apoptosis was induced in cells 20-24 h 
after they were electroporated either with a construct expressing 
GFP—ICAD or in the absence of added DNA (mock transfection). 
Cells were either treated with 68 AM etoposide for 1 h and kept in 
drug-free medium for a subsequent 6-7 h or treated with 1 AM 
staurosporine for 16-24 h. To examine GFP—ICAD cleavage, both 
floating cells and attached cells were collected, resuspended into 
sample buffer and subjected to SDS—PAGE. 
Microscopy. Chicken DU249 cells and LLCPK cells were cultured 
in RPMI 1640 medium containing 10% (v/v) fetal bovine serum. After 
electroporation with a construct expressing GFP—ICAD, cells were 
grown on coverslips. These coverslips were rinsed with PBS/EDTA, 
fixed in a 4 % formaldehyde solution for 5 mm, rinsed with PBS! 
EDTA, and mounted with Vectashield (Vector) containing DAPI (2 




icroscope equipped with a Princeton Instruments Micromax cooled 
CD camera, driven by IP Lab Spectrum software. 
RESULTS AND DISCUSSION 
ICAD/DFF is nuclear in growing cells: The initial 
vidence that ICAD/DFF is a nuclear protein in a va-
iety of cell types was obtained when we constructed a 
ision protein between murine ICAD and the Aequoria 
ictoria green fluorescent protein (GFP). Although GF-
-ICAD expressed in E. colt was relatively insoluble, 
his protein was able to inhibit the CAD-mediated 
leavage of plasmid DNA, indicating that this molecule 
emains competent to interact with CAD (data not 
hown). Following transient transfection, this GFP—
CAD fusion protein was detected solely in the nucleus 
f healthy human, pig, and chicken cells (Fig. 1). The 
FP—ICAD fusion protein was excluded from nucleoli. 
)therwise this protein showed a relatively homoge-
eous distribution throughout the nuclei. GFP on its 
wn does not target to the nucleus ([201 and data not 
hown). 
Although the nuclear localization of GFP—ICAD 
asion protein was extremely reproducible, being de-
ected in all transfected cells, it was nevertheless 
mportant to demonstrate that these results reflect 
he distribution of the endogenous ICAD/DFF, par-
icularly since both ICAD and DFF were originally 
olated from cytoplasmic lysates [15, 171. We there-
ore subcloned murine ICAD into a vector that ex-
ressed the protein in E. coli as a fusion with a 
exa-histidine tag. This protein was expressed in E. 
oh, purified to homogeneity by nickel chelate chro-
riatography, and used to immunize two rabbits. The 
esultant sera recognize both murine and human 
CAD in immunoblots (Fig. 2). 
The specificity of one of these ICAD antisera is dem-
nstrated in Fig. 2A. The serum recognized a single 
olypeptide of Ca. 45 kDa in nuclei isolated from HeLa 
ells (lane n). As expected [141, this endogenous 
olypeptide was cleaved when untransfected cells were 
nduced to undergo apoptosis in the presence of 1 AM 
taurosporine (data not shown). When nuclei were iso-
ated from HeLa cells transfected with GFP—ICAD, the 
intibody recognized both the endogenous human 
CAD/DFF and the 75-kDa GFP—ICAD fusion protein 
lane n'). The antiserum did not recognize any polypep-
ides in a clarified cytosolic fraction prepared by sedi-
nenting a postnuclear supernatant at 85,000g for 1 h 
lane c). This antiserum did not give a reproducible 
ignal above background in indirect immunofluores-
ence. 
The localization of endogenous ICAD in nuclei was 
onfirmed in subsequent experiments in which HeLa 
ells were lysed and subjected to a single centrifuga- 
tion at 2400g for 10 mm (Fig. 213). This fractionates 
cells into a crude nuclear pellet and total cytosol. The 
efficacy of this fractionation was confirmed by immu-
noblotting with antibodies to DNA topoisomerase I, a 
nuclear protein, and p-tubulin, a cytoplasmic pro-
tein. As expected, topoisomerase I was found pre-
dominantly in nuclei (lane n), with a small propor-
tion of the protein being found in the crude cytosol 
(lane c). This cytosolic material may arise from low 
levels of nuclear breakage during cell lysis. When 
cells were fractionated by this method, p-tubulin was 
found solely in the cytosol. 
The distribution of ICAD in two independent frac-
tionation experiments is also shown in Fig. 2B. In both 
experiments, the endogenous ICAD was found to be 
predominantly nuclear, with a trace amount of the 
antigen being detected in crude cytosol. Given the pres-
ence of low levels of topoisomerase I in the cytoplasm in 
these experiments, we feel it likely that some or all of 
the cytoplasmic ICAD is likely to derive from nuclear 
breakage. This would be consistent with the absence of 
detectable ICAD in clarified cytosol (Fig. 2A). However, 
the presence of a small pool of cytoplasmic ICAD can-
not be excluded by these experiments. Presumably 
ICAD/DFF was isolated from cytosol in previous exper-
iments because the protein leaked from nuclei during 
extract preparation [14, 171. 
GFP—ICAD Can Remain Associated with DNA 
in Apoptotic Cells 
Current models of ICAD/DFF function assume that 
the protein is cytoplasmic, and experiments reveal that 
the protein is destroyed at the onset of apoptotic exe-
cution [14, 171. Given our observation that ICAD/DFF 
is predominantly nuclear, we wished to confirm that 
the protein is in fact processed normally during apop-
tosis. In addition we wished to follow the fate of the 
GFP moiety during apoptosis. If GFP remains intact 
during apoptosis, then the GFP derived from GFP—
ICAD might serve as a marker of nuclear integrity 
during apoptotic execution. 
In order to follow the fate of GFP—ICAD during apop-
tosis, HeLa cultures transfected with constructs ex-
pressing the chimeric protein were induced to enter 
apoptosis by exposure to either etoposide or stauro-
sporine. Six hours after a 1-h exposure to etoposide 
10% of transfected HeLa cells had an apoptotic mor-
phology. Following exposure to staurosporine for 24 h 
all cells had an abnormal morphology, with the great 
majority of these cells looking frankly apoptotic. Fol-
lowing induction of apoptosis, cells were harvested and 
lysed by passage through a needle, and a crude nuclear 
fraction was prepared by centrifugation at 2400g for 10 
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FIG. 1. GFP—ICAD is a nuclear protein. Aequoria victoria green fluorescent protein (GFP) was fused in-frame to murine ICAID and 
xpressed by transient transfection in (A) human (HeLa), (B) pig (LLCPK), and (C) chicken (DU249) cells. The expressed protein was 
bserved solely in cell nuclei. (A—C) Phase contrast. (A'—C') GFP fluorescence. (A"— C") DNA stained with DAPI. 
vas then followed by immunoblotting with a monoclo-
ial antibody to GFP (gift of Ilan Davis). These experi-
nents revealed that GFP—ICAD is cleaved as expected 
n apoptotic HeLa cells (Fig. 2C). GFP is not degraded, 
1 least during the early stages of apoptotic execution. 
'his experiment shows that although the chimeric pro-
ein is predominantly located in the cell nucleus, it 
emains accessible to the caspases that target ICAD 
luring apoptosis. 
We have used fluorescence microscopy to follow the  
fate of the GFP moiety derived from GFP—ICAD follow-
ing induction of apoptosis in HeLa cells. In many apop-
totic cells, GFP remained in close association with the 
chromatin, in both condensed and noncondensed re-
gions (Fig. 3A). In other apoptotic cells, much of the 
GFP signal appeared to be no longer associated with 
the DNA (Fig. 3C). Both classes of cells could be seen to 
have at least two classes of cytoplasmic blebs, some of 
which contained both DNA and GFP, and others that 
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FIG. 2. Subcellular fractionation confirms that ICAD is a nuclear 
rotein. (A) Confirmation of the specificity of the ICAD antibody. 
nti-ICAD recognizes endogenous human ICAD in a crude nuclear 
raction prepared by centrifugation of HeLa whole-cell extract at 
400g for 10 mm (lane W. ICAD is not detected in clarified cytosol 
35,000g for 1 h, lane c). Anti-ICAD recognizes GFP—ICAD in a 
imilar fractionation of transfected cells (lane n'). (B) Confirmation 
hat ICAD is highly enriched in nuclei and detected at only trace 
mounts in crude cytosol (lysates were centrifuged at 2400g for 10 
oin yielding nuclei, lane n, and cytosol, lane c). (B and C) Immuno-
lots of fractionated HeLa cells. (C) GFP—ICAD is cleaved in trans-
acted cells following induction of apoptosis by exposure of cells to 
taurosporine. Mock-transfected cells (lanes 1 and 2) or cells trans-
acted with a construct expressing GFP—ICAD (lanes 3 and 4) were 
ultured as normal (lanes 1 and 3) or exposed to 1 j.M staurosporine 
or 24 h (lanes 2 and 4), lysed, and subjected to SDS—PAGE and 
mmunoblotting. Detection was with a monoclonal antibody to GFP 
gift of Ilan Davis). 
Because GFP expressed on its own is distributed evenly 
hroughout the cytoplasm of transfected cells [20], the 
luorescence signal would be expected to diffuse rela-
ively freely following caspase cleavage of the ICAD. 
rherefore, since GFP—ICAD is completely cleaved in 
hese apoptotic cells (Fig. 2), we suggest that the nu-
lear envelope is likely to remain intact in those cells 
vhere the GFP stayed in close association with the 
ondensed chromatin. This is consistent with the ob-
;ervation of apparently intact nuclear envelopes in 
poptotic cells examined by electron microscopy [21]. 
i,ells with a more widespread distribution of GFP are 
ikely to represent those in which apoptotic execution 
vas accompanied by a loss of nuclear envelope integ-
ity. Blebs in these cells that lack detectable GFP (ar-
ows, Fig. 3C) may have formed and been sealed off 
)rior to the loss of nuclear envelope integrity. In other 
;tudies, we have directly observed lysis of the nuclear 
nve1ope in time-lapse movies of late-stage apoptotic 
IeLa cells expressing a GFP—lamin A chimera (L. M. 
Martins, K. Samejima, and W. C. Earnshaw, unpub-
lished results). 
Conclusions 
It has previously been proposed that ICAD/DFF is 
a cytoplasmic factor that is cleaved upon caspase 
activation and then either enters the nucleus to ac-
tivate nucleases [17] or releases an inactive cytoplas-
mic nuclease which subsequently enters the nucleus 
and degrades the cellular DNA [15]. The studies 
described above are inconsistent with both such 
models, since they have shown that ICAD/DFF is 
primarily located in the nuclei of growing and apo-
ptotic HeLa cells. Thus, it is unlikely that the protein 
functions primarily in the cytoplasm, either as an 
anchor [15] or as a latent "trigger" waiting to enter 
the nucleus at the onset of apoptotic execution [17]. 
Instead, our data suggest that ICAD/DFF most likely 
functions in the nucleus. 
How does ICAD gain access to the nucleus? Many 
studies have shown that GFP does not possess an in-
trinsic nuclear localization sequence (NLS), and in-
spection of the ICAD sequence led Enari et al. to con-
clude that ICAD also is unlikely to possess an 
autonomous NLS [15]. This suggests that the nuclear 
ICAD may be transported into the nucleus in a complex 
with another factor that does possess a functional NLS. 
This second factor could be CAD or it could be another 
as yet unidentified factor that interacts with ICAD. 
Candidates for such factors include the proapoptotic 
molecules CIDE A and B [22]. It is important to recog-
nize that the cellular location of CAD remains to be 
determined. If CAD and ICAD are of relatively similar 
abundance, then our results would suggest that CAD 
must be nuclear, since the great majority of ICAD is 
nuclear. However, if CAD is considerably less abun-
dant than ICAD, it is possible that CAD is indeed 
sequestered in the cytoplasm of nonapoptotic cells, 
where it could be complexed with the trace levels of 
ICAD that we did observe in crude cytosolic fractions. 
In the absence of antibody to CAD, these questions of 
abundance and localization are impossible to address 
at present. However, it is worth noting that the frac-
tionation protocol used in the original identification of 
DFF yielded complexes in which DFF45/ICAD and 
DFF40/CPAN/CAD were present in roughly equimolar 
amounts [17]. 
Our results suggest that ICAD likely functions 
within the cell nucleus. ICAD could act as a direct 
inhibitor of a putative pool of nuclear CAD, or its 
function might be mediated by interactions with 
other proapoptotic factors. In either case, caspase 
inactivation of ICAD would occur within the nucleus 
following activation of one or more intranuclear 
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FIG. 3. Distribution of the GFP moiety of GFP—ICAD fusion protein in apoptotic HeLa cells. Cells transiently transfected with a construct 
xpressing GFP—ICAD were exposed to (A, B) etoposide or (C) staurosporine to induce apoptosis. The expressed protein was observed in 
issociation with the DNA or in certain cases throughout the entire cytoplasm. In the case in which the GFP was cytoplasmic, not all 
)romrnent surface blebs were observed to contain the GFP fragment (arrows in C). (A—C) Phase contrast. (A'—C') GFP fluorescence. (A"—C") 
)NA stained with DAPI. 
aspases and cleavage of ICAD. Consistent with this 
nodel, intranuclear forms of active caspases have 
een detected in both HL-60 and K562 cells under-
oing drug-induced apoptosis [23, 241. It is also pos-
;ible that ICAD may function in a more general role 
,ban previously assumed, perhaps as a chaperone or 
;torage factor for other proapoptotic activities. The 
urther characterization of the factor or factors asso- 
ciated with nuclear ICAD is an important goal for 
future research. 
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Differential Localization of ICAD-L and ICAD-S in Cells Due to Removal 
of a C-Terminal NLS from ICAD-L by Alternative Splicing 
Kumiko Samejima and William C. Earnshaw' 
Institute of Cell and Molecular Biology, University of Edinburgh, Edinburgh E119 3JR, Scotland, United Kingdom 
CAIJ/CPANIDFF40 is an apoptotic nuclease that is 
associated with the regulatory subunit ICAIIDFF in 
healthy cells. ICA]J has two forms, ICAI-L1DFF45 and 
[CAD-SIDFF35, which are transcribed from a single 
gene by alternative splicing. They differ at the C-ter-
minus: 70 amino acids of ICAIJ-L are replaced by 4 
different amino acids in ICAJJ-S. We previously 
showed that both transfected and endogenous ICAD-L 
are nuclear; however, the localization of ICAI and 
CAI remains controversial and an important issue to 
clarify. Here we present the evidence that ICAI-L is 
nuclear due to the presence of an autonomous nuclear 
localization signal located in the C-terminal 20 amino 
acids. This NLS is missing from ICAI-S, which is dis-
tributed throughout the cell. We also showed that a 
GFP:CAJJ fusion protein is located in the nucleus of 
transfected cells. Q 2000 Academic Press 
Key Words: apoptosis; ICAIJ-L; ICAI-S; CAI. 
INTRODUCTION 
One aspect of the regulation of apoptotic execution 
that has recently attracted considerable study is the 
movement of apoptotic factors from one intracellular 
compartment to another. The best studied example of 
this involves movement of factors, including cyto-
chrome c, AIF, and caspases from the mitochondrial 
intermembrane space into the cytosol at the onset of 
apoptotic execution [1-31. Less well understood is a 
requirement for nuclear transport of proteins, which is 
essential for the onset of apoptotic execution following 
the induction of apoptosis by Fas/CD95 [4]. The iden-
tity of the essential factors that must enter the nucleus 
is not known; however, the apoptotic nuclease CAD! 
CPAN/DFF40 [5-8] remains one attractive possibility, 
together with the recently discovered protein acinus 
[91. 
'To whom correspondence and reprint requests should be ad-
dressed. Fax: (0131) 650-7100. E-mail: bill.earnshaw@ed.ac.uk.  
In healthy cells, CAD/CPAN/DFF40 exists in a com-
plex with its inhibitory chaperone ICAD-L/DFF-45. 
ICAD-L, after functioning as a folding chaperone for 
CAD during translation [51, then remains bound to the 
nuclease, keeping it in inactive form. The absolute 
requirement for ICAD-L as a folding chaperone is re-
vealed by the phenotype of DFF-45 knockout mice, 
whose cells undergo apoptosis in the absence of de-
tectible DNA cleavage despite the continued presence 
of CAD [101. At the onset of apoptosis, caspases with 
specificities characteristic of caspases -3 and -7 cleave 
ICAID-L at two sites [11, 121.  This relieves the inhibi-
tion of CAD and initiates the fragmentation of the 
chromosomal DNA during apoptosis [121. CAD activa-
tion is observed after diverse apoptotic stimuli in a 
variety of cultured cells [131, as well as in animals, in 
which CAD may play a role after traumatic brain in-
jury [141. 
The location of CAD/CPAN/DFF40 in cells remains 
controversial, with the original claims that the protein 
is located in the cytoplasm [5] being challenged by 
other results suggesting that expressed exogenous pro-
tein is in the nucleus [7, 151. In general, studies that 
have examined the location of expressed ICAD-L/ 
DFF45 in transfected cells have found the protein in 
the nucleus [7, 151, whereas subcellular fractionation 
studies have found the protein to be cytoplasmic to a 
greater or lesser extent [14, 16, 171. Our own subcellu-
lar fractionation study using HeLa cells found the en-
dogenous protein to be predominantly nuclear when 
steps were taken to minimize leakage from nuclei [15]. 
Apart from methodological differences, it is, of course, 
possible that the localization of these proteins could 
vary in differing cell types. 
The localization of CAD/CPAN/DFF40 and ICAD! 
DFF45 in healthy cells is an important issue to clarify, 
as one possible mechanism for the inhibition of CAD by 
ICAD-L [5, 18, 191 has been suggested to involve 
ICAD-L binding to CAD and occluding the CAD nu-
clear localization signal (NLS). In the original descrip-
tions of DFF45/ICAD-L, no obvious NLS was noted, 
0014-4827/00 $35.00 	 314 
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and it was suggested that the protein (and therefore 
bhe complex of ICAD with CAD) was cytoplasmic [5, 
111. This model was questioned by our subsequent 
lemonstration that both an exogenous GFP:ICAD-L 
Fusion protein and an endogenous ICAD-L were nu-
clear in human (HeLa), pig (LLCPK), and chicken 
DU249) cells [151. 
The purpose of the present study was to determine 
the mechanism of ICAD-L entry into the nucleus and, 
in particular, whether ICAD-L enters the nucleus as a 
consequence of the function of an NLS that was not 
recognized in previous studies or whether the protein 
must enter the nucleus in a complex with another 
NLS-bearing protein or proteins. The data presented 
here clearly indicate that the C-terminus of ICAD-L 
functions as an autonomous NLS that is able to direct 
the entry of a GFP fusion protein into the nucleus. 
multiple cloning site, was ligated into pCDNA3 (Invitrogen) contain-
ing enhanced GFP with a flexible linker (gift of Larry M. Karnitz, 
Mayo Research Foundation, Rochester, MN) which had been di-
gested with NotI and ApaI. 
Construction of pCDNA3 GFP:ICAD-L31233' from ICAD-L. The 
C-terminal 20 amino acids of ICAD-L were obtained by PCR using 
primer (5'-CATAGCGGCCGCAGGAGGAGCCCAC-3') and primer 
(5'-GCACC'F1'CCAGGGTCAAG-3') and then digested with NotI and 
ApaI. The resulting fragment was ligated into pCDNA3 GFP linear-
ized by digestion of the MCS with NotI and ApaI. 
Microscopy. HeLa cells were cultured in RPMI 1640 medium 
containing 5% (vlv) calf serum. After electroporation with various 
constructs [20], cells were grown on coverslips overnight. These 
coverslips were rinsed with PBS, fixed in a 4% formaldehyde solution 
for 5 mm, stained with DAPI (2 g/ml) for 5 mm, rinsed with PBS, 
and mounted with Vectashield (Vector). Images were acquired on a 
Zeiss Axioplan II epifluorescence microscope equipped with a Prince-
ton Instruments Micromax cooled CCD camera, driven by IP Lab 
Spectrum software. 
RESULTS AND DISCUSSION 
MATERIALS AND METHODS 
Materials. DAPI (4,4-diamidino-2-phenylindole) was obtained 
from Sigma. All restriction enzymes were obtained from New En-
gland Biolabs. 
Construction of GFP:ICAD-L1311. The C-terminus of ICAD-L 
lacking 20 amino acids was obtained by PCR using primer (5'-
CTGCTGTCAGAAGAGGACCTC-3') and primer (5 '-GCCCAAGCT-
TCTAGAATTCTTATGCTGATAG-3') and then digested with HincII 
and HindIll. The resulting fragment was ligated into vector pRSET 
A (Invitrogen) containing full-length ICAD-L1331 which had been 
digested with Hincli and Hindlil. Next, pRSET A ICAD-L' 31' was 
digested with XhoI and XbaI and the resulting fragment was ligated 
into vector pCDNA GFP:ICAD-L [15] which had been digested with 
XhoI and XbaI. 
Construction of GFP.ICAD-S1265. The C-terminus of ICAD-S was 
obtained by PCR using primer (5'-CTGCTGTCAGAAGAGGACCTC-
3') and primer (5'-TAGGGCCC'N'AGTTCTTGCCCACCTC-
CAAATCCTG-3') and then digested with XcmI and ApaI. The result-
ing fragment was ligated into vector pCDNA GFP:ICAD-L which had 
been digested with XcmI and ApaI. 
Construction of GFP:ICAD-S' 26 . The C-terminus of ICAD-S126' 
lacking four amino acids was obtained by PCR using primer (5'-
CTGCTGTCAGAAGAGGACCTC-3') and primer (5'-GCCCAAGCT-
TCTAGAATTCTTACTCCAAJ'ITC-3') and then digested with Hincli 
and Hindill. The resulting fragment was ligated into vector pRSET 
A ICAD-L (Invitrogen) which had been digested with Hincil and 
FIindllhI. Next, this pRSET A ICAD-S' 261 was digested with XhoI and 
XbaI. The resulting fragment was ligated into vector pCDNA GFP: 
ICAD-L which had been digested with XhoI and XbaI. 
Construction of Zeo GFP:ICAD-L, Zeo GFP:ICAD-L1311, Zeo GFP: 
ICAD-S, and Zeo GFP:ICAD-S3261. GFP:ICAI)-L, GFP:ICAD-L1311, 
GFP:ICAD-S, and GFP:ICAD-S' 26' in pCDNA3 (Invitrogen) were 
digested with Hindlil and ApaI. The resulting fragments were li-
gated into vector pZeo SV2 + (Invitrogen) which had been digested 
with Hin dill and ApaI. 
Construction of Zeo GFP.-CAD. First, CAD in pBluescript KS 
(Stratagene) was digested with NotI and XhoI. The resulting frag-
ment was ligated into vector pCDNA3 GFP linearized by digestion of 
the multiple cloning site (MCS) with NotI and XhoI. This GFP:CAD 
was digested with Hindill and ligated into vector pZeo SV2+ which 
had been digested with Hindlil. 
Construction of pCDNA3 GFP with MCS. pBluescript KS was 
digested with NotI and ApaI. The resulting fragment, a part of the 
The C-Terminus Determines the Nuclear Localization 
of ICAD-LIDFF45 
In a previous publication [151, we showed that both 
endogenous and transfected ICAD-L/DFF45 are nu-
clear in growing cells. To investigate the mechanisms 
underlying the subcellular localization of ICAD-L and 
ICAD-S, we constructed a fusion protein between mu-
rine ICAD and the Aequoria victoria green fluorescent 
protein (GFP). Following transient transfection, this 
GFP:ICAD-L fusion protein was detected solely in the 
nucleus of healthy human epithelial and chicken hep-
atoma cells (Fig. 1, panels A). In contrast, a GFP: 
ICAD-S fusion protein was located diffusely through-
out the cell (Fig. 1, panels B). 
The transcripts encoding ICAD-L/DFF45 and ICAD-
S/DFF35 arise by alternative splicing of a single pre-
cursor transcript. The two proteins are identical except 
for their C-terminal regions, in which the 70 C-termi-
nal residues of ICAD-L are replaced by 4 different 
residues in ICAD-S. It therefore appeared likely that 
the different localization of ICAD-L and ICAD-S might 
be due to the differing C-termini of these proteins. We 
have considered two hypotheses explaining the differ-
ential localization of the two proteins. First, a nuclear 
localization signal might be present in the 70 residues 
of ICAD-L that are missing from ICAD-S. Second, the 
four different amino acids at the C-terminus of ICAD-S 
might function as part of a cytoplasmic retention or 
nuclear export signal. 
To test the latter hypothesis, we constructed a GFP: 
ICAD-S fusion that lacks the four novel C-terminal 
amino acids (GFP:ICAD-S' 261). When expressed by 
transient transfection, GFP:ICAD-S' 261 was distrib-
uted diffusely throughout the cell, appearing indistin-
guishable from the GFP:ICAD-S protein (Fig. 1, Panels 







mouse 	SPLPGEPQjPKPTADS S-cooH 
human SASPPGDLQNPKR1AQDPT-cooH 
FIG. 2. A possible bipartite NLS in the C-terminal 20 amino acid 
residues of ICAD-L is conserved between mouse and human. Basic 
residues are shadowed. 
not specify the cytoplasmic localization of this protein. 
It therefore seemed much more likely that the C-ter-
minal region of ICAD-L contains a nuclear localization 
signal. 
Identification of a Nuclear Localization Signal at the 
C-Terminus of ICAD-L 
The nuclear localization of ICAD-LIDFF45 could be 
explained by the protein having its own nuclear local-
ization signal or by an interaction with other proteins, 
such as CAD/CPAN/DFF40. We suspected that the nu-
clear localization of ICAD-L was unlikely to be due to 
the protein being transported into the nucleus in a 
complex with a carrier protein, such as CAD, since the 
GFP:ICAD-L protein was detected almost solely in the 
nucleus, even in cells in which the transfected protein 
was highly overexpressed. 
Previous descriptions of the sequence of ICAD-L/ 
DFF45 have not described a putative nuclear localiza-
tion signal within the molecule. Nonetheless, upon ex-
amination of the ICAD-L deduced amino acid 
sequence, we noticed a cluster of basic residues in the 
C-terminal 20 amino acids that might possibly function 
as a bipartite nuclear localization signal (Fig. 2) [211. 
To test the possibility that this region functions as a 
nuclear localization sequence, we constructed a fusion 
protein between GFP and ICAD-L from which these 20 
amino acids had been removed (GFP:ICAD-L' 311). Fol-
lowing transient transfection, GFP:ICAD-L1311 was lo-
calized diffusely throughout the cell, thus confirming 
that this region of ICAD-L is essential for the nuclear 
localization of the protein (Fig. 1, Panels D). It is worth 
noting that these 20 amino acids do not include the 
region which has been proposed to be necessary for 
interaction between ICAD and CAD [19, 22]. 
To confirm that the C-terminal 20 amino acids of 
ICAD-L possess autonomous NLS function, we con-
structed a vector encoding a fusion between GFP and 
this 20-amino-acid-peptide (GFP: ICAD-L312331). In con- 
trol experiments, GFP on its own did not target to the 
nucleus (Fig. 3, panels B). However, following tran-
sient transfection, GFP: ICAD-L31233' was predomi-
nantly nuclear (Fig. 3, panels A). This result strongly 
supports the hypothesis that ICAD-L localizes in the 
nucleus due to the action of a C-terminal nuclear local-
ization signal. 
CAD Is also a Nuclear Protein 
It has been proposed that CAD/CPANIDFF40 exists 
as a 1 to 1 complex with ICAD-L/DFF45 in healthy 
cells [5, 11], although it has not proven possible to 
detect significant complexes between CAD and ICAD-
SIDFF35 in cells [18]. Furthermore, it has been 
claimed that CAD contains a nuclear localization sig-
nal near its C-terminus (CAD: amino acid residues 
331-345) [5]. To confirm the localization of CAD within 
cells, we constructed a plasmid encoding a GFP:CAD 
fusion protein. Following transient transfection, this 
fusion protein was detected almost solely in the nu-
cleus of human epithelial and chicken hepatoma cells 
(Fig. 1, panels E). To exclude the possibility that the 
nuclear localization of GFP:CAD was due to its over-
expression and failure to form a complex with ICAD, 
we also cotransfected HeLa cells with plasmids ex-
pressing GFP:CAD plus HA-tagged ICAD-L. Both pro-
teins were highly concentrated in the nucleus of hu-
man epithelial cells (data not shown). In addition, 
endogenous CAD was detected in the nuclear fraction 
following subcellular fractionation and immunoblot-
ting (K.S. and S. Kandels-Lewis, preliminary observa-
tions). 
The CAD.ICAD-L Complex Is Stored within Nuclei 
These data reveal that both CAD and its inhibitory 
chaperone ICAD-L possess autonomous nuclear local-
ization sequences. This is consistent with prior obser-
vations both from ourselves [151 and from others [71 
indicating that both CAD and ICAD-L are stored in the 
nucleus of healthy cells. It has previously been shown 
using a model for the induction of apoptosis by Fast 
CD95 that nuclear transport of proteins is essential for 
cells to enter apoptotic execution [4]. Our results sug-
gest that activated CAD is unlikely to be the key factor 
that must translocate into the nucleus. 
The nature of the translocating factor is unknown. 
Likely candidates include apoptosis inducing factor 
FIG. 1. The C-terminal 20 amino acids (aa) of ICAD-L are required for localization of the protein in cell nuclei. Aequoria victoria green 
fluorescent protein (GFP) was fused in flame to murine ICAD-L, ICAD-S, and CAD and expressed by transient transfection in human (HeLa) 
cells. (Panels A) The expressed GFP:ICA.D-L' 331 (full length ICAD-L) was solely observed in nuclei. In contrast, GFP:ICAD-S1265 (full length 
ICAD-S) (panels B), GFP:ICAD-S' 26' (panels C), and GFP:ICAD-L1311 (panels D) were all found to be distributed throughout the cell in both 
nucleus and cytoplasm. (Panels E) GFP:CAD was highly concentrated in nuclei. Panels A—E, phase contrast; Panels A'—E', detection of GFP 
fluorescence; Panels A"—E", DAPI fluorescence of cellular DNA. The bar shows 10 micrometers. 
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FIG. 3. The C-terminal 20 aa of ICAD-L functions as an autonomous nuclear localization sequence capable of targeting GFP to the cell 
nucleus. Aequoria victoria green fluorescent protein (GFP) was fused in flame to a peptide comprising the C-terminal 20 amino acids from 
murine ICAD-L and expressed by transient transfection in HeLa cells. (Panels A) The expressed GFP:ICAD-L312331 was highly concentrated 
in nuclei. (Panels B) GFP expressed on its own is distributed throughout the cell in both nucleus and cytoplasm. Panels A and B, phase 
contrast; Panels A' and B', detection of GFP fluorescence; Panels A" and B", DAPI fluorescence of cellular DNA. The bar shows 10 
micrometers. 
AIF [231, Acinus [9], and in view of the results de-
scribed here, activated caspase-3 and possibly 
caspase-7, since these enzymes appear to be responsi-
ble for the activation of CAD in cells [24-29]. The 
intracellular localization and translocation of caspases 
during apoptosis is still under investigation; however, 
we previously detected an activity comigrating with 
activated caspase-3 in the nucleus by activity labeling 
and two-dimensional gel analysis [301. It has recently 
been reported that, following cleavage of procaspase-3, 
which exists primarily in the cytoplasm and mitochon-
dria [31, 321, active caspase-3 is found in the nuclear, 
mitochondrial, and cytosolic fractions [17, 331. In con-
trast, caspase-7 shifts quantitatively from the cytosol 
to the microsomal fraction following activation [17]. 
What Is the Role of ICAD-S? 
The levels of expression of ICAD-LJDFF-45 and 
ICAD-smFF35 are similar at least in mouse WR19L 
and human Jurkat T lymphoma cells [18]. It has been 
suggested that ICAD-S might function as a safety de-
vice for preventing the mistaken activation of CAD in 
healthy cells [191. Promoter analysis of the murine 
ICAD and CAD genes suggests that expression of these 
genes is regulated by different mechanisms [34]. Alter-
native splicing of the ICAD pre-mRNA could serve as a 
mechanism for regulating the level of ICAD-L in re-
sponse to the expression level of functional CAD. 
Changes in the efficiency of alternative splicing of the 
ICAD pre-mRNA would alter the ratio of ICAD-L to 
ICAD-S without necessitating changes in the tran-
scription of the gene. 
Although ICAD-S/DFF35 cannot act as a folding 
chaperone to enable the synthesis of functional CAD! 
CPANTDFF40, in vitro it can bind to active CAD! 
DFF40 and inhibit its nuclease activity [18, 191. This is 
because amino acid residues 101-180 of DFF35!45 me-
diate the binding to DFF40, whereas residues 23-100 
are implicated in the inhibition of the nuclease in vitro 
[19]. Despite the fact that ICAD-S can inhibit CAD in 
cells [12, 191, ICAD-S exists primarily in free form in 
vivo [18]. Our data suggest that this may be because 
much of ICAD-S is cytoplasmic, whereas CAD is nu-
clear. Whether ICAD-S has a distinct cytoplasmic func-
tion in addition to interaction with CAD is not cur-




suggested an association of ICAD with cytoskeletal 
components (K.S. unpublished data), possibly indica-
tive of unknown functions for ICAD in the cytoplasm, 10. 
either during apoptosis or in healthy cells. 
CONCLUSIONS 
Cells contain two forms of ICAD, ICAD-L and 
ICAD-S, which differ at their C-termini (ICAD-S re-
places the C-terminal 70 residues of ICAD-L with a 
stretch of 4 different residues). Because the region of 
ICAD-L that is missing from ICAD-S is precisely the 
region containing the NLS, these two splice forms oc-
cupy very different cellular locations. ICAD-S is found 
in both the nucleus and the cytoplasm, whereas 
ICAD-L is almost exclusively nuclear. Interestingly, 
these two forms of ICAD are functionally distinct [18, 
191. Whether ICAD-S has a distinct function in the 
cytoplasm is not currently known, and it is not known 
whether the cytoplasmic pool of ICAD-S is associated 
with CAD. All in all, current results are consistent 
with models in which the primary location of CAD in 
growing cells is nuclear, making it unlikely that regu-
lation of CAD entry into the nucleus is a critical factor 
in the control of the onset of apoptotic execution. 
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DNA topoisomerase ha interacts with CAD nuclease and is 
involved in chromatin condensation during apoptotic execution 
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Apoptotic execution is characterized by dramatic 
changes in nuclear structure accompanied by cleavage 
of nuclear proteins by caspases (reviewed in [11). 
Cell-free extracts have proved useful for the 
identification and functional characterization of 
activities involved in apoptotic execution [2-41 and for 
the identification of proteins cleaved by caspases [5]. 
More recent studies have suggested that nuclear 
disassembly is driven largely by factors activated 
downstream of caspases [6]. One such factor, the 
caspase-activated DNase, CAD/CPAN/DFF40 [4,7,8] 
(CAD) can induce apoptotic chromatin condensation in 
isolated HeLa cell nuclei in the absence of other 
cytosolic factors [6,8]. As chromatin condensation occurs 
even when CAD activity is inhibited, however, CAD 
cannot be the sole morphogefletic factor triggered by 
caspases [6]. Here we show that DNA topoisomerase lla 
(Topo Ila), which is essential for both condensation and 
segregation of daughter chromosomes in mitosis [9], 
also functions during apoptotic execution. Simultaneous 
inhibition of Topo ha and caspases completely abolishes 
apoptotic chromatin condensation. In addition, we show 
that CAD binds to Topo llct, and that their association 
enhances the decateflation activity of Topo Ila in vitro. 
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(Figure ic) 161- A similar phenotype was observed when 
nuclei were preincuhated with the highly specific Topo II 
inhibitors ICRF-159, ICRF-187 or etoposide (VP16) for 
30 minutes before addition of E/X extracts (Figure id—f). 
Simultaneous inhibition of caspase and Topo II activity 
completely abolished apoptotic chromatin condensation 
(Figure 1dfv). This was not simply a kinetic effect, as 
nuclei retained this normal appearance for at least 6 hours 
at 37°C (data not shown). This inhibition of apoptotic 
chromatin condensation was unlikely to arise from global 
changes in the accessibility of chromatin to condensation 
factors, as simultaneous inhibition of caspases and 
Topo ha had no effect on the ability of CAD nuclease to 
cleave nuclear DNA into an ohigonucleosomal ladder 
(Figure 2e). These experiments provide the first evi-
dence that Topo ha has a role in chromatin condensation 
during apoptosis. 
The abolition of apoptotic chromatin condensation follow-
ing simultaneous inhibition of Topo ha and caspases was 
seen with three different Topo II inhibitors, suggesting 
that the effect is due to the action of the drugs on 
Topo ha. In a further control, apoptotic chromatin con-
densation was restored when highly purified human 
Topo ha 1101 (Figure 2d) was added to nuclei in E/X 
extract in the presence of Topo II and caspase inhibitors 
(Figure 1d"—f"). This rescue was abrogated when the puri-
fied Topo ha was pretreated with monospecific anti-Topo 
Ha antibodies (Figure 2h, and data not shown). Topo ha 
alone had no effect on the morphology of nuclei in buffer 
after 2 hours (Figure 2a). Finally, simultaneous inhibition 
of Topo I and caspases had no effect on chromatin conden- 
sation induced by E/X extracts (Figure 2c). These controls 
strongly support the conclusion that both Topo ha and 
caspases act in pathways that promote apoptotic chromatin 
condensation. The rescue by purified Topo Ha in the 
presence of inhibitors raises the possibility that Topo Ha 
could be functioning in a non-enzymatic role, either as a 
structural or targeting factor, as has been proposed for its 
role in mitotic chromosome condensation 1111. 
Simultaneous inhibition of caspases and CAD (by addition 
of the CAD-inhibitory chaperone ICAD-L) also blocked 
chromatin condensation in E/X extracts (Figure lh). This 
confirmed our previous results suggesting that CAD and 
caspases act in parallel pathways of apoptotic chromatin 
condensation [6]. Surprisingly, inhibition of chromatin 
condensation could be reversed upon addition of purified 
human Topo ha (Figure ii), suggesting that Topo ha 
Results and discussion 
HeLa nuclei incubated in E/X extracts underwent chro-
matin condensation in two stages: condensation against 
the nuclear rim was followed by the formation of discrete 
apoptotic bodies (Figure lb). The rim-condensation 
also occurred when caspase activity was inhibited with 
the peptide_fl uoromCthylketo1 	inhibitor DEVD—fmk 
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acts downstream of CAD or promotes condensation in a 
pathway parallel to the CAD pathway. It was also possible, 
however, that the added Topo Ha might interfere with 
the interaction between CAD and the exogenous ICAD 
added in these reactions as a CAD inhibitor. 
Fiaure 1 
Topo la is required for apoptotic chromatin condensation in the 
absence of caspase activity. Isolated HeLa cell nuclei were 
preincubated with (a—c) diluent alone or with (d) 50 pg/mI ICRF-1 59, 
(e) 50 pg/mI ICRF-1 87 or (f) 100 pM etoposide (VP1 6). The nuclei 
were then added to (a) buffer or (b—f) apoptotic E/X extract [61 and 
incubated for 2 In at 37°C. (d—f) Inhibition of Topo Ila alone only partly 
inhibited apoptotic chromatin condensation. (d'—fl Inhibition of Topo Hot 
plus caspases (with 100 pM DEVD—fmk) abolished chromatin 
condensation. (d"—f") This block was reversed if 1 pg (2.9 pM) purified 
human Topo llct was added at the start of the 37°C incubation. 
Inhibition of CAD with 160 ng of the uncleavable mutant 
DM-ICAD-L does not block apoptotic chromatin condensation. 
Simultaneous inhibition of CAD plus caspases blocks morphological 
apoptosis. (I) Added Topo ha (1.5 pg) rescues apoptotic morphology 
after inhibition of CAD plus caspases. The percentage of apoptotic 
cells scored in the microscope is indicated below each micrograph. 
To confirm that Topo ha can hind CAD in cell extracts, 
we made stable suhlines of chicken MSB-1 cells express- 
ing green fluorescent protein (GFP) fused to histidine 
(His) and haemagglutinin (I-IA) tags (His—HA—GFP) or 
very low levels of 1-us—HA—CAD. The expressed CAD 
was immunoprecipitated from lysates using anti-HA anti-
body. These immunoprecipitates reproducibly contained 
Topo ha, which was not seen in immunoprecipitates of 
the much more highly expressed control protein, His—
HA—(;FP (Figure 3h). This shows that CAD can interact 
with Topo ha in cell extracts. It is not surprising that only 
a fraction of Topo ha was hound to CAD, as Topo ha is 
abundant in MSB-1 cells, and is presumably present in 
vast excess over CAD. 
The interaction between Topo ha and CAD appears to 
he functionally significant. In a quantitative assay for 
DNA decatenation, purified GST—CAD, either on its own 
or as a complex with His—ICAD-L, stimulated the decate-
nation activity of Topo ha two to threefold, whereas 
buffer, GST or GST—ICAD-L had no effect (Figure 3c). 
Under these conditions CAD is enzymatically inactive, 
and does not interfere with the Topo II assay (which mea-
sures the release of intact minicircles from kinetoplast 
networks, see Supplementary material). In other experi-
ments, we could not detect an effect of Topo ha inhibi-
tion or addition on CAD activity against nuclear chromatin 
(Figure 2e, and data not shown). 
Physical and functional interactions between Topo ha 
and CAD were readily detected both in vitro and in cell 
extracts. Purified Topo Ha bound quantitatively to GST—
CAD on glutathione—sepharose, but not to GST alone, 
GST—ICAD-L, GST—BuhRl, GST—AIRK2, or GST-13 
tubulin (data not shown), or sepharose alone (Figure 3a). 
As a control, purified poly(ADP-ribose) polymerase 
(PARP) added to the mix did not bind to any protein 
(Figure 3a). Similar Topo ha binding was also observed 
with Intein—CAD (data not shown). 
It is widely accepted that Topo ha is nuclear [9], and that 
CAD must be nuclear during apoptotic execution [4]. The 
localization of CAD in non-apoptotic cells has., however, 
been more controversial. DFF  [3], and then CAD/ICAD 
[4] were first identified in cytoplasmic extracts. The first 
evidence that the CAD/ICAD complex might he nuclear 
was the observation that exogenous ICAD expressed in a 
variety of cell types was nuclear [6,8]. Also, our subcel]ular 
fractionation experiments confirmed that endogenous 
ICAD is predominantly nuclear [6]. Consistent with this, 
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we have identified an autonomous nuclear localization 
sequence at the carboxyl terminus of ICAD-L [121. Here 
we address the localization of the CAD nuclease itself. 
GFP-CAD is exclusively nuclear when expressed at low 
to moderate levels in cultured cells (Figure 4a, panel 2; 
see also [121),  and is distributed throughout the nucleus in 
a micropunctate pattern that largely follows the DNA dis-
tribution. Endogenous Topo Ha is similarly distributed in 
interphase cell nuclei (Figure 4a, panel 3), and in a 
merged image (Figure 4a, panel 4), the CAD and Topo 
ha signals superimpose as a yellow signal distributed 
throughout the nucleus. To confirm the nuclear localiza-
tion of endogenous CAD, we used a rabbit antiserum to 
cloned murine CAD in subcellular fractionation experi-
ments (Figure 4h). A substantial portion of the CAD is 
revealed in the nuclear fraction. Although it is possible 
that some CAD is normally resident in the cytoplasm, our 
results show that much of this protein is nuclear, and 
would therefore be available to interact with lopo ha. 
Our results are consistent with models in which CAD and 
Topo ha act in independent pathways in E/X extracts, but 
both are modulated by caspases. Several other proteins 
that appear to induce apoptotic chromatin condensation in 
nuclei have been identified. These include the mitochon-
drial flavoprotein AIF (apopwsis-inducing factor) 1131, 
L-DNase 11 [14] and Acinus [15]. The experiments 
reported here suggest that, in the absence of caspases, 
none of these activities is sufficient to induce apoptotic 
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Figure 2 
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Control experiments for the involvement of Topo Ha in apoptotic 
chromatin condensation. (a) Purified human Topo ha (1 ig is 2.9 pM) did 
not induce chromatin condensation in nuclei in buffer. (b) Purified human 
Topo ha immunoadsorbed with the anti-Topo Ha antibody Ki-S1 does not 
reverse the block to apoptotic chromatin condensation imposed by 
simultaneous inhibition of lope ha and caspases. (c) Inhibition of 
caspases and Topo I (with 10 1tM camptothecin (CPT)) had no effect on 
apoptotic chromatin condensation beyond that seen when caspases 
alone were inhibited. (d) Protein purity was verified by SOS-PAGE of the 
Topo Ha preparation in a 10% gel and silver stained. (e) Inhibition of 
Topo Ha plus caspases did not affect the digestion of chromosomal DNA 
by CAD. Nuclei (5 x 105 per loading) were incubated for 2 h in (1) buffer, 
(2) E/X extract, (3) E/X extract plus DEVD-fmk plus ICRF-1 59, (4) ICRF-
187, or (5) etoposide. Nuclear DNA was isolated and electrophoresed in 
a 1% gel containing 0.5 mg/ml ethidium bromide. 
chromatin condensation unless either CAD or Topo ha is 
also present and functional. 
Figure 3 
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Functional interaction between Topo Ha and CAD in vivo and in vitro. 
(a) Human lope Ha binds in vitro to GST-CAD, but not to GST, 
GST-ICAD-L GST-cBubRl or GST-hAlRK2. PARP tested as a 
control does not bind (see Supplementary material). The Coomassie 
Blue-stained gel shows the relative amount of each protein on the 
beads. (b) A subfraction of endogenous lope [let associates with 
tagged CAD in viva HA-tagged proteins were immunoprecipitated from 
stable transfectants expressing His-HA-CAD or His-HA-Gm and 
subjected to SOS-PAGE Left, blot with anti-Topo Ila showing the input 
and unbound fractions (equivalent to 8x 101  cells), and the fractions 
bound to the beads (5x 106 cells for His-HA-CAD and 1 x106 cells 
for His-HA-GFP). Right, blot with anti-HA showing the input and 
unbound fractions (equivalent to 8 x 105 cells for His-HA-CAD and 
1.6 x 105 cells for His-HA-Gm)- We estimate that His-HA-Gm is 
expressed roughly 25-100-fold more abundantly than His-HA-CAD in 
these cells. (c) GST-CAD stimulates lope Ikx activity measured using a 
kinetoplast minicircle decatenation assay (see Supplementary material). 
The error bars represent SEM for two independent assays. 
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(a) Topo lIri and GFP-CAD co-localize in healthy cell nuclei. Chicken 
DU249 cells were transfected with constructs expressing GFP-CAD 
and stained for endogenous Topo ha. The two proteins were 
distributed in the nucleus in an overlapping micropunctate pattern. 
A single deconvolved optical section is shown. The scale bar 
represents 5 pm. (b) A significant portion of endogenous CAD is 
nuclear. HeLa S3 cells were fractionated into nucleus and cytoplasm 
[6] and immunoblotted with rabbit anti-mouse CAD, mouse anti-
tubulin, and human autoantibody against Topo I. 
Although a role for Topo ha in apoptotic execution has 
been controversial [16,17], its involvement in generating 
high-molecular-weight DNA fragments following oxida-
tive stress has recently been demonstrated 1181. In addi-
tion, Topo ha has been shown to stimulate the activity of 
CAD against a naked DNA substrate approximately eight-
fold, although the cleavage of chromatin was essentially 
unaffected [191. The direct interaction between Topo Ila 
and CAD we show here might result in targeting of CAD 
to sites occupied by Topo ha at the base of chromosomal 
loop domains. At those sites, CAD might initially stimu-
late Topo ha activity and then subsequently, upon cleav-
age of ICAD-L by caspases, it might commence the 
wholesale digestion of DNA characteristic of apoptosis, 
possibly being further stimulated by interactions with 
Topo ha. Our results predict that CAD cleavage might 
initiate at or near 'l'opo ha-binding sites. 
Supplementary material 
Supplementary material, including a full description of the methods with 
references, is available at httpi/current-biology.com/supmat/sup-
matin.htm.  
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Figure Si 
The kinetoplast minicircle decatenation assay. 
(a) Experiment. All samples contained: 5 nM 
kinetoplast-DNA 1 mM ATP and 10 nM 
Topo II (except where indicated) in 50 mM 
Tris pH 7.9, 100 mM KCI, 10  MM MgCI21 
0.5 mM NSEDTA pH 8.0, 2.5% glycerol. The 
positions of the kinetoplast network 
(substrate), released minicircles (Topo II 
reaction product) and linear DNA (product of 
cleavage by CAD) are indicated. Less than 
3% of the kinetoplast DNA minicircles are 
cleaved. Because decalenation is determined 
by quantifying released DNA minicircles (and 
not by disappearance of the kinetoplast DNA 
substrate), any CAD-mediated DNA cleavage 
would deplete the Topo II decatenation 
substrate and thus decrease (not increase) 
observed levels of decatenation. (b) Controls. 
This experiment is the same as in (a), except 
that Topo II was omitted from all GST, 
GST-CAD, GST-CAD/His-ICAD, and 
GST-ICAD samples. That is, the only sample 
that contained Topo II is that labelled Topo II. 
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Supplementary materials and methods 
Preparation of apoptotic extracts and in vitro apoptosis 
reaction 
Apoptotic (E/X) extracts [Si] were prepared from chicken DU249 cells 
treated for 12 h with 0.5 1.tM staurosporine (Sigma). Cells were washed 
in KPM buffer (50 mM PIPES-KOH pH 7.0, 50 mM KCI, 10 mM EGTA, 
2 mM MgCl2, 20 mM cytochalasin B (Sigma), 1 mM DTT, 0.1 mM 
PMSF, 1 .Lg/ml each of chymostatin, leupeptin, antipain, pepstatin A) 
[S2], subjected to several cycles of freezing and thawing and further 
disrupted by mild sonication. The cell lysate was then centrifuged at 
1 39,000g for 2 h, yielding clear cytosolic extracts with a protein con-
centration of 20-30 mg/mI (measured by the Bradford assay [31). 
HeLa nuclei (lOs per incubation) were preincubated for 30 min at 37°C 
with either the Topo lia inhibitors ICRF-i 59, ICRF-1 87 (50 ig/mI, both 
gifts of A. Imondi, Pharmacia) or etoposide (VP-1 6, 100 tM, Sigma), or 
the Topo I inhibitor camptothecin (0.1, 1 or 10 pM, Calbiochem), or 
diluent. For CAD inhibition, E/X extracts were preincubated with ICAD-L 
or CAD buffer (10 mM HEPES pH 7.4, 50 mM NaCl, 5 m EGTA, 
2 mM M9Cl2, 1 mM DTI) for iS min at 37°C. For caspase inhibition, 
E/X extracts were preincubated with DEVD-fmk (100 I.M, Calbiochem) 
or diluent for 15 min at 37°C. Nuclei were then added (up to 106 nuclei 
per 20 p1 of extract) and incubated at 37°C for up to 6 h in the presence 
of an ATP regeneration system [S2]. In certain experiments, i or 1.5 pg 
of purified human Topo 11cc expressed in Saccharomyces cerevisiae 
[S4,S5] was added to the incubation. This corresponds to 2.9 pmol 
dinner, a -3x physiological level of 1.7x106 molecules per nucleus 
[S61. Nuclei were subsequently stained with DAM to observe chromatin 
condensation, solubilized in SDS-sample buffer for protein analysis, or 
lysed for analysis of DNA ladder formation. 
Construction of clones 
For construction of intein-ICAD, mouse full-length ICAD-L [S7] (gift of S. 
Nagata, Osaka) was cloned into the NcolISmal cloning sites of pTYB4 
(New England BioLabs Inc.). GST-CAD was prepared by cloning full-
length murine CAD into the pGEX 4T-1 (Pharmacia Biotech) EcoRl and 
Xhol cloning site. To make the plasmid encoding the GST-CAD His6-
tagged ICAD combination (GST-CAD/His-ICAD), His-ICAD in 
pRSETB [51] was obtained by PCR with primer (5'-TGAGACGTC-
TAATACGACTCAC-3') and primer (5'-GTCGACGTCAGCAAAAAAC 
CCC-3') and cloned into the Aaf I site of pGEX 4T-1 containing GST-CAD. 
To make the Zeo-His-HA vector, first a His tag was constructed by 
ligation of oligonucleotides (5'-CTAGCATGCATCATCATCATCATCAC 
CGCGGA-3') and (5'-AGCi7CCGCGGTGATGATGATGATGAT& 
CATG-3'). The resulting fragment was ligated into vector pZeoSV2+ 
(Invitrogen) that had been digested with NheI and H/ndIll. The HA tag in 
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pBluescript KS (Stratagene) was digested with Sacil and blunt-ended 
with T4 DNA polymerase plus 100 pM ctNTPs, and digested with EcoR I. 
The resulting fragment was ligated into vector pZeo-His that had been 
digested with Kpnl and blunt-ended with T4 DNA polymerase plus 
100 pM dNTPs, and digested with EcoR I. To make Zeo-His-HA-CAD 
and Zeo-His-HA-GFP, the CAD ORF was obtained by PCR from a 
plasmid containing the full-length CAD cDNA (gift of S. Nagata), cloned 
into pBluescript KS (Stratagene) and digested with EcoRl and Xhol. GFP 
was obtained by PCR using primer T7 and primer (5'-CCGCTCGAGT-
TAC1TGTACAGC-3') from an enhanced GFP-lamin A in pCDNA 3 (gift 
of Larry M. Karnitz, Mayo Research Foundation), then digested with 
EcoRl and Xhol. The resulting fragments were ligated into vector 
Zeo-His-HA that had been digested with EcoRl and Xhol. 
Expression and purification of GST-ICAD, GST-CAD, 
GST-CAD/His -I CAD and GST 
Plasmids encoding the glutathione-S-transferase (GST) fusion proteins 
GST-ICAD, GST-CAD, GST-CAD/His-ICAD, GST-BR1, GST-hAIRK2 
and GST alone transformed into E. co/i 6L21 (DE3)Lys S cells were 
grown to OD6 = 0.5-0.7, and protein expression was induced with 
isopropylthiogalactoside (IPTG; 0.3-0.5 mM) for 3-5 h. Cells were col-
lected by centrifugation at 5000g for 10 coin and frozen at -80°C. 
GST-CAD/His-ICAD was first purified with 0.5 ml Ni-agarose (Qiagen) 
as described previously for the purification of His6-ICAD purification 
[S1 I. Protein eluted from the column was diluted 20-fold into GST wash 
buffer (PBS, 5 m EDTA, 5 m DTT, 1% Triton X-100), and then puri-
fied a second time over glutathione-sepharose as described below. 
Pellets of E co/i expressing GST-ICAD, GST-CAD or GST were 
thawed on ice and resuspended in lysis buffer (PBS, 5 m EDTA, 
5 mM DTT) with lysozyme (final concentration 1 mg/ml) and incubated 
on ice for 30 mm. After sonicatmon, Triton X-1 00 was added to 1% and 
the lysate was centrifuged at 4000g for 20 mm. The supernatant was 
mixed with glutathione-sepharose 46 (Pharmacia Biotech) which had 
been equilibrated with PBS and incubated on a rotating mixer for 1 h at 
4°C. The sepharose beads were washed in batch three times with 
wash buffer. GST-ICAD and GST were eluted with elution buffer 1 
(10 mM glutathione, 50 mM Tris-HCl pH 8.0). GST-CAD, and 
GST-CAD/His-ICAD were eluted with elution buffer 2 (20 mM glu-
tathione, 100 mM Tns-HCI pH 8.0, 120 mM NaCI). The eluted proteins 
were dialysed for at least 3 h against two changes of CAD buffer 
(10 mM HEPES pH 7.4, 50 mM NaCl, 5 mM EGTA, 2 mM MgCl,, 
1 mM DTT), aliquoted, and frozen in liquid nitrogen. 
Expression and purification of intein-ICAD 
Intein-ICAD encoded by pTYB4/ICAD-L was expressed in E. co/i 
ER2566 and purified using the IMPACP'1  T7 system (New England 
Biol-abs Inc.) following the manufacturer's instructions. lntein-ICAD 
bound to chitin beads was left at 4°C overnight in cleavage buffer 
(20 mM Tns-HCl pH 8.0, 50 mM NaCl, 0.1 mM EDTA, 30 mM DTT). 
The protein was eluted with cleavage buffer without DTT. The eluted 
protein was dialysed for at least 3 h against two changes of CAD buffer 
(10 mM HEPES pH 7.4, 50 mM NaCI, 5 m EGTA, 2 m MgCl2, 
1 mM DTT) aliquoted and frozen in liquid nitrogen. 
Binding of Topo I/a to GST fusion proteins in vitro 
Purified Topo tIm (125 ng) and 53.3 ng purified PARP (in PBS + 5 m 
DTT, 10 mM EDTA, 1% Triton X-100) was incubated with glutathione-
sepharose beads either alone, or with bound GST, GST-ICAD-L, 
GST-CAD, GST-cBubRl or GST-hAIRK2. The bound fraction was 
resolved by SDS-PAGE (10% gel), and Topo Ila was detected by 
immunoblotting with monoclonal antibody l(i-S1. PARP was detected 
by immunoblotting with monoclonal antibody C2-1 0. 
Immunoprecipitalion of HA-tagged CAD and GFP from stable 
cell lines 
Stable lines of MSB-1 chicken lymphoblastoid cells expressing His-
HA-CAD and His-HA-GFP were obtained by electroporation with 
Zeo-His-HA-CAD and Zeo-His-HA-GFP (310 V 975 iF (BioRad 
Gene-Pulser with 0.4 mm cuvettes), selected with 400 pg/mI Zeosin 
(Invitrogen) and confirmed by immunoblotting with anti-HA tag anti-
body. For immunoprecipitation, cells were harvested, washed twice 
with PBS/EDTA and lysed by sonication in IPP150 (10mM Tns 
pH 8.0, 150 mM NaCl, 0.1% NP-40), and insoluble material removed 
by centrifugation for 5 min at 81619 at 4°C. HA-conjugated proteins 
were immunoadsorbed using monoclonal antibody 1 2CA5 preloaded 
onto Afti-Prep Protein A Support beads (BioRad). After incubation for 
1 h at 4°C the beads were washed three times for 5 min with 25 bed 
volumes of either IPP1 50, IPP200 (200 mM NaCI) or IPP300 (300 mM 
NaCI). Bound proteins were subjected to SDS-PAGE in 10% 
Prosieve 50 Acrylamide gels (FMC), transferred to Hybond C nitrocel-
tulose (Arnersham ), and detected by enhanced chemiluminescence. 
Topo tIm was detected with Rabbit G [S81 diluted 1:1000. HA-CAD 
was detected with mouse monoclonal 1 2CA5 diluted 1:1 000. 
Kircetoplast minicircle decatenation assay 
Kinetoplast DNA (0.3 pg) was incubated with 10 nM purified human 
Topo 11a plus 10 nM GST-CAD, GST-ICAD, GST-CAD + GST-ICAD, 
or GST alone for 10 coin at 37°C 1S91. The reaction was stopped by 
addition of DNA loading buffer, heated at 65°C for 10 coin, loaded onto 
a iWo agarose gel containing 0.5 mg/ml ethidium bromide and run at 90 
V for 2 h (Figure 51), and the minicireles released by decatenation were 
quantified. No detectable intact minicircles were released in incubations 
with GST-CAD or GST-CAD + His-ICAD-L in the absence of Topo 
tIm. Under these conditions, the GST-CAD is catalytically inactive and 
does not interfere with the assay. 
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